PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
3196704-1	1988	Activation of prothrombin to alpha-thrombin generates not only the catalytic site and associated regions but also an independent site (an exosite) which binds anionic substances, such as Amberlite CG-50 resin [cross-linked poly(methylacrylic acid)].	cysteinylglycine	197-199	coagulation factor II, thrombin	Homo sapiens	17-25
2458166-0	1988	Spinal effects of chronic intrathecal administration of the thyrotrophin-releasing hormone analogue (CG 3509) in rats.	cysteinylglycine	101-103	thyrotropin releasing hormone	Rattus norvegicus	60-90
2458166-1	1988	The effect of repeated intrathecal administration of a thyrotrophin-releasing hormone (TRH) analogue (CG 3509; 2 micrograms twice daily for 5 days) on wet-dog shake (WDS) and forepaw-licking (FPL) behaviours and spinal cord TRH and indoleamine levels and choline acetyltransferase (ChAT) activity was examined in adult rats.	cysteinylglycine	102-104	TRH	Canis lupus familiaris	87-90
2458166-3	1988	Repeated CG 3509 administration selectively elevated ChAT activity and the level of 5-hydroxytryptamine (5-HT) in the ventral but not in the dorsal horn of the spinal cord, while 5-hydroxyindoleacetic acid (5-HIAA) and TRH levels were unaltered in either region.	cysteinylglycine	9-11	TRH	Canis lupus familiaris	219-222
3129125-2	1988	Cerebroventricular injection of TRH (1 or 10 micrograms) or the TRH analog, CG 3509 (0.1 or 1 microgram), significantly enhanced the decline of body temperature in the young, anaesthetized rats, both in the normal and cold environments, but had no effect whatsoever on the decrease in body temperature in the chloral hydrate-treated aged animals.	cysteinylglycine	76-78	thyrotropin releasing hormone	Rattus norvegicus	64-67
2841577-5	1988	Directed mutagenesis changing these GC residues to CG residues in CYC7 led to CYC1-like expression of CYC7 both in a CYP1 wild-type strain and in a strain carrying the semidominant mutation CYP1-16 which reverses the oxygen-dependent expression of the two genes.	cysteinylglycine	51-53	cytochrome c isoform 2	Saccharomyces cerevisiae S288C	66-70
2841577-5	1988	Directed mutagenesis changing these GC residues to CG residues in CYC7 led to CYC1-like expression of CYC7 both in a CYP1 wild-type strain and in a strain carrying the semidominant mutation CYP1-16 which reverses the oxygen-dependent expression of the two genes.	cysteinylglycine	51-53	cytochrome c isoform 1	Saccharomyces cerevisiae S288C	78-82
2841577-5	1988	Directed mutagenesis changing these GC residues to CG residues in CYC7 led to CYC1-like expression of CYC7 both in a CYP1 wild-type strain and in a strain carrying the semidominant mutation CYP1-16 which reverses the oxygen-dependent expression of the two genes.	cysteinylglycine	51-53	cytochrome c isoform 2	Saccharomyces cerevisiae S288C	102-106
2841577-5	1988	Directed mutagenesis changing these GC residues to CG residues in CYC7 led to CYC1-like expression of CYC7 both in a CYP1 wild-type strain and in a strain carrying the semidominant mutation CYP1-16 which reverses the oxygen-dependent expression of the two genes.	cysteinylglycine	51-53	Hap1p	Saccharomyces cerevisiae S288C	117-121
2841577-5	1988	Directed mutagenesis changing these GC residues to CG residues in CYC7 led to CYC1-like expression of CYC7 both in a CYP1 wild-type strain and in a strain carrying the semidominant mutation CYP1-16 which reverses the oxygen-dependent expression of the two genes.	cysteinylglycine	51-53	Hap1p	Saccharomyces cerevisiae S288C	190-194
3287456-4	1988	Traumatized rats treated with CG-4203 exhibited significantly lower plasma activities of the lysosomal hydrolase cathepsin D (p less than 0.05).	cysteinylglycine	30-32	cathepsin D	Rattus norvegicus	113-124
3127235-2	1988	Other TRH analogues (CG 3509, RGH 2202) and TRH itself also stimulated VO2.	cysteinylglycine	21-23	thyrotropin releasing hormone	Rattus norvegicus	6-9
2885102-1	1987	The effect of carcinogen treatment on gamma-glutamyl transpeptidase (GGT)-mediated hydrolysis of GSH to glutamate and cysteinylglycine in the blood and bile compartments was investigated in livers perfused in situ.	cysteinylglycine	118-134	gamma-glutamyltransferase 1	Rattus norvegicus	38-67
3501325-2	1987	The median immunoreactive CGRP (i-CGRP) level from 158 CSF specimens was 8.0 pmol/l, as measured with an antiserum recognizing the whole molecule of CGRP (CC-2/1) and 12.0 pmol/l with an antiserum recognizing the C-terminal region of CGRP (CG-39).	cysteinylglycine	26-28	calcitonin related polypeptide alpha	Homo sapiens	34-38
3501325-2	1987	The median immunoreactive CGRP (i-CGRP) level from 158 CSF specimens was 8.0 pmol/l, as measured with an antiserum recognizing the whole molecule of CGRP (CC-2/1) and 12.0 pmol/l with an antiserum recognizing the C-terminal region of CGRP (CG-39).	cysteinylglycine	26-28	calcitonin related polypeptide alpha	Homo sapiens	34-38
3501325-2	1987	The median immunoreactive CGRP (i-CGRP) level from 158 CSF specimens was 8.0 pmol/l, as measured with an antiserum recognizing the whole molecule of CGRP (CC-2/1) and 12.0 pmol/l with an antiserum recognizing the C-terminal region of CGRP (CG-39).	cysteinylglycine	26-28	calcitonin related polypeptide alpha	Homo sapiens	34-38
2886057-7	1987	Furthermore, in 4-wk-old rats, inhibition of hepatic GGT by acivicin markedly decreased the biliary excretion of Cys-Gly and Cys and increased that of GS without influencing the excretion of total GS-related sulfur in bile.	cysteinylglycine	113-120	gamma-glutamyltransferase 1	Rattus norvegicus	53-56
3126291-4	1988	The overall relationship between the C-peptide (Cc), glyburide (Cd), and glucose (Cg) serum concentrations is successfully described by operator equations of the form, Cc(t) = t-infinity psi p(t-u)phi t(Cd(u), Cg(u)) du or Cc(t) = t-infinity psi p(t-u)phi t(Cd(u), Cg(u),u) du.	cysteinylglycine	82-84	insulin	Homo sapiens	37-46
2885102-1	1987	The effect of carcinogen treatment on gamma-glutamyl transpeptidase (GGT)-mediated hydrolysis of GSH to glutamate and cysteinylglycine in the blood and bile compartments was investigated in livers perfused in situ.	cysteinylglycine	118-134	gamma-glutamyltransferase 1	Rattus norvegicus	69-72
3030765-0	1987	Effect on blood pressure and the renin-angiotensin system of repeated doses of the converting enzyme inhibitor CGS 14824A.	cysteinylglycine	111-114	renin	Homo sapiens	33-38
3040985-3	1987	Chronic intracerebroventricular infusion of the purified TRH antibody markedly increased the length of pentobarbitone-induced sleep-time while enhancing the effects of CG 3509 both on locomotor activity and pentobarbitone-induced sleep.	cysteinylglycine	168-170	thyrotropin releasing hormone	Homo sapiens	57-60
3030582-8	1987	The method can also be used to assay two other ACE inhibitors, pentopril and CGS 14831, demonstrating that the method can be readily adapted to any ACE inhibitor having a single active component in plasma.	cysteinylglycine	77-80	angiotensin I converting enzyme	Homo sapiens	47-50
3030582-8	1987	The method can also be used to assay two other ACE inhibitors, pentopril and CGS 14831, demonstrating that the method can be readily adapted to any ACE inhibitor having a single active component in plasma.	cysteinylglycine	77-80	angiotensin I converting enzyme	Homo sapiens	148-151
3030765-1	1987	A new, orally active angiotensin converting enzyme (ACE) inhibitor, CGS 14824A, was evaluated in 12 healthy male volunteers.	cysteinylglycine	68-71	angiotensin I converting enzyme	Homo sapiens	21-50
3030765-1	1987	A new, orally active angiotensin converting enzyme (ACE) inhibitor, CGS 14824A, was evaluated in 12 healthy male volunteers.	cysteinylglycine	68-71	angiotensin I converting enzyme	Homo sapiens	52-55
2867670-3	1985	Cysteinylglycine, the first metabolite in the glutathione breakdown by gamma-glutamyltranspeptidase, showed a rapid and equimolar reactivity to acetaldehyde and such was comparable to the reaction seen with L-cysteine or D-penicillamine.	cysteinylglycine	0-16	inactive glutathione hydrolase 2	Homo sapiens	71-99
3089541-2	1986	for two weeks and the reversal of pentobarbital-induced anaesthesia, hypothermia and respiratory depression by central administration of a TRH analogue (CG 3509) was measured.	cysteinylglycine	153-155	thyrotropin releasing hormone	Rattus norvegicus	139-142
2867670-0	1985	Conjugation of acetaldehyde with cysteinylglycine, the first metabolite in glutathione breakdown by gamma-glutamyltranspeptidase.	cysteinylglycine	33-49	inactive glutathione hydrolase 2	Homo sapiens	100-128
6150096-1	1984	A simple in-vitro enzyme system has been used to demonstrate that human angiotensin I interacts competitively with the two non-thiol converting enzyme inhibitors CGS 13934 and MK-422 to inhibit the hydrolysis of a synthetic substrate by human plasma ACE.	cysteinylglycine	162-165	angiotensinogen	Homo sapiens	72-85
2988972-4	1985	CGS 14824A 5 mg reduced the response to angiotensin I within 75 min to 50%, and 10 mg within 1 h to less than 25%, and for a period of more than 4 h. Subsequently, plasma renin and converting enzyme activity, plasma angiotensin I, angiotensin II and aldosterone were measured serially before and up to 72 h following oral administration of 2, 5, 10 or 20 mg CGS 14824A to groups of 5 volunteers.	cysteinylglycine	0-3	angiotensinogen	Homo sapiens	40-53
6150096-1	1984	A simple in-vitro enzyme system has been used to demonstrate that human angiotensin I interacts competitively with the two non-thiol converting enzyme inhibitors CGS 13934 and MK-422 to inhibit the hydrolysis of a synthetic substrate by human plasma ACE.	cysteinylglycine	162-165	angiotensin I converting enzyme	Homo sapiens	250-253
6468729-5	1984	Limited proteolysis within the membrane phase was, however, indicated by the shift towards dominance of the intermediate hydrophobic DBH in the buffer-dialysed CG.	cysteinylglycine	160-162	dopamine beta-hydroxylase	Bos taurus	133-136
6353423-0	1983	Role of renin release in the hemodynamic, renal and dipsogenic actions of the prostacyclin analogue CG 4203 in conscious rats.	cysteinylglycine	100-102	renin	Rattus norvegicus	8-13
6353423-2	1983	CG 4203 infused intravenously starting at 1 microgram X kg-1 X min-1 induced both a fall in blood pressure and an increase of plasma renin activity.	cysteinylglycine	0-2	renin	Rattus norvegicus	133-138
6353423-3	1983	The angiotensin II antagonist saralasine infused simultaneously intensified the hypotensive effect of CG 4203 (1.0 microgram X kg-1 X min-1).	cysteinylglycine	102-104	angiotensinogen	Rattus norvegicus	4-18
6353423-7	1983	In conclusion, it is demonstrated that CG 4203 like prostacyclin itself already at hypotensive threshold dosages stimulates a functionally relevant renin release.	cysteinylglycine	39-41	renin	Rattus norvegicus	148-153
6353423-8	1983	The activation of the renin-angiotensin-aldosterone system attenuates the intrinsic hypotensive effects of CG 4203. the antidiuretic and dipsogenic efficacy of CG 4203 can also be attributed to renin-dependent angiotensin II formation.	cysteinylglycine	107-109	renin	Rattus norvegicus	22-27
6353423-8	1983	The activation of the renin-angiotensin-aldosterone system attenuates the intrinsic hypotensive effects of CG 4203. the antidiuretic and dipsogenic efficacy of CG 4203 can also be attributed to renin-dependent angiotensin II formation.	cysteinylglycine	107-109	renin	Rattus norvegicus	194-199
6353423-8	1983	The activation of the renin-angiotensin-aldosterone system attenuates the intrinsic hypotensive effects of CG 4203. the antidiuretic and dipsogenic efficacy of CG 4203 can also be attributed to renin-dependent angiotensin II formation.	cysteinylglycine	107-109	angiotensinogen	Rattus norvegicus	210-224
6353423-8	1983	The activation of the renin-angiotensin-aldosterone system attenuates the intrinsic hypotensive effects of CG 4203. the antidiuretic and dipsogenic efficacy of CG 4203 can also be attributed to renin-dependent angiotensin II formation.	cysteinylglycine	160-162	renin	Rattus norvegicus	22-27
6353423-8	1983	The activation of the renin-angiotensin-aldosterone system attenuates the intrinsic hypotensive effects of CG 4203. the antidiuretic and dipsogenic efficacy of CG 4203 can also be attributed to renin-dependent angiotensin II formation.	cysteinylglycine	160-162	renin	Rattus norvegicus	194-199
6353423-8	1983	The activation of the renin-angiotensin-aldosterone system attenuates the intrinsic hypotensive effects of CG 4203. the antidiuretic and dipsogenic efficacy of CG 4203 can also be attributed to renin-dependent angiotensin II formation.	cysteinylglycine	160-162	angiotensinogen	Rattus norvegicus	210-224
6133861-1	1983	Glycine and taurine conjugates of bile acids modulate gamma-glutamyl transpeptidase by interacting with the cysteinylglycine binding site (acceptor site) of the enzyme.	cysteinylglycine	108-124	inactive glutathione hydrolase 2	Homo sapiens	54-83
6126478-1	1982	Characterization of a particulate rat renal dipeptidase that catalyzes the hydrolysis of cysteinylglycine.	cysteinylglycine	89-105	dipeptidase 1	Rattus norvegicus	38-55
6102993-2	1980	The apparent glutathione oxidase activity of gamma-glutamyl transpeptidase is due to nonenzymatic oxidation and transhydrogenation reactions of cysteinylglycine, an enzymatic product formed from glutathione by hydrolysis or autotranspeptidation.	cysteinylglycine	144-160	gamma-glutamyltransferase 1	Rattus norvegicus	45-74
6797955-1	1981	The effect of clomiphene citrate (CG) on sex hormone binding globulin (SHBG) was studied in 10 oligozoospermic patients with varicocele and 6 normospermic men.	cysteinylglycine	34-36	sex hormone binding globulin	Homo sapiens	41-69
6797955-1	1981	The effect of clomiphene citrate (CG) on sex hormone binding globulin (SHBG) was studied in 10 oligozoospermic patients with varicocele and 6 normospermic men.	cysteinylglycine	34-36	sex hormone binding globulin	Homo sapiens	71-75
6118826-1	1981	gamma-Glutamyl transpeptidase catalyzes transfer of the gamma-glutamyl moiety of glutathione to amino acids, dipeptides, and to glutathione itself; the enzyme also catalyzes the hydrolysis of glutathione to glutamate and cysteinyl-glycine.	cysteinylglycine	221-238	inactive glutathione hydrolase 2	Homo sapiens	0-29
7198474-2	1981	administration of 14C-labelled rac.-1-(e)-(m-methoxyphenyl)-2-(e)-dimethylaminomethyl-cyclohexan-1-(a)-ol hydrochloride (tramadol hydrochloride, CG 315, Tramal) to mice, hamsters, rats, guinea pigs, rabbits, dogs and man the metabolic pathways were investigated and the results compared.	cysteinylglycine	145-147	Rac family small GTPase 1	Mus musculus	31-37
7332869-3	1981	Excess iron, after saturation of the transferrin iron-binding sites with 55Fe, supplied as Fe-citrate, was efficiently removed by its binding to Amberlite CG-400 anion-exchange resin.	cysteinylglycine	155-157	transferrin	Mus musculus	37-48
7260258-3	1980	The anisotropy of the volume susceptibilities of frog rhodopsin is calculated to be 4.4 X 10(-8) cgs unit/cm3, which corresponds to 1.5 X 10(-27) cgs unit/molecule, or 9.0 X 10(-4) cgs unit/mol.	cysteinylglycine	97-100	rhodopsin	Homo sapiens	54-63
7404574-3	1980	Ion-exchange resin, CG-50, H+ form, packed in a small column (diameter 4 mm, height 6 mm), was proved effective to remove the interfering substances and to concentrate the AVP in the sample.	cysteinylglycine	20-22	arginine vasopressin	Homo sapiens	172-175
7260258-3	1980	The anisotropy of the volume susceptibilities of frog rhodopsin is calculated to be 4.4 X 10(-8) cgs unit/cm3, which corresponds to 1.5 X 10(-27) cgs unit/molecule, or 9.0 X 10(-4) cgs unit/mol.	cysteinylglycine	146-149	rhodopsin	Homo sapiens	54-63
7260258-3	1980	The anisotropy of the volume susceptibilities of frog rhodopsin is calculated to be 4.4 X 10(-8) cgs unit/cm3, which corresponds to 1.5 X 10(-27) cgs unit/molecule, or 9.0 X 10(-4) cgs unit/mol.	cysteinylglycine	146-149	rhodopsin	Homo sapiens	54-63
716766-1	1978	The effect of insulin on the concentration of different glycosaminoglycan (CG) fractions was different in different segments of aorta.	cysteinylglycine	75-77	insulin	Oryctolagus cuniculus	14-21
44298-1	1979	A highly sensitive assay for tyrosine hydroxylase (TH) activity by high-performance liquid chromatography (HPLC) with amperometric detection was devised based on the rapid isolation of enzymatically formed DOPA by a double-column procedure, the columns fitted together sequentially (the top column of Amberlite CG-50 and the bottom column of aluminium oxide).	cysteinylglycine	311-313	tyrosine hydroxylase	Homo sapiens	51-53
219006-3	1979	The hEGF/hUG in homogenates of human salivary glands and a wide variety of other endocrine and nonendocrine tissues was extracted by Amberlite CG-50 cation exchange chromatography and immune affinity chromatography using the immunoglobulin fraction of rabbit anti-hEGF serum covalently bound to agarose.	cysteinylglycine	143-145	epidermal growth factor	Homo sapiens	4-8
9762154-1	1978	The compound para-nitrobenzyloxycarbonylglycyl-(S-4-nitrobenzo-2-oxa- 1,3-diazole)-L-cysteinylglycine [NO2ZGly(S-NBD)CysGly] with an absorption maximum at 423 nm is readily hydrolyzed by angiotensin-converting enzyme (EC 3.4.15.1. peptidlyldipeptide hydrolase) to yield the S-benzfurazan derivative of cysteinylglycine.	cysteinylglycine	85-101	angiotensin I converting enzyme	Homo sapiens	187-216
44298-1	1979	A highly sensitive assay for tyrosine hydroxylase (TH) activity by high-performance liquid chromatography (HPLC) with amperometric detection was devised based on the rapid isolation of enzymatically formed DOPA by a double-column procedure, the columns fitted together sequentially (the top column of Amberlite CG-50 and the bottom column of aluminium oxide).	cysteinylglycine	311-313	tyrosine hydroxylase	Homo sapiens	29-49
701473-7	1978	When CIG was quantified by electroimmunoassay, intact lung parenchyma contained  approximately equal to 0.4% CIG, ASG contained 3-4.5% CIG, ABM contained 0.1-0.9% CIG and TBM contained 1.5%-7.2% Cg.	cysteinylglycine	195-197	fibronectin 1	Homo sapiens	5-8
33187988-0	2021	Crystal structures of glutathione- and inhibitor-bound human GGT1: Critical interactions within the cysteinylglycine binding site.	cysteinylglycine	100-116	gamma-glutamyltransferase 1	Homo sapiens	61-65
331268-8	1977	This clear difference in U54 reactivity, together with the identification of an extra A60:U54 pair in the U psi CG containing fragment suggests the presence of a 6 base pair T psi C stem and a 5 nucleotide T psi C loop in this tRNA.	cysteinylglycine	112-114	small nucleolar RNA, C/D box 54	Homo sapiens	90-93
32126843-5	2021	Catechins bearing the galloyl moiety (CG, ECG, GCG, and EGCG) exerted potent inhibition of TGF-beta-induced cell migration as well as EMT, and inhibited VM, in part through inhibition of Snail and matrix metalloproteinase-2 secretion.Conclusions: Our data suggest that diet-derived catechins exhibit chemopreventive properties that circumvent the TGF-beta-mediated signaling which contributes to the ovarian cancer metastatic phenotype.	cysteinylglycine	38-40	transforming growth factor alpha	Homo sapiens	91-99
32126843-5	2021	Catechins bearing the galloyl moiety (CG, ECG, GCG, and EGCG) exerted potent inhibition of TGF-beta-induced cell migration as well as EMT, and inhibited VM, in part through inhibition of Snail and matrix metalloproteinase-2 secretion.Conclusions: Our data suggest that diet-derived catechins exhibit chemopreventive properties that circumvent the TGF-beta-mediated signaling which contributes to the ovarian cancer metastatic phenotype.	cysteinylglycine	38-40	snail family transcriptional repressor 1	Homo sapiens	187-192
32126843-5	2021	Catechins bearing the galloyl moiety (CG, ECG, GCG, and EGCG) exerted potent inhibition of TGF-beta-induced cell migration as well as EMT, and inhibited VM, in part through inhibition of Snail and matrix metalloproteinase-2 secretion.Conclusions: Our data suggest that diet-derived catechins exhibit chemopreventive properties that circumvent the TGF-beta-mediated signaling which contributes to the ovarian cancer metastatic phenotype.	cysteinylglycine	38-40	matrix metallopeptidase 2	Homo sapiens	197-223
32126843-5	2021	Catechins bearing the galloyl moiety (CG, ECG, GCG, and EGCG) exerted potent inhibition of TGF-beta-induced cell migration as well as EMT, and inhibited VM, in part through inhibition of Snail and matrix metalloproteinase-2 secretion.Conclusions: Our data suggest that diet-derived catechins exhibit chemopreventive properties that circumvent the TGF-beta-mediated signaling which contributes to the ovarian cancer metastatic phenotype.	cysteinylglycine	38-40	transforming growth factor alpha	Homo sapiens	347-355
33187988-3	2021	To enhance our understanding of themolecular mechanism of substrate cleavage, wehave solved the crystal structures of humanGGT1 (hGGT1) with glutathione (a substrate)and a phosphate-glutathione analog (anirreversible inhibitor) bound in the active site.These are the first structures of any eukaryoticGGT with the cysteinylglycine region of thesubstrate-binding site occupied.	cysteinylglycine	314-330	gamma-glutamyltransferase 1	Homo sapiens	129-134
31677195-6	2020	Cytokeratin-18 M30 (AUROC = 0.688) and M65 (AUROC = 0.678) had suboptimal performance for diagnosing nonalcoholic steatohepatitis in the CG + GG group, whereas both had good performance (AUROC = 0.814 and 0.813, respectively) in the CC group.	cysteinylglycine	137-139	keratin 18	Homo sapiens	0-14
32124388-6	2020	Competition dopamine receptor binding experiments demonstrated that in the acute cocaine group, the A2AR agonist CGS-21680 produced significantly larger increases in the D2R Ki, High values (reduction of high-affinity) versus the saline-injected (i.e. control) group.	cysteinylglycine	113-116	adenosine A2a receptor	Rattus norvegicus	100-104
32233050-8	2020	Women harbouring the variant G allele of the TP53 rs1042522 were at increased risk of cervical cancer in allelic (G vs. C; OR = 1.30, 95% Cl = 1.12-1.50), homozygous (GG vs. CC; OR=1.62, 95% CI = 1.20-2.19), and recessive (GG vs.CG+GG; OR=1.74, 95% CI = 1.34-2.25) genetic models.	cysteinylglycine	229-231	tumor protein p53	Homo sapiens	45-49
31998439-4	2020	Some lines of evidence show that the prooxidant environment present in atherosclerotic tissue could modify filtered proteins also by protein-SH group oxidation, and demonstrate that particularly albumin, once filtered, represents a harmful source of homocysteine and cysteinylglycine inside the plaque.	cysteinylglycine	267-283	albumin	Homo sapiens	195-202
31688113-8	2020	RESULTS: Adipocytes in the collagen fibers appeared at 3 weeks, and a zonal fat layer was noted under the panniculus carnosus at 4 weeks in the FGF-2-combined CGS groups.	cysteinylglycine	159-162	fibroblast growth factor 2	Mus musculus	144-149
31878259-2	2019	Among human GSH degradation enzymes, the ChaC2 enzyme acts on GSH to form 5-l-oxoproline and Cys-Gly specifically in the cytosol.	cysteinylglycine	93-100	ChaC glutathione specific gamma-glutamylcyclotransferase 2	Homo sapiens	41-46
30981681-10	2020	After Diet P, in the group of subjects without G allele CC, insulin levels (delta: -2.9 +- 1.0 UI/L vs. -0.6 +- 0.2 UI/L: P <.05) and HOMA-IR (delta (CC vs. CG + GG): -0.8 +- 0.2 units vs. -0.4 +- 0.3 units: P <.05) decreased, too.	cysteinylglycine	160-162	insulin	Homo sapiens	60-67
31878957-5	2019	RESULTS: Significant methylation changes were observed in three CRTC1 CpG sites (i.e., cg07015183, cg12034943, and cg 17006757) in patients with early and important weight gain (i.e., equal or higher than 5% after 1 month; FDR p value = 0.02).	cysteinylglycine	87-89	CREB regulated transcription coactivator 1	Homo sapiens	64-69
31311430-7	2019	Results indicate significant differences in the MeG with respect to the experience that was salient to them (e.g., MDD group - sadness; SP group - social anxiety; CG group - happiness).	cysteinylglycine	163-165	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	48-51
31486299-5	2019	Fluoride release (N = 10) was evaluated in CG, SG and UG after cariogenic challenge for 11 days.	cysteinylglycine	43-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-24
30264643-6	2019	RESULTS: The concentration of adiponectin in the accAN was higher than in the CG (P = 0.05) and increased in recAN (P = 0.01).	cysteinylglycine	78-80	adiponectin, C1Q and collagen domain containing	Homo sapiens	30-41
31724726-8	2019	An analysis of variance revealed that patients with the AGO2 rs2292779C>G genotypes (CC: 6.52 +- 2.55; CG: 7.46 +- 3.02; GG: 8.42 +- 2.74; P = 0.044) and the dominant model (CC: 6.52 +- 2.55; CG+GG: 7.70 +- 2.97; P = 0.029) exhibited significantly increased white blood cell levels.	cysteinylglycine	103-105	argonaute RISC catalytic component 2	Homo sapiens	56-60
31724726-8	2019	An analysis of variance revealed that patients with the AGO2 rs2292779C>G genotypes (CC: 6.52 +- 2.55; CG: 7.46 +- 3.02; GG: 8.42 +- 2.74; P = 0.044) and the dominant model (CC: 6.52 +- 2.55; CG+GG: 7.70 +- 2.97; P = 0.029) exhibited significantly increased white blood cell levels.	cysteinylglycine	192-194	argonaute RISC catalytic component 2	Homo sapiens	56-60
31758001-3	2019	We have demonstrated that alpha-SNAP -and its functional partner NSF- mediate fusion of CGs with the plasma membrane in mouse oocytes.	cysteinylglycine	88-91	N-ethylmaleimide sensitive fusion protein attachment protein alpha	Mus musculus	26-36
31758001-3	2019	We have demonstrated that alpha-SNAP -and its functional partner NSF- mediate fusion of CGs with the plasma membrane in mouse oocytes.	cysteinylglycine	88-91	N-ethylmaleimide sensitive fusion protein	Mus musculus	65-68
31451183-10	2019	The "C"allele of IL-6 rs1800797 was implicated with higher prevalence of DN (C versus G: P = 0.0001; CC versus GG: P = 0.0003; CC versus GG + CG: P = 0.0227; CC + CG versus GG: P = 0.0001) while IL-6 rs2069837 and rs2069840 were not correlated with the susceptibility to DN.	cysteinylglycine	142-144	interleukin 6	Homo sapiens	17-21
31451183-10	2019	The "C"allele of IL-6 rs1800797 was implicated with higher prevalence of DN (C versus G: P = 0.0001; CC versus GG: P = 0.0003; CC versus GG + CG: P = 0.0227; CC + CG versus GG: P = 0.0001) while IL-6 rs2069837 and rs2069840 were not correlated with the susceptibility to DN.	cysteinylglycine	163-165	interleukin 6	Homo sapiens	17-21
31702992-15	2019	After 4 weeks, the concentration of IL-10 decreased in all groups (AG: 9.8%, CG: 38.54%, PG: 27.42%), but the decrease was smaller in the AG than CG group (P = .0046).	cysteinylglycine	77-79	interleukin 10	Homo sapiens	36-41
31702992-15	2019	After 4 weeks, the concentration of IL-10 decreased in all groups (AG: 9.8%, CG: 38.54%, PG: 27.42%), but the decrease was smaller in the AG than CG group (P = .0046).	cysteinylglycine	146-148	interleukin 10	Homo sapiens	36-41
31702992-16	2019	The ratio of pro-inflammatory IL-10 to anti-inflammatory TNF-alpha increased 27.29% in the AG and decreased 26.79% in the CG and 18.56% in the PG groups.	cysteinylglycine	122-124	interleukin 10	Homo sapiens	30-35
31702992-16	2019	The ratio of pro-inflammatory IL-10 to anti-inflammatory TNF-alpha increased 27.29% in the AG and decreased 26.79% in the CG and 18.56% in the PG groups.	cysteinylglycine	122-124	tumor necrosis factor	Homo sapiens	57-66
31311430-9	2019	This study demonstrated the presence of a MeG in individuals in a MDD, SP, and CG group and in positive and negative affective experiences.	cysteinylglycine	79-81	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	42-45
31527889-7	2019	PNPLA3 G allele increased the risk of LT for CLF in both allelic and recessive models (CG + GG vs. CC: OR, 1.90; 95% CI, 1.017-3.472, P = 0.045 and GG vs. CC + CG: OR, 2.94; 95% CI, 1.032-7.513, P = 0.042).	cysteinylglycine	87-89	patatin like phospholipase domain containing 3	Homo sapiens	0-6
29209987-9	2019	OGG1 presented a high risk towards lung cancer (CG: OR = 2.44, p = 0.0003; CG + GG: OR = 1.88, p = 0.0093).	cysteinylglycine	48-50	8-oxoguanine DNA glycosylase	Homo sapiens	0-4
29209987-9	2019	OGG1 presented a high risk towards lung cancer (CG: OR = 2.44, p = 0.0003; CG + GG: OR = 1.88, p = 0.0093).	cysteinylglycine	75-77	8-oxoguanine DNA glycosylase	Homo sapiens	0-4
29209987-10	2019	On the same lines adenocarcinoma for OGG1 were potent risk factors towards lung cancer (CG: OR = 4.72, p = 0.0002; CG + GG: OR = 3.63, p = 0.0018).	cysteinylglycine	88-90	8-oxoguanine DNA glycosylase	Homo sapiens	37-41
29209987-10	2019	On the same lines adenocarcinoma for OGG1 were potent risk factors towards lung cancer (CG: OR = 4.72, p = 0.0002; CG + GG: OR = 3.63, p = 0.0018).	cysteinylglycine	115-117	8-oxoguanine DNA glycosylase	Homo sapiens	37-41
31325764-7	2019	We found that both TP53 Arg72Pro (CG/GG vs. CC: adjusted OR = 0.82, 95% CI = 0.69-0.98) and miR-34b/c rs4938723 (TC/CC vs. TT: adjusted OR = 0.64, 95% CI = 0.54-0.75) were associated with decreased neuroblastoma susceptibility.	cysteinylglycine	34-36	tumor protein p53	Homo sapiens	19-23
31527889-7	2019	PNPLA3 G allele increased the risk of LT for CLF in both allelic and recessive models (CG + GG vs. CC: OR, 1.90; 95% CI, 1.017-3.472, P = 0.045 and GG vs. CC + CG: OR, 2.94; 95% CI, 1.032-7.513, P = 0.042).	cysteinylglycine	160-162	patatin like phospholipase domain containing 3	Homo sapiens	0-6
31144443-5	2019	The total number of CGS-derived CpG dinucleotides in the window near MS4A4A was associated with AD risk (p = 2.67 x 10-10 ), brain DNA methylation (p = 2.15 x 10-10 ), and gene expression in brain (p = 0.03) and blood (p = 2.53 x 10-4 ).	cysteinylglycine	20-23	membrane spanning 4-domains A4A	Homo sapiens	69-75
31326566-6	2019	KEY FINDINGS: The results showed that treatment with CG could significantly stimulate hAMSC ALP activity and calcium deposition compared to treatment with DAG, while HA had little effect.	cysteinylglycine	53-55	alkaline phosphatase, placental	Homo sapiens	92-95
31326566-8	2019	In addition, treatment with CG significantly increased the gene expressions involved in regulation of the TGF-beta/Smad signalling pathway compared to treatment with DAG.	cysteinylglycine	28-30	transforming growth factor beta 1	Homo sapiens	106-114
31326566-9	2019	Furthermore, the pro-osteogenic differentiation effects as well as the up-regulated expression of genes observed in the CG treatment group were significantly inhibited when the cells were pre-treated with SB431542, an inhibitor of the TGF-beta/Smad pathway.	cysteinylglycine	120-122	transforming growth factor beta 1	Homo sapiens	235-243
31516760-8	2019	On the other hand, significant changes were found for DBP after 24 hours for the CG (P = 0.007) and AEG (P = 0.015).	cysteinylglycine	81-83	D-box binding PAR bZIP transcription factor	Homo sapiens	54-57
31521144-7	2019	Furthermore, AURKC rs11084490 (GG + CG vs. CC: OR, 1.71; 95% CI, 1.04-2.81; p = 0.033) was associated with increased GC risk.	cysteinylglycine	36-38	aurora kinase C	Homo sapiens	13-18
31331996-5	2019	The effect of ATMS1 on chromatin silencing is related to decreased levels of DNA methylation (CG, CHG, and CHH) and histone-3 lysine-9 dimethylation.	cysteinylglycine	94-96	Cobalamin-independent synthase family protein	Arabidopsis thaliana	14-19
30980593-0	2019	Structural analyses reveal that MBD3 is a methylated CG binder.	cysteinylglycine	53-55	methyl-CpG binding domain protein 3	Homo sapiens	32-36
30980593-2	2019	Recent reports show that MBD3 recognizes both methylated CG (mCG)- and hydroxymethylated CG (hmCG)-containing DNA, with a preference for hmCG.	cysteinylglycine	57-59	methyl-CpG binding domain protein 3	Homo sapiens	25-29
30980593-2	2019	Recent reports show that MBD3 recognizes both methylated CG (mCG)- and hydroxymethylated CG (hmCG)-containing DNA, with a preference for hmCG.	cysteinylglycine	62-64	methyl-CpG binding domain protein 3	Homo sapiens	25-29
30317605-6	2019	Bioinformatics analysis indicated that the 5" upstream region of NANOG-ch5 does not have typical CpG islands but contains several CG enrichment regions and several LIN28A binding sites.	cysteinylglycine	130-132	Nanog homeobox	Capra hircus	65-70
31281467-5	2019	We found that after adjusting for other covariates, NSCLC patients who smoked and who respectively had CG, CT, and TC heterozygotes of HMGB1 rs2249825, rs1045411, and rs1360485, were at lower risk of developing mutant EGFR, compared to those patients with wild-type homozygotes.	cysteinylglycine	103-105	high mobility group box 1	Homo sapiens	135-140
31281467-6	2019	Moreover, significant inverse associations between the CG and CG + GG genotypes of HMGB1 rs2249825 and the EGFR hotspot mutation, an exon 19 in-frame deletion, were also observed among NSCLC patients.	cysteinylglycine	55-57	high mobility group box 1	Homo sapiens	83-88
31281467-6	2019	Moreover, significant inverse associations between the CG and CG + GG genotypes of HMGB1 rs2249825 and the EGFR hotspot mutation, an exon 19 in-frame deletion, were also observed among NSCLC patients.	cysteinylglycine	55-57	epidermal growth factor receptor	Homo sapiens	107-111
31281467-6	2019	Moreover, significant inverse associations between the CG and CG + GG genotypes of HMGB1 rs2249825 and the EGFR hotspot mutation, an exon 19 in-frame deletion, were also observed among NSCLC patients.	cysteinylglycine	62-64	high mobility group box 1	Homo sapiens	83-88
31281467-6	2019	Moreover, significant inverse associations between the CG and CG + GG genotypes of HMGB1 rs2249825 and the EGFR hotspot mutation, an exon 19 in-frame deletion, were also observed among NSCLC patients.	cysteinylglycine	62-64	epidermal growth factor receptor	Homo sapiens	107-111
31210340-8	2019	The expression levels of c-Jun, a component of activator protein-1 (AP-1), and gamma-glutamylcysteine synthetase (gamma-GCS), the rate-limiting enzyme in the synthesis of glutathione (gamma-glutamyl-cysteinyl-glycine, GSH), an endogenous antioxidant, were measured with immunohistochemical staining and in situ hybridization.	cysteinylglycine	198-216	glutamate-cysteine ligase, catalytic subunit	Rattus norvegicus	114-123
31370295-7	2019	Additionally, N-cadherin and vimentin expression were lowered significantly by the treatment of CG-745.	cysteinylglycine	96-98	cadherin 2	Mus musculus	14-24
31370295-7	2019	Additionally, N-cadherin and vimentin expression were lowered significantly by the treatment of CG-745.	cysteinylglycine	96-98	vimentin	Mus musculus	29-37
31144980-6	2019	There was a higher prevalence of AA (86.9%), CG (51.1%) and AT (46.2%) genotypes for the PCSK9, INSIG2 and FTO polymorphisms, respectively.	cysteinylglycine	45-47	proprotein convertase subtilisin/kexin type 9	Homo sapiens	89-94
31133247-7	2019	The bioinformatics predictive analysis were found that the -1546 CG site was located in the CCAAT/enhancer-binding protein alpha (CEBPA) binding site and the -1464 CG site was located in the Sp1 binding site.	cysteinylglycine	65-67	CCAAT/enhancer-binding protein alpha	Ovis aries	92-128
30877508-10	2019	MEPC and alkaloid PC-1 demonstrated an anti-edematogenic effect in Cg-induced paw edema in 2 and 4 h, and also significantly reduced mechanical hyperalgesia, cold response to acetone in mice, at 3 and 4 h after injection, as well as leukocyte migrationin the pleurisy model.	cysteinylglycine	67-69	minisatellite 6 hypermutable	Mus musculus	18-22
30517775-9	2019	In male participants, reduced susceptibility to periodontitis was observed in carriers of TLR7-rs3853839 (CC versus GG and CG, P = 0.02, OR 0.30, 95% CI 0.11-0.85) and TLR8-rs3764879 (CC versus GG and CG, P = 0.02, OR 0.31, 95% CI 0.12-0.82).	cysteinylglycine	123-125	toll like receptor 7	Homo sapiens	90-94
30517775-9	2019	In male participants, reduced susceptibility to periodontitis was observed in carriers of TLR7-rs3853839 (CC versus GG and CG, P = 0.02, OR 0.30, 95% CI 0.11-0.85) and TLR8-rs3764879 (CC versus GG and CG, P = 0.02, OR 0.31, 95% CI 0.12-0.82).	cysteinylglycine	123-125	toll like receptor 8	Homo sapiens	168-172
30517775-9	2019	In male participants, reduced susceptibility to periodontitis was observed in carriers of TLR7-rs3853839 (CC versus GG and CG, P = 0.02, OR 0.30, 95% CI 0.11-0.85) and TLR8-rs3764879 (CC versus GG and CG, P = 0.02, OR 0.31, 95% CI 0.12-0.82).	cysteinylglycine	201-203	toll like receptor 7	Homo sapiens	90-94
31133247-7	2019	The bioinformatics predictive analysis were found that the -1546 CG site was located in the CCAAT/enhancer-binding protein alpha (CEBPA) binding site and the -1464 CG site was located in the Sp1 binding site.	cysteinylglycine	65-67	CCAAT/enhancer-binding protein alpha	Ovis aries	130-135
31089070-7	2019	In the animal model of liver fibrosis, all doses of volatile oil of CG significantly reduced the serum levels of AST, ALT, MDA, Hyp, gamma-GT, LDH, ALP, and Alb.	cysteinylglycine	68-70	gamma-glutamyltransferase 1	Rattus norvegicus	133-141
31089070-7	2019	In the animal model of liver fibrosis, all doses of volatile oil of CG significantly reduced the serum levels of AST, ALT, MDA, Hyp, gamma-GT, LDH, ALP, and Alb.	cysteinylglycine	68-70	albumin	Rattus norvegicus	157-160
30300034-11	2019	In addition, a positive association between IL-6 rs1800796 and the risk of chronic periodontitis was detected under the models of allele [G vs. C], GG vs. CC, GG vs. CC+ CG and carrier [G vs. C] (all P < 0.05, OR > 1).	cysteinylglycine	170-172	interleukin 6	Homo sapiens	44-48
30185085-4	2019	TNF-alpha (10 ng/mL, 24 h) depleted reduced glutathione (GSH) and eNOS levels, increased reactive oxygen species (ROS) production, glutathione peroxidase (GPx) and reductase (GR) activities, and protein oxidation (carbonyl groups, CG) in EA.hy926 cells.	cysteinylglycine	231-233	tumor necrosis factor	Homo sapiens	0-9
30565027-4	2019	In GP synaptosomal membranes, H3R activation with immepip reduced A2AR affinity for the agonist 2-p-(2-carboxyethyl)phenethylamino-5"-N-ethylcarboxamidoadenosine hydrochloride hydrate (CGS-21680) (Ki control 4.53 nM; + immepip 9.32 nM), whereas A2AR activation increased H3R affinity for immepip (Ki control 0.63 nM; + CGS-21680 0.26 nM).	cysteinylglycine	185-188	adenosine A2a receptor	Rattus norvegicus	66-70
30565027-4	2019	In GP synaptosomal membranes, H3R activation with immepip reduced A2AR affinity for the agonist 2-p-(2-carboxyethyl)phenethylamino-5"-N-ethylcarboxamidoadenosine hydrochloride hydrate (CGS-21680) (Ki control 4.53 nM; + immepip 9.32 nM), whereas A2AR activation increased H3R affinity for immepip (Ki control 0.63 nM; + CGS-21680 0.26 nM).	cysteinylglycine	319-322	adenosine A2a receptor	Rattus norvegicus	66-70
30056659-7	2019	In addition, the increased concentrations of beta-hydroxybutyric acid, triglycerides, malondialdehyde, total antioxidant capacity and activities of superoxide dismutase activity and catalase were found in the RG1 group, and the concentrations of cholinesterase in the RG1 group were reduced compared with the CG group (p<0.05).	cysteinylglycine	309-311	protein phosphatase 1 regulatory subunit 3A	Homo sapiens	209-212
30738435-6	2019	The PNPLA3 I148M variant was significantly associated with the risk of NAFLD in an additive model (CG, OR = 2.092, 95% CI: 1.551-2.820, P = 0.000; GG, OR = 4.566, 95% CI: 3.141-6.638, P = 0.000, respectively).	cysteinylglycine	99-101	patatin like phospholipase domain containing 3	Homo sapiens	4-10
30621769-12	2019	Activation was strictly dependent on the presence of CG-motifs, known to be recognized by TLR9.	cysteinylglycine	53-55	toll-like receptor 9	Mus musculus	90-94
30236761-8	2019	RESULTS: CLA1 and CLA3 showed higher number of entries in the open arms and time spent in the central area in EPM, they translocated and ambulated more in the clear area of the LDB and presented more rearing in the OF compared to CG (p < 0.05); moreover, they presented higher concentration of glutathione and lower MDA in brain tissue (p < 0.05).	cysteinylglycine	230-232	spinocerebellar ataxia, autosomal recessive 2	Homo sapiens	9-13
30236761-8	2019	RESULTS: CLA1 and CLA3 showed higher number of entries in the open arms and time spent in the central area in EPM, they translocated and ambulated more in the clear area of the LDB and presented more rearing in the OF compared to CG (p < 0.05); moreover, they presented higher concentration of glutathione and lower MDA in brain tissue (p < 0.05).	cysteinylglycine	230-232	cerebellar ataxia, infantile nonprogressive, autosomal recessive	Homo sapiens	18-22
30307408-8	2019	Although the C-NHEJ defect alone did not cause CG hypomethylation, CDCA7 and HELLS are involved in maintaining CG methylation at centromeric and pericentromeric repeats.	cysteinylglycine	111-113	cell division cycle associated 7	Homo sapiens	67-72
30307408-8	2019	Although the C-NHEJ defect alone did not cause CG hypomethylation, CDCA7 and HELLS are involved in maintaining CG methylation at centromeric and pericentromeric repeats.	cysteinylglycine	111-113	helicase, lymphoid specific	Homo sapiens	77-82
31468389-6	2019	Cardiac angiotensin II levels significantly elevated in CG, TDW, and TDG.	cysteinylglycine	56-58	angiotensinogen	Rattus norvegicus	8-22
31054980-10	2019	CONCLUSION: We demonstrated for the first time that PNPLA3 CG+GG increase the risk of NAFLD among Brazilian subjects.	cysteinylglycine	59-61	patatin like phospholipase domain containing 3	Homo sapiens	52-58
31333000-6	2019	MTNR1beta gene polymorphism rs10830963 genotype in SLE patients showed that 50% had GG, 35% CG and 15% CC.	cysteinylglycine	92-94	melatonin receptor 1B	Homo sapiens	0-9
30043156-7	2019	In a genotype-phenotype correlation analysis using 24 normal left atrial appendage samples, increasing gradients of atrial RANKL expression levels positively correlated with atrial collagen volume fraction were identified in samples with CC, CG and GG genotypes.	cysteinylglycine	242-244	TNF superfamily member 11	Homo sapiens	123-128
30355852-8	2018	Seven CG sites in three genes CASZ1, CDH13 and ING2 were significantly hypermethylated in ESCC as compared with normal controls.	cysteinylglycine	6-8	castor zinc finger 1	Homo sapiens	30-35
30643822-9	2018	The IGFBP3 rs2854746 analyses showed the CG genotype having a protective effect for endometrial polyp (OR=0,37; IC 95%= 0,19-0,73), fact also observed when grouping CG and GG carriers (OR=0,51; IC 95%= 0,28-0,93).	cysteinylglycine	41-43	insulin like growth factor binding protein 3	Homo sapiens	4-10
30643822-9	2018	The IGFBP3 rs2854746 analyses showed the CG genotype having a protective effect for endometrial polyp (OR=0,37; IC 95%= 0,19-0,73), fact also observed when grouping CG and GG carriers (OR=0,51; IC 95%= 0,28-0,93).	cysteinylglycine	165-167	insulin like growth factor binding protein 3	Homo sapiens	4-10
30241868-3	2018	The range of E for CG-PVA/LBP/K film was 16.92~171.53 kJ/mol.	cysteinylglycine	19-21	lipopolysaccharide binding protein	Homo sapiens	26-29
30355852-8	2018	Seven CG sites in three genes CASZ1, CDH13 and ING2 were significantly hypermethylated in ESCC as compared with normal controls.	cysteinylglycine	6-8	cadherin 13	Homo sapiens	37-42
30355852-8	2018	Seven CG sites in three genes CASZ1, CDH13 and ING2 were significantly hypermethylated in ESCC as compared with normal controls.	cysteinylglycine	6-8	inhibitor of growth family member 2	Homo sapiens	47-51
30321140-7	2018	RESULTS The miR-146a C>G polymorphism was remarkably different (CC vs. CG+GG: P=0.027; CC+CG vs. GG: P=0.020; C vs. G: P=0.006).	cysteinylglycine	74-76	microRNA 146a	Homo sapiens	12-20
30446008-9	2018	CONCLUSIONS: Our findings highlight CMT3-SUVH4/KYP as the major pathway silencing the intragenic EK via inducing non-CG methylation.	cysteinylglycine	117-119	histone-lysine N-methyltransferase, H3 lysine-9 specific SUVH4-like protein	Arabidopsis thaliana	41-46
30446008-5	2018	Strong transcriptional activation of EK accompanied by significant reduction in non-CG methylation was found in cmt3 and kyp2, but not in ddm1 or RdDM mutants.	cysteinylglycine	84-86	chromomethylase 3	Arabidopsis thaliana	112-116
30446008-9	2018	CONCLUSIONS: Our findings highlight CMT3-SUVH4/KYP as the major pathway silencing the intragenic EK via inducing non-CG methylation.	cysteinylglycine	117-119	chromomethylase 3	Arabidopsis thaliana	36-40
30321140-7	2018	RESULTS The miR-146a C>G polymorphism was remarkably different (CC vs. CG+GG: P=0.027; CC+CG vs. GG: P=0.020; C vs. G: P=0.006).	cysteinylglycine	93-95	microRNA 146a	Homo sapiens	12-20
30099007-5	2018	The selective A2A receptor agonist CGS 21680 inhibited C3a-mediated degranulation, while the A2B and A3 receptor agonists BAY 60-6583 and IB-MECA, respectively, had no effect.	cysteinylglycine	35-38	complement C3	Homo sapiens	55-58
30106146-9	2018	CCR3 mRNA expression was not detected in the CCR3-/- and CCR3-/-AR groups, whereas expression levels in the AR group were markedly higher compared with expression in the CG group.	cysteinylglycine	170-172	chemokine (C-C motif) receptor 3	Mus musculus	0-4
30285664-6	2018	RESULTS: Combined analysis revealed that the lnc-LAMC2-1:1 rs2147578 C > G polymorphism was associated with increased neuroblastoma susceptibility (CG vs. CC: adjusted OR = 1.33, 95% CI = 1.01-1.75, P = 0.045; CG/GG vs. CC: adjusted OR = 1.34, 95% CI = 1.03-1.74, P = 0.028).	cysteinylglycine	151-153	laminin subunit gamma 2	Homo sapiens	49-54
30285664-6	2018	RESULTS: Combined analysis revealed that the lnc-LAMC2-1:1 rs2147578 C > G polymorphism was associated with increased neuroblastoma susceptibility (CG vs. CC: adjusted OR = 1.33, 95% CI = 1.01-1.75, P = 0.045; CG/GG vs. CC: adjusted OR = 1.34, 95% CI = 1.03-1.74, P = 0.028).	cysteinylglycine	213-215	laminin subunit gamma 2	Homo sapiens	49-54
30106146-10	2018	Compared with the CG-associated groups (i.e., the CG and CCR3-/-CG groups), the levels of EPO, ECP, MBP, IL-4, and IgE were significantly increased in the AR-associated groups (that is, R and CCR3-/-AR).	cysteinylglycine	18-20	chemokine (C-C motif) receptor 3	Mus musculus	57-61
30254599-8	2018	In vivo models have been replicated in vitro on primary microglial cell cultures exposed to A2aR agonist CGS-21680 or antagonist SCH-58261.	cysteinylglycine	105-108	adenosine A2a receptor	Rattus norvegicus	92-96
30254599-16	2018	In the same experimental conditions, a partial increased of M1 cytokines was observed in response to A2aR agonist CGS-21680.	cysteinylglycine	114-117	adenosine A2a receptor	Rattus norvegicus	101-105
30027138-6	2018	In addition, we found an association of the PNPLA3 rs738409 G allele with the presence of diabetes (22% versus 28% versus 58% for CC versus CG versus GG genotype, respectively; P = 0.02).	cysteinylglycine	140-142	patatin like phospholipase domain containing 3	Homo sapiens	44-50
30140027-7	2018	CG also alleviated dyslipidemia, ameliorated liver steatosis, increased the activity of serum lipase and alleviated inflammation.	cysteinylglycine	0-2	lipase, endothelial	Mus musculus	94-100
30140027-8	2018	The activities of liver pyruvate kinase and glucokinase as well as liver content of glycogen were increased after CG treatment.	cysteinylglycine	114-116	glucokinase	Mus musculus	44-55
30122956-4	2018	Results: We found that PPARG rs1801282 C>G polymorphism was correlated with a decreased susceptibility of HCC (CG vs CC, adjusted OR 0.47, 95% CI 0.27-0.82, P=0.007; CG/GG vs CC, adjusted OR 0.52, 95% CI 0.31-0.88, P=0.015).	cysteinylglycine	114-116	peroxisome proliferator activated receptor gamma	Homo sapiens	23-28
30122956-4	2018	Results: We found that PPARG rs1801282 C>G polymorphism was correlated with a decreased susceptibility of HCC (CG vs CC, adjusted OR 0.47, 95% CI 0.27-0.82, P=0.007; CG/GG vs CC, adjusted OR 0.52, 95% CI 0.31-0.88, P=0.015).	cysteinylglycine	169-171	peroxisome proliferator activated receptor gamma	Homo sapiens	23-28
29793048-6	2018	DNA methylation levels at specific CG sites within the NR3C1 exon 1F were related to childhood emotional abuse severity.	cysteinylglycine	35-37	nuclear receptor subfamily 3 group C member 1	Homo sapiens	55-60
31245744-6	2018	Our results suggest that chronic cold and low light stress (10 C, 150 mumol m-2 s-1) influences non-CG methylation to a greater degree in msh1 mutants compared to wild-type Col-0.	cysteinylglycine	100-102	MUTL protein homolog 1	Arabidopsis thaliana	138-142
29956501-5	2018	RESULTS: Nineteen CG sites were differentially methylated between women with obesity and with normal weight in CD4+ cells, 16 CG sites in CD8+ cells, and 0 CG sites in CD16+ neutrophils (q < 0.05).	cysteinylglycine	18-20	CD4 molecule	Homo sapiens	111-114
29956501-5	2018	RESULTS: Nineteen CG sites were differentially methylated between women with obesity and with normal weight in CD4+ cells, 16 CG sites in CD8+ cells, and 0 CG sites in CD16+ neutrophils (q < 0.05).	cysteinylglycine	18-20	Fc gamma receptor IIIa	Homo sapiens	168-172
30038710-5	2018	Results: The following frequency of occurrence of APEH gene was observed: CC: 37.1%, CG: 43.6% and GG: 19.3%.	cysteinylglycine	85-87	acylaminoacyl-peptide hydrolase	Homo sapiens	50-54
29977885-14	2018	The levels of miR-146b and miR-155 were higher in the CG group than in the AG group (P < 0.05).	cysteinylglycine	54-56	microRNA 146b	Homo sapiens	14-22
29977885-14	2018	The levels of miR-146b and miR-155 were higher in the CG group than in the AG group (P < 0.05).	cysteinylglycine	54-56	microRNA 155	Homo sapiens	27-34
29977885-15	2018	The levels of ROR-gammat (retinoic acid receptor-related orphan nuclear receptor gamma), FoxP3 (forkhead transcription factor), IL-10 (interleukin-11) and TGF-beta (transforming growth factor beta) were lower in the CG group than in the AG group (P < 0.05).	cysteinylglycine	216-218	interleukin 11	Homo sapiens	135-149
29977885-15	2018	The levels of ROR-gammat (retinoic acid receptor-related orphan nuclear receptor gamma), FoxP3 (forkhead transcription factor), IL-10 (interleukin-11) and TGF-beta (transforming growth factor beta) were lower in the CG group than in the AG group (P < 0.05).	cysteinylglycine	216-218	transforming growth factor beta 1	Homo sapiens	155-163
29977885-15	2018	The levels of ROR-gammat (retinoic acid receptor-related orphan nuclear receptor gamma), FoxP3 (forkhead transcription factor), IL-10 (interleukin-11) and TGF-beta (transforming growth factor beta) were lower in the CG group than in the AG group (P < 0.05).	cysteinylglycine	216-218	transforming growth factor beta 1	Homo sapiens	165-196
29256007-5	2018	RESULTS: IL-1beta decreased genomic methylation of human intestinal epithelial cells and induced demethylation at cg-specific sites at the promoter of pro-inflammatory genes IL6 and IL8; conversely it did not change the methylation of the IL10 promoter.	cysteinylglycine	114-116	interleukin 1 beta	Homo sapiens	9-17
29512780-7	2018	The A1R antagonist DPCPX (100 nM) and A2aR agonist CGS 21680 (100 nM) inhibited microglial activation, reduced the production of inflammatory cytokines and attenuated oligodendrocyte damage, along with elevating the levels of phosphorylated nuclear factor (NF)-kappaB and cyclic adenosine monophosphate response element binding protein (CREB).	cysteinylglycine	51-54	adenosine A2a receptor	Homo sapiens	38-42
29779017-6	2018	Pooled analysis indicated that the XPG rs17655 G>C polymorphism increased the risk of overall cancer (CC vs. GG: OR=1.10, 95% CI=1.00-1.20; CG vs. GG: OR=1.06, 95% CI=1.02-1.11; CG+CC vs. GG: OR=1.07, 95% CI=1.02-1.12; C vs. G: OR=1.05, 95% CI=1.01-1.09).	cysteinylglycine	143-145	ERCC excision repair 5, endonuclease	Homo sapiens	35-38
29779017-6	2018	Pooled analysis indicated that the XPG rs17655 G>C polymorphism increased the risk of overall cancer (CC vs. GG: OR=1.10, 95% CI=1.00-1.20; CG vs. GG: OR=1.06, 95% CI=1.02-1.11; CG+CC vs. GG: OR=1.07, 95% CI=1.02-1.12; C vs. G: OR=1.05, 95% CI=1.01-1.09).	cysteinylglycine	181-183	ERCC excision repair 5, endonuclease	Homo sapiens	35-38
29747660-5	2018	RESULTS: The frequencies of CC, CG and GG genotypes of the APOA1 rs964184 SNP were 68.86, 29.18 and 1.96% in the Maonan population, and 63.78, 30.85 and 5.37% in the Han population (P < 0.001).	cysteinylglycine	32-34	apolipoprotein A1	Homo sapiens	59-64
29476752-7	2018	Further study indicated that CPA and CGS-21680 treatment induced phosphorylation of extracellular signal-regulated kinase (ERK) and Akt, and CPA-induced or CGS-21680-induced cell proliferation was inhibited by ERK and Akt inhibitors.	cysteinylglycine	37-40	mitogen-activated protein kinase 1	Homo sapiens	84-121
29476752-7	2018	Further study indicated that CPA and CGS-21680 treatment induced phosphorylation of extracellular signal-regulated kinase (ERK) and Akt, and CPA-induced or CGS-21680-induced cell proliferation was inhibited by ERK and Akt inhibitors.	cysteinylglycine	37-40	mitogen-activated protein kinase 1	Homo sapiens	123-126
29476752-7	2018	Further study indicated that CPA and CGS-21680 treatment induced phosphorylation of extracellular signal-regulated kinase (ERK) and Akt, and CPA-induced or CGS-21680-induced cell proliferation was inhibited by ERK and Akt inhibitors.	cysteinylglycine	37-40	AKT serine/threonine kinase 1	Homo sapiens	132-135
29476752-7	2018	Further study indicated that CPA and CGS-21680 treatment induced phosphorylation of extracellular signal-regulated kinase (ERK) and Akt, and CPA-induced or CGS-21680-induced cell proliferation was inhibited by ERK and Akt inhibitors.	cysteinylglycine	37-40	mitogen-activated protein kinase 1	Homo sapiens	210-213
29476752-7	2018	Further study indicated that CPA and CGS-21680 treatment induced phosphorylation of extracellular signal-regulated kinase (ERK) and Akt, and CPA-induced or CGS-21680-induced cell proliferation was inhibited by ERK and Akt inhibitors.	cysteinylglycine	37-40	AKT serine/threonine kinase 1	Homo sapiens	218-221
29476752-7	2018	Further study indicated that CPA and CGS-21680 treatment induced phosphorylation of extracellular signal-regulated kinase (ERK) and Akt, and CPA-induced or CGS-21680-induced cell proliferation was inhibited by ERK and Akt inhibitors.	cysteinylglycine	156-159	mitogen-activated protein kinase 1	Homo sapiens	123-126
29476752-7	2018	Further study indicated that CPA and CGS-21680 treatment induced phosphorylation of extracellular signal-regulated kinase (ERK) and Akt, and CPA-induced or CGS-21680-induced cell proliferation was inhibited by ERK and Akt inhibitors.	cysteinylglycine	156-159	mitogen-activated protein kinase 1	Homo sapiens	210-213
29476752-7	2018	Further study indicated that CPA and CGS-21680 treatment induced phosphorylation of extracellular signal-regulated kinase (ERK) and Akt, and CPA-induced or CGS-21680-induced cell proliferation was inhibited by ERK and Akt inhibitors.	cysteinylglycine	156-159	AKT serine/threonine kinase 1	Homo sapiens	218-221
29427770-4	2018	The pooled analyses showed association between carriers of SLC22A1 rs628031A allele (GA + AA vs GG, OR: 0.58, 95% CI: 0.38-0.88, P = 0.011) or rs683369G allele (CG + GG vs CC, OR: 0.64, 95% CI: 0.42-0.96, P = 0.032) and a lower MMR rate.	cysteinylglycine	161-163	solute carrier family 22 member 1	Homo sapiens	59-66
29256007-5	2018	RESULTS: IL-1beta decreased genomic methylation of human intestinal epithelial cells and induced demethylation at cg-specific sites at the promoter of pro-inflammatory genes IL6 and IL8; conversely it did not change the methylation of the IL10 promoter.	cysteinylglycine	114-116	interleukin 6	Homo sapiens	174-177
29256007-5	2018	RESULTS: IL-1beta decreased genomic methylation of human intestinal epithelial cells and induced demethylation at cg-specific sites at the promoter of pro-inflammatory genes IL6 and IL8; conversely it did not change the methylation of the IL10 promoter.	cysteinylglycine	114-116	C-X-C motif chemokine ligand 8	Homo sapiens	182-185
29256007-5	2018	RESULTS: IL-1beta decreased genomic methylation of human intestinal epithelial cells and induced demethylation at cg-specific sites at the promoter of pro-inflammatory genes IL6 and IL8; conversely it did not change the methylation of the IL10 promoter.	cysteinylglycine	114-116	interleukin 10	Homo sapiens	239-243
29193861-0	2018	The adenosine A2A receptor agonist, CGS 21680, attenuates a probabilistic reversal learning deficit and elevated grooming behavior in BTBR mice.	cysteinylglycine	36-39	adenosine A2a receptor	Mus musculus	4-26
29278768-5	2018	There was statistically association between ERAP1 rs27044 polymorphism and risk of AS, and the carriers with rs27044 CG genotype have an increased the risk for AS (CG versus GG, OR=1.70, 95% CI=1.10-2.62, P=0.015).	cysteinylglycine	117-119	endoplasmic reticulum aminopeptidase 1	Homo sapiens	44-49
29091301-6	2018	The frequencies of 634C/G genotype of IL-6 promoter were CC 38.29%, CG 46.81%, and GG 14.90%, while CC 59.51%, CG 35.11%, GG 6.38% in the control group (P < 0.01).	cysteinylglycine	68-70	interleukin 6	Homo sapiens	38-42
29466369-4	2018	In Arabidopsis thaliana, MET1 controls maintenance of cytosine methylation at symmetrical CG positions.	cysteinylglycine	90-92	methyltransferase 1	Arabidopsis thaliana	25-29
29407903-9	2018	Decreased fetal/placental weight ratio and increased total weight of the Type A placentome were found in the RG1 group compared to CG (P < .05).	cysteinylglycine	131-133	protein phosphatase 1 regulatory subunit 3A	Homo sapiens	109-112
29520298-8	2018	Out of these, the LD-block 3 in calpastatin, tagged by SNPs located at 7-98566391 and 7-98581038, had a significant effect on tenderness with the TG-CG diplotype being approximately 1 kg more tender than the toughest diplotype, TG-CG.	cysteinylglycine	149-151	calpastatin	Bos taurus	32-43
29402846-9	2018	However, the rs1520220 and rs2195239 variants were correlated with M1 and E1 in patients with IgAN (M0/M1: CC vs. CG+GG: OR = 1.62, P = 0.04; E0/E1: CC vs. CG+GG: OR = 1.95, P = 0.004; GG vs. GC+CC: OR = 1.90, P = 0.004, respectively).	cysteinylglycine	114-116	IGAN1	Homo sapiens	94-98
29040831-4	2018	In the synergy between proper thrombin stimulation and the fast absorption of the sponge, TCGS exhibits outstanding hemostatic performance, ultrafast bleeding cessation, within 100s, which is superior to both CGS and equal amounts of native thrombin.	cysteinylglycine	91-94	coagulation factor II, thrombin	Homo sapiens	241-249
28750137-5	2018	The SNP DAO +8956 C>G was associated with a strong protective effect, with OR values of 0.83 for CG and 0.11 for GG genotype (P = .04 for the codominant model), suggesting an allele dose effect.	cysteinylglycine	100-102	D-amino acid oxidase	Homo sapiens	8-11
29386357-8	2018	Using this assay, the combination of unmethylated CG-enriched oligodeoxynucleotide (CpG)-a Toll-like receptor 9 (TLR9) ligand-and anti-OX40 antibody provided the most impressive results.	cysteinylglycine	50-52	toll like receptor 9	Homo sapiens	113-117
29386357-8	2018	Using this assay, the combination of unmethylated CG-enriched oligodeoxynucleotide (CpG)-a Toll-like receptor 9 (TLR9) ligand-and anti-OX40 antibody provided the most impressive results.	cysteinylglycine	50-52	TNF receptor superfamily member 4	Homo sapiens	135-139
29555105-9	2018	RESULTS: The statistical analysis showed that IL-31 level was significantly higher in AD patients than in the control group (AD vs CG, p 0.0001).	cysteinylglycine	131-133	interleukin 31	Homo sapiens	46-51
29040831-4	2018	In the synergy between proper thrombin stimulation and the fast absorption of the sponge, TCGS exhibits outstanding hemostatic performance, ultrafast bleeding cessation, within 100s, which is superior to both CGS and equal amounts of native thrombin.	cysteinylglycine	91-94	coagulation factor II, thrombin	Homo sapiens	30-38
29402846-9	2018	However, the rs1520220 and rs2195239 variants were correlated with M1 and E1 in patients with IgAN (M0/M1: CC vs. CG+GG: OR = 1.62, P = 0.04; E0/E1: CC vs. CG+GG: OR = 1.95, P = 0.004; GG vs. GC+CC: OR = 1.90, P = 0.004, respectively).	cysteinylglycine	156-158	IGAN1	Homo sapiens	94-98
28532223-6	2017	Celastrol and G Rh2 were rapidly released from CG-M under acidic and enzymatic conditions, but slowly released in normal physiological environments.	cysteinylglycine	47-49	Rh associated glycoprotein	Homo sapiens	16-19
28532223-7	2017	In cellular studies, the internalization of celastrol and G Rh2 by human non-small cell lung cancer (A549) cells treated with CG-M was 5.8-fold and 1.8-fold higher than that of non-micelle control.	cysteinylglycine	126-128	Rh associated glycoprotein	Homo sapiens	60-63
29049342-8	2017	A significant association was found between miR-146a rs2910164 polymorphisms and the risk of SCCHN in Chinese patients according to the overall data [CC+CG vs. GG: OR = 1.13; 95%CI = 1.00-1.29; CC vs. GG: OR = 1.19; 95%CI = 1.03-1.38].	cysteinylglycine	153-155	microRNA 146a	Homo sapiens	44-52
29108203-7	2017	A subgroup analysis of race, source of control population, and Hardy-Weinberg equilibrium were performed in these five genetic models, and miR-146a single nucleotide polymorphism increased the susceptibility to HCC only in the control population-based subgroups of the recessive model CG+GG/CC (OR = 1.20, 95% CI 1.02-1.40, P = 0.024).	cysteinylglycine	285-287	microRNA 146a	Homo sapiens	139-147
28976982-3	2017	In mammalian somatic cells, hemimethylated-CG-binding protein UHRF1 plays a critical role in maintaining CG methylation by recruiting DNMT1 to hemimethylated CG sites.	cysteinylglycine	43-45	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	62-67
28953888-7	2017	A focused screen using small inhibitory RNAs revealed that zinc-finger antiviral protein (ZAP) inhibited virion production by cells infected with CG-enriched HIV-1.	cysteinylglycine	146-148	zinc finger CCCH-type containing, antiviral 1	Homo sapiens	90-93
28976982-3	2017	In mammalian somatic cells, hemimethylated-CG-binding protein UHRF1 plays a critical role in maintaining CG methylation by recruiting DNMT1 to hemimethylated CG sites.	cysteinylglycine	43-45	DNA methyltransferase 1	Homo sapiens	134-139
28976982-3	2017	In mammalian somatic cells, hemimethylated-CG-binding protein UHRF1 plays a critical role in maintaining CG methylation by recruiting DNMT1 to hemimethylated CG sites.	cysteinylglycine	105-107	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	62-67
28976982-3	2017	In mammalian somatic cells, hemimethylated-CG-binding protein UHRF1 plays a critical role in maintaining CG methylation by recruiting DNMT1 to hemimethylated CG sites.	cysteinylglycine	105-107	DNA methyltransferase 1	Homo sapiens	134-139
28976982-8	2017	Whole genome bisulfite sequencing revealed that blastocysts derived from KO oocytes have a greatly reduced level of CG methylation, suggesting that maternal UHRF1 is essential for maintaining CG methylation, particularly at the imprinting control regions, in preimplantation embryos.	cysteinylglycine	116-118	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	157-162
28976982-8	2017	Whole genome bisulfite sequencing revealed that blastocysts derived from KO oocytes have a greatly reduced level of CG methylation, suggesting that maternal UHRF1 is essential for maintaining CG methylation, particularly at the imprinting control regions, in preimplantation embryos.	cysteinylglycine	192-194	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	157-162
28976982-9	2017	Surprisingly, UHRF1 was also found to contribute to de novo CG and non-CG methylation during oocyte growth: in Uhrf1 KO oocytes, transcriptionally-inactive regions gained less methylation, while actively transcribed regions, including the imprinting control regions, were unaffected or only slightly affected.	cysteinylglycine	60-62	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	14-19
27862719-7	2017	RESULTS: Of 238 patients, PNPLA3 genotype frequencies were: CC, 0.14; CG, 0.46; and GG, 0.40.	cysteinylglycine	70-72	patatin like phospholipase domain containing 3	Homo sapiens	26-32
28832760-6	2017	In the overall analysis, a significant association between the PADI4 -92C/G polymorphism and RA was found in the Chinese population (G vs C: OR=1.32, 95%CI=1.02-1.71; GG+CG vs CC: OR=1.75, 95%CI=1.20-2.53).	cysteinylglycine	170-172	peptidyl arginine deiminase 4	Homo sapiens	63-68
29037553-6	2017	RESULTS: Our results showed that there are significant differences in CG genotype frequencies between case and control groups regarding miR-146a rs2910164 polymorphism (OR = 2.03, CI = 1.3-3, P = 0.001).	cysteinylglycine	70-72	microRNA 146a	Homo sapiens	136-144
28870318-5	2017	Through the activity of DNMT1, the hemimethylated CG recognition sequence of the double stranded DNA are methylated and DNA S2 strand is cleaved and removed after the subsequently treatment with EpiTect fast bisulfite conversion kits and USER, leaving the DNA S1 to form the G-quadruplex-hemin DNAzyme for signal amplification.	cysteinylglycine	50-52	DNA methyltransferase 1	Homo sapiens	24-29
28847947-2	2017	Here we demonstrate that the distribution of 5hmC in CG and non-CG dinucleotides is distinct and that it reflects the binding specificity and genome occupancy of methylcytosine binding protein 2 (MeCP2).	cysteinylglycine	53-55	methyl-CpG binding protein 2	Homo sapiens	196-201
29026722-6	2017	Analysis of variance revealed that MTHFR 4869C>G was associated with altered CD56+ natural killer cell percentages (CC, 17.91%+-8.04%; CG, 12.67%+-4.64%; p=0.024) and folate levels (CC, 12.01+-7.18 mg/mL; CG, 22.15+-26.25 mg/mL; p=0.006).	cysteinylglycine	138-140	methylenetetrahydrofolate reductase	Homo sapiens	35-40
29026722-6	2017	Analysis of variance revealed that MTHFR 4869C>G was associated with altered CD56+ natural killer cell percentages (CC, 17.91%+-8.04%; CG, 12.67%+-4.64%; p=0.024) and folate levels (CC, 12.01+-7.18 mg/mL; CG, 22.15+-26.25 mg/mL; p=0.006).	cysteinylglycine	208-210	methylenetetrahydrofolate reductase	Homo sapiens	35-40
29246001-5	2017	We found PPARG rs1801282 C>G polymorphism had a tendency of decreased risk to CRC risk (CG vs. CC: adjusted OR, 0.67, 95% CI = 0.43-1.04 for CG vs. CC, P = 0.073; GG vs. CC: adjusted OR, 0.68; 95% CI, 0.44-1.05; P = 0.078).	cysteinylglycine	91-93	peroxisome proliferator activated receptor gamma	Homo sapiens	9-14
29246001-5	2017	We found PPARG rs1801282 C>G polymorphism had a tendency of decreased risk to CRC risk (CG vs. CC: adjusted OR, 0.67, 95% CI = 0.43-1.04 for CG vs. CC, P = 0.073; GG vs. CC: adjusted OR, 0.68; 95% CI, 0.44-1.05; P = 0.078).	cysteinylglycine	144-146	peroxisome proliferator activated receptor gamma	Homo sapiens	9-14
29246001-6	2017	The stratified analysis revealed PPARG rs1801282 C>G polymorphism also had a tendency of decreased risk to colon cancer (CG vs. CC: adjusted OR = 0.54, 95% CI = 0.27-1.08, P = 0.083).	cysteinylglycine	124-126	peroxisome proliferator activated receptor gamma	Homo sapiens	33-38
28761205-11	2017	RESULTS: The expression of HSP70 was significantly higher in the keratinocytes of the TG (20.25+-3.53; P<0.001) than in the keratinocytes of the CG (10.50+-2.44; P<0.001).	cysteinylglycine	148-150	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	27-32
28596482-4	2017	Two immune related genes, GSTM1 and LMO2, were chosen to validate its aging-related CG hypermethylation in different leukocytes.	cysteinylglycine	84-86	glutathione S-transferase mu 1	Homo sapiens	26-31
28596482-4	2017	Two immune related genes, GSTM1 and LMO2, were chosen to validate its aging-related CG hypermethylation in different leukocytes.	cysteinylglycine	84-86	LIM domain only 2	Homo sapiens	36-40
28084098-6	2017	With regard to the MTNR1B rs10830963 polymorphism, we observed a statistically significant prevalence of GG and CG genotypes and the G allele among pregnant women with GDM (GG + CG vs CC, OR 1.50, 95% CI 1.02-2.22, p = 0.04; G vs C, OR 1.43, 95% CI 1.07-1.90, p = 0.016).	cysteinylglycine	112-114	melatonin receptor 1B	Homo sapiens	19-25
28697836-6	2017	RESULTS: Compared with the CC genotypes, the IL-6 C-572G G-positive genotype (CG+GG genotype) was significantly associated with an increased susceptibility to moderate to late SPTB (OR=1.35, 95%CI: 1.01-1.80, P=0.04).	cysteinylglycine	78-80	interleukin 6	Homo sapiens	45-49
28477138-5	2017	Decreased methylation at three specific CG sites in the promoter of the Nts1 gene encompassing the distal consensus AP-1 site was correlated with increased Nts1 expression.	cysteinylglycine	40-42	neurotensin	Mus musculus	72-76
28477138-5	2017	Decreased methylation at three specific CG sites in the promoter of the Nts1 gene encompassing the distal consensus AP-1 site was correlated with increased Nts1 expression.	cysteinylglycine	40-42	neurotensin	Mus musculus	156-160
28084098-6	2017	With regard to the MTNR1B rs10830963 polymorphism, we observed a statistically significant prevalence of GG and CG genotypes and the G allele among pregnant women with GDM (GG + CG vs CC, OR 1.50, 95% CI 1.02-2.22, p = 0.04; G vs C, OR 1.43, 95% CI 1.07-1.90, p = 0.016).	cysteinylglycine	178-180	melatonin receptor 1B	Homo sapiens	19-25
28438863-6	2017	RESULTS: p16 540C G genotype distribution was found to be: CC: 66.2%, CG: 28.4%, GG: 5.4%; p16 580C T genotype distribution was found to be: CC: 82.4%, CT: 17.6%, TT: 0% and MDM2 genotype distribution was found to be: TT: 31.1%, TG: 47.3%, GG: 21.6% in patients with prolactinoma.	cysteinylglycine	70-72	cyclin dependent kinase inhibitor 2A	Homo sapiens	9-12
28019133-8	2017	A relationship was detected between H score, FSH, LH, total testosterone, HDL-C and TG levels and CG + GG genotypes of IL-6.	cysteinylglycine	98-100	interleukin 6	Homo sapiens	119-123
28263183-6	2017	Entropy of VVS is higher than CG what could be interpreted as substantial presence of noisy ingredients in SBP of VVS.	cysteinylglycine	30-32	VVS	Homo sapiens	114-117
28263183-11	2017	SIGNIFICANCE: Our observations about opposite switches in entropy between CG and VVS might support a hypothesis that baroreflex in VVS affects stronger the heart rate because of the inefficient regulation (possibly impaired local vascular tone alternations) of the blood pressure.	cysteinylglycine	74-76	VVS	Homo sapiens	131-134
28222651-1	2017	INTRODUCTION: Homocysteine increase and glutathione derivative cysteinyl-glycine fall are indirect biomarkers for oxidative stress, for instance due to dopamine D1 receptor stimulation.	cysteinylglycine	63-80	dopamine receptor D1	Homo sapiens	152-172
28507475-6	2017	The findings revealed that MIF -173 G > C variant increased the risk of TB in codominant (OR = 1.54, 95 %CI = 1.26-1.88, p < 0.0001; CG vs GG), and dominant (OR = 1.62, 95 %CI = 1.33-1.96, p < 0.00001; GC+CC vs GG) inheritance models tested.	cysteinylglycine	139-141	macrophage migration inhibitory factor	Homo sapiens	27-30
28280329-3	2017	Furthermore, results of cellular uptake on human corneal epithelial primary cells (HCEpiC) and retinal pigment epithelial (ARPE-19) cells indicated that both clathrin-mediated endocytosis and active transport of PepT-1 are involved in the internalization of CG-VV-LDH nanoparticles and CG-VV-LDH nanosheets.	cysteinylglycine	258-260	solute carrier family 15 member 1	Homo sapiens	212-218
28241063-8	2017	We also identified a polymorphic CTCF-binding site in intron 1 of ORMDL3 carrying a CG SNP rs4065275 and determined its methylation level.	cysteinylglycine	84-86	ORMDL sphingolipid biosynthesis regulator 3	Homo sapiens	66-72
28280329-3	2017	Furthermore, results of cellular uptake on human corneal epithelial primary cells (HCEpiC) and retinal pigment epithelial (ARPE-19) cells indicated that both clathrin-mediated endocytosis and active transport of PepT-1 are involved in the internalization of CG-VV-LDH nanoparticles and CG-VV-LDH nanosheets.	cysteinylglycine	286-288	solute carrier family 15 member 1	Homo sapiens	212-218
27923813-3	2017	In this work, we examined the reactions of NO2-CLA with low molecular weight thiols (glutathione, cysteine, homocysteine, cysteinylglycine, and beta-mercaptoethanol) and human serum albumin.	cysteinylglycine	122-138	selectin P ligand	Homo sapiens	47-50
28260989-8	2017	In 200 HBsAg negative HCC patients, we observed that the CHI3L1 rs4950928 polymorphisms carriers with the variant genotype CG+GG had higher frequencies of vascular invasion.	cysteinylglycine	123-125	chitinase 3 like 1	Homo sapiens	57-63
27920275-4	2017	A fragment of five CG sites (CpG1-5) in the promoter region of BNP gene was measured.	cysteinylglycine	19-21	natriuretic peptide B	Homo sapiens	63-66
29441892-7	2017	In addition, the genotype frequencies of SNP rs6632677 in ACE2 in the structural AF male patients vs male controls were as follows: GG, 70.5 vs 83.1%; CG 26.3 vs 15.6%; and CC 3.2 vs 1.3% (P=0.029).	cysteinylglycine	151-153	angiotensin converting enzyme 2	Homo sapiens	58-62
27986907-3	2017	To address this problem, we immunized mice with peptide Ag 2W1S coupled to PE in CFA and treated with the selective A2aR agonist CGS-21680 (CGS).	cysteinylglycine	129-132	adenosine A2a receptor	Mus musculus	116-120
27901485-7	2017	The overall data indicated a significant association between miR-146a rs2910164 polymorphism and HNC risk [C vs. G: odds ratio (OR) = 1.14; 95% confidence interval (CI) = 1.00-1.31; CC+CG vs. GG: OR=1.21; 95%CI=1.02-1.43].	cysteinylglycine	185-187	microRNA 146a	Homo sapiens	61-69
28182039-7	2017	The range of eGFR (ml/min/1.73 m2) at the time of initiation of MHD was 1.26-11.78 by CG formula and 2.18-16.4 by MDRD equation.	cysteinylglycine	86-88	epidermal growth factor receptor	Homo sapiens	13-17
27833020-11	2016	In our epigenetic study, SMG C-6 cells showed highly methylated CG pairs in the CFTR CpG island and most of the methylated CG pairs were demethylated by 5-Aza-CdR.	cysteinylglycine	64-66	CF transmembrane conductance regulator	Rattus norvegicus	80-84
28050235-5	2016	RESULTS: The PNPLA3 rs738409 genotype distribution for CC, CG and GG was 39.2%, 52.6% and 8.2%.	cysteinylglycine	59-61	patatin like phospholipase domain containing 3	Homo sapiens	13-19
28740514-6	2017	Nonetheless, CDCs cultured on CG-N secreted significantly higher levels of osteopontin, FGF6, FGF7, NT-3, IGFBP4, and TIMP-2 compared to those cultured on CG-P, suggesting overall a reduced trophic and antiremodelling paracrine profile of CDCs when in contact with ECM from pathological cardiac fibroblasts.	cysteinylglycine	30-32	secreted phosphoprotein 1	Homo sapiens	75-86
28740514-6	2017	Nonetheless, CDCs cultured on CG-N secreted significantly higher levels of osteopontin, FGF6, FGF7, NT-3, IGFBP4, and TIMP-2 compared to those cultured on CG-P, suggesting overall a reduced trophic and antiremodelling paracrine profile of CDCs when in contact with ECM from pathological cardiac fibroblasts.	cysteinylglycine	30-32	fibroblast growth factor 6	Homo sapiens	88-92
28740514-6	2017	Nonetheless, CDCs cultured on CG-N secreted significantly higher levels of osteopontin, FGF6, FGF7, NT-3, IGFBP4, and TIMP-2 compared to those cultured on CG-P, suggesting overall a reduced trophic and antiremodelling paracrine profile of CDCs when in contact with ECM from pathological cardiac fibroblasts.	cysteinylglycine	30-32	fibroblast growth factor 7	Homo sapiens	94-98
28740514-6	2017	Nonetheless, CDCs cultured on CG-N secreted significantly higher levels of osteopontin, FGF6, FGF7, NT-3, IGFBP4, and TIMP-2 compared to those cultured on CG-P, suggesting overall a reduced trophic and antiremodelling paracrine profile of CDCs when in contact with ECM from pathological cardiac fibroblasts.	cysteinylglycine	30-32	3'-nucleotidase	Homo sapiens	100-104
28740514-6	2017	Nonetheless, CDCs cultured on CG-N secreted significantly higher levels of osteopontin, FGF6, FGF7, NT-3, IGFBP4, and TIMP-2 compared to those cultured on CG-P, suggesting overall a reduced trophic and antiremodelling paracrine profile of CDCs when in contact with ECM from pathological cardiac fibroblasts.	cysteinylglycine	30-32	insulin like growth factor binding protein 4	Homo sapiens	106-112
28740514-6	2017	Nonetheless, CDCs cultured on CG-N secreted significantly higher levels of osteopontin, FGF6, FGF7, NT-3, IGFBP4, and TIMP-2 compared to those cultured on CG-P, suggesting overall a reduced trophic and antiremodelling paracrine profile of CDCs when in contact with ECM from pathological cardiac fibroblasts.	cysteinylglycine	30-32	TIMP metallopeptidase inhibitor 2	Homo sapiens	118-124
27686769-8	2016	Further, in the exposed group, the MN frequencies were lower in TP53 rs1042522 CG and CG+GG genotype carriers((3.63+-2.61)% and(3.66+-2.61)%, respectively)than in TP53 rs1042522 CC genotype carriers(3.95+-3.06)%(FR=0.87 and 0.90; 95% CI: 0.83-0.96 and 0.84-0.97, respectively).	cysteinylglycine	79-81	tumor protein p53	Homo sapiens	64-68
27374075-9	2016	Multiple logistic regression analysis, however, showed that only rs2364723 significantly reduced levels of serum HMOX1 in T2DM patients for the GG genotype carriers compared with participants with CG+CC genotype.	cysteinylglycine	197-199	heme oxygenase 1	Homo sapiens	113-118
27980779-7	2016	Moreover, all functional effects of dSLIM  strictly depend on the presence of CG-motifs within its dumbbell-shaped, covalently closed structural context.	cysteinylglycine	78-80	scruin like at the midline	Drosophila melanogaster	36-41
27980779-9	2016	Finally, we showed that the implementation of ProMune  (ODN2006) base sequence into the characteristic dSLIM  dumbbell form resulted in dSLIM2006 with all beneficial effects for immunostimulation combined from both TLR9 classes without any CG-independent effects.	cysteinylglycine	240-242	scruin like at the midline	Drosophila melanogaster	103-108
27980779-9	2016	Finally, we showed that the implementation of ProMune  (ODN2006) base sequence into the characteristic dSLIM  dumbbell form resulted in dSLIM2006 with all beneficial effects for immunostimulation combined from both TLR9 classes without any CG-independent effects.	cysteinylglycine	240-242	toll like receptor 9	Homo sapiens	215-219
27777502-6	2016	Analysis of the family history in the CYP1B1-positive families revealed POAG in confirmed or presumed heterozygous relatives in one family with PCG and two families with ASD/CG; POAG was associated with the c.1064_1076del, p.(Arg355Hisfs*69) allele in two of these pedigrees.	cysteinylglycine	145-147	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	38-44
27686769-8	2016	Further, in the exposed group, the MN frequencies were lower in TP53 rs1042522 CG and CG+GG genotype carriers((3.63+-2.61)% and(3.66+-2.61)%, respectively)than in TP53 rs1042522 CC genotype carriers(3.95+-3.06)%(FR=0.87 and 0.90; 95% CI: 0.83-0.96 and 0.84-0.97, respectively).	cysteinylglycine	86-88	tumor protein p53	Homo sapiens	163-167
27626477-10	2016	The serum levels of osteocalcin were higher in patients (CG = 8.6+-3.6 ng/mL vs PHPT = 36.5+-38.4 ng/mL; p<0.005), but no associations were observed between osteocalcin and insulin or between insulin and both marrow adipose tissue and bone mass.	cysteinylglycine	57-59	bone gamma-carboxyglutamate protein	Homo sapiens	20-31
27095432-10	2016	Epidermal Ki67 immunopositivity was significantly suppressed in B6.Cg-Tyr(c-2J) Hr(hr) /J mice at 24 h post-UV.	cysteinylglycine	67-69	antigen identified by monoclonal antibody Ki 67	Mus musculus	10-14
27161371-7	2016	In addition, CG prevents aging through inhibiting NF-kappaB-mediated inflammatory response and caspase-3-medicated neurodegeneration in the brain of D-gal treated mice.	cysteinylglycine	13-15	caspase 3	Mus musculus	95-104
27588274-8	2016	The association of COL1A1 rs2269336 with high myopia was observed in recessive model (CC vs CG+GG, P=0.03) and in heterozygous model (CG vs GG, P=0.04), but not in other models.	cysteinylglycine	92-94	collagen type I alpha 1 chain	Homo sapiens	19-25
27588274-8	2016	The association of COL1A1 rs2269336 with high myopia was observed in recessive model (CC vs CG+GG, P=0.03) and in heterozygous model (CG vs GG, P=0.04), but not in other models.	cysteinylglycine	134-136	collagen type I alpha 1 chain	Homo sapiens	19-25
27588274-9	2016	CONCLUSION: This Meta-analysis shows that COL1A1 rs2269336 (CC vs CG+GG) affects individual susceptibility to high myopia, whereas there is no association detected between SNPs rs2075555 and high myopia.	cysteinylglycine	66-68	collagen type I alpha 1 chain	Homo sapiens	42-48
27681698-11	2016	CONCLUSIONS: OGG1 rs1052133 (CG and CG+GG genotypes) might be risk factor for ARC, particularly in cortical cataract risk.	cysteinylglycine	29-31	8-oxoguanine DNA glycosylase	Homo sapiens	13-17
27681698-11	2016	CONCLUSIONS: OGG1 rs1052133 (CG and CG+GG genotypes) might be risk factor for ARC, particularly in cortical cataract risk.	cysteinylglycine	36-38	8-oxoguanine DNA glycosylase	Homo sapiens	13-17
27706635-5	2016	Moreover, the CG+GG genotype of miR-146a was associated with an increased risk of ovarian cancer compared with the CC genotype (OR = 1.68, 95%CI = 1.06-2.66), and the GG genotype had a higher risk of ovarian cancer than the CC+CG genotype (OR = 3.02, 95%CI = 1.55-5.98).	cysteinylglycine	14-16	microRNA 146a	Homo sapiens	32-40
27055186-0	2016	Cysteinyl-glycine reduces mucosal proinflammatory cytokine response to fMLP in a parenterally-fed piglet model.	cysteinylglycine	0-17	formyl peptide receptor 1	Homo sapiens	71-75
27055186-6	2016	Cysteinyl-glycine lowered TNF-alpha response to fMLP in PN-fed animals and IFN-gamma response to fMLP in both groups (P < 0.05).	cysteinylglycine	0-17	tumor necrosis factor	Homo sapiens	26-35
27055186-6	2016	Cysteinyl-glycine lowered TNF-alpha response to fMLP in PN-fed animals and IFN-gamma response to fMLP in both groups (P < 0.05).	cysteinylglycine	0-17	formyl peptide receptor 1	Homo sapiens	48-52
27055186-2	2016	We hypothesized that cysteinyl-glycine would ameliorate the inflammatory effect of a bacterial peptide, formyl-methionyl-leucyl-phenylalanine (fMLP), in both sow-fed and parenterally-fed piglets.	cysteinylglycine	21-38	formyl peptide receptor 1	Homo sapiens	143-147
27219123-7	2016	Levels of IL-18 were significantly higher in patients in relation to the CG (p = 0.0013).	cysteinylglycine	73-75	interleukin 18	Homo sapiens	10-15
27340861-6	2016	Patients with ERCC1 rs3212961 AA/AC genotype exhibited longer OS than CC genotype (adjusted HR=0.63, P=0.028); ERCC5 rs2094258 AA/AG genotype revealed significantly favorable OS compared with GG genotype (adjusted HR=0.65, P=0.033); DDB2 rs830083 CG genotype could increase OS compared with GG genotype (adjusted HR=0.61, P=0.042).	cysteinylglycine	247-249	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
27340861-6	2016	Patients with ERCC1 rs3212961 AA/AC genotype exhibited longer OS than CC genotype (adjusted HR=0.63, P=0.028); ERCC5 rs2094258 AA/AG genotype revealed significantly favorable OS compared with GG genotype (adjusted HR=0.65, P=0.033); DDB2 rs830083 CG genotype could increase OS compared with GG genotype (adjusted HR=0.61, P=0.042).	cysteinylglycine	247-249	ERCC excision repair 5, endonuclease	Homo sapiens	111-116
27021952-3	2016	The promoter of vertebrate ACHE gene carries highly conserved CG-rich regions, implying its likeliness to be methylated for epigenetic regulation.	cysteinylglycine	62-64	acetylcholinesterase	Mus musculus	27-31
25854875-6	2016	The frequency of the DRD4 rs1800544 CG genotype was significantly higher (P = 0.003) in responders (51.4%) than in nonresponders (35.8%), and patients with the CG genotype showed an 81.7% response rate.	cysteinylglycine	36-38	dopamine receptor D4	Homo sapiens	21-25
26988593-7	2016	Compared with rs4950928 GG homozygosity, presence of C-allele was associated with a doubling (CG) or tripling (CC) in YKL-40 levels, but not with risk of venous thromboembolism.	cysteinylglycine	94-96	chitinase 3 like 1	Homo sapiens	118-124
27016586-3	2016	We sought to determine if A2AR activation with CGS-21680 (CGS) is more effective when CGS is administered during sensitization or rechallenge.	cysteinylglycine	47-50	adenosine A2a receptor	Mus musculus	26-30
27016586-3	2016	We sought to determine if A2AR activation with CGS-21680 (CGS) is more effective when CGS is administered during sensitization or rechallenge.	cysteinylglycine	58-61	adenosine A2a receptor	Mus musculus	26-30
27016586-6	2016	A2AR activation with CGS (0.1 mug kg(-1) min(-1) sc) only during sensitization reduced numbers of IL-6(+) and IL-12(+) myeloid cells in the lungs and reversed the effects of OVA rechallenge to increase airway hyperresponsiveness to methacholine.	cysteinylglycine	21-24	adenosine A2a receptor	Mus musculus	0-4
27016586-6	2016	A2AR activation with CGS (0.1 mug kg(-1) min(-1) sc) only during sensitization reduced numbers of IL-6(+) and IL-12(+) myeloid cells in the lungs and reversed the effects of OVA rechallenge to increase airway hyperresponsiveness to methacholine.	cysteinylglycine	21-24	interleukin 6	Mus musculus	98-102
27016586-8	2016	Most of the effects of CGS administered during sensitization were eliminated by myeloid-selective A2AR deletion.	cysteinylglycine	23-26	adenosine A2a receptor	Mus musculus	98-102
26934706-7	2016	Moreover, the production of IL-6 was significantly increased in rs2269067 GG cases compared to CG cases or CC cases (P = 0.002, P = 0.001, respectively).	cysteinylglycine	95-97	interleukin 6	Homo sapiens	28-32
27139004-4	2016	HbA1c reduction after use of DPP-4 inhibitors for 3 months was significantly greater in patients with a risk allele for type 2 diabetes (GG -0.4%, CG -0.5%, CC -0.8%, p = 0.02 for rs7754840 and AA -0.4%, AG -0.5%, GG -0.8%, p = 0.01 for rs7756992).	cysteinylglycine	147-149	dipeptidyl peptidase 4	Homo sapiens	29-34
26987369-7	2016	In contrast, in the dorsal striatum the CGS 21680-induced antagonistic modulation in the D2-likeR agonist high affinity state was abolished after cocaine self-administration versus the yoked saline group probably due to a local dysfunction/disruption of the A2AR-D2-like R heteroreceptor complexes.	cysteinylglycine	40-43	adenosine A2a receptor	Homo sapiens	258-262
27241145-6	2016	:  RESULTS: The frequencies of -11391G/A (AA) and EC-SOD (CG+GG) were 50.67% and 50.33% in NAFLD cases, 23.83% and 24.17% in healthy controls, respectively.	cysteinylglycine	58-60	superoxide dismutase 3	Homo sapiens	50-56
27241145-7	2016	Statistical tests showed significantly higher frequencies of -11391G/A (AA) and EC-SOD (CG+GG) in the NAFLD group (-11391G/A: P=0.0051; EC-SOD: P=0.0057).	cysteinylglycine	88-90	superoxide dismutase 3	Homo sapiens	80-86
27241145-9	2016	The individuals who carried EC-SOD (CG+GG) had a high risk of NAFLD (OR=3.1800, 95% CI 1.7974 to 5.2391).	cysteinylglycine	36-38	superoxide dismutase 3	Homo sapiens	28-34
27241145-10	2016	Combined analysis of the polymorphisms showed that percentage of -11391G/A (AA)/EC-SOD (CG+GG) in the NAFLD group was significantly higher than that in the control groups (25.50% vs 5.83%, P=0.0039).	cysteinylglycine	88-90	superoxide dismutase 3	Homo sapiens	80-86
27241145-11	2016	The people who carried with -11391G/A (AA)/EC-SOD (CG+GG) had a high risk of NAFLD (OR=10.3190, 95% CI 8.1869 to 20.5102).	cysteinylglycine	51-53	superoxide dismutase 3	Homo sapiens	43-49
26619844-5	2016	Increased cervical cancer risks were also found in the TP53 Arg72Pro under a heterozygous comparison and overdominant model (CG vs. GG: adjusted OR = 1.44, 95 % CI = 1.06-1.95; CG vs. GG/CC: adjusted OR = 1.47, 95 % CI = 1.12-1.94, respectively).	cysteinylglycine	125-127	tumor protein p53	Homo sapiens	55-59
26619844-5	2016	Increased cervical cancer risks were also found in the TP53 Arg72Pro under a heterozygous comparison and overdominant model (CG vs. GG: adjusted OR = 1.44, 95 % CI = 1.06-1.95; CG vs. GG/CC: adjusted OR = 1.47, 95 % CI = 1.12-1.94, respectively).	cysteinylglycine	177-179	tumor protein p53	Homo sapiens	55-59
26619844-8	2016	Combined analysis revealed that the genotypes of rs4938723 CT/CC and TP53 Arg72Pro CG/CC had an increased cervical cancer risk (OR = 2.21, 95 % CI = 1.38-3.53).	cysteinylglycine	83-85	tumor protein p53	Homo sapiens	69-73
26619918-5	2016	Meta-analysis indicated an association between the ADAM33 S2 and AR in allele comparison (G/C:OR=1.40, 95% CI 1.08-1.82, P=0.012), heterozygote comparison ( CG/CC: OR=1.24, 95% CI 1.04-1.48, P=0.015), and dominant comparison (CG+GG/CC:OR=1.39, 95% CI 1.05-1.85, P=0.023).	cysteinylglycine	157-159	ADAM metallopeptidase domain 33	Homo sapiens	51-57
26619918-5	2016	Meta-analysis indicated an association between the ADAM33 S2 and AR in allele comparison (G/C:OR=1.40, 95% CI 1.08-1.82, P=0.012), heterozygote comparison ( CG/CC: OR=1.24, 95% CI 1.04-1.48, P=0.015), and dominant comparison (CG+GG/CC:OR=1.39, 95% CI 1.05-1.85, P=0.023).	cysteinylglycine	226-228	ADAM metallopeptidase domain 33	Homo sapiens	51-57
27349023-10	2016	In SCF patients, the average serum IL-6 levels (pg/mL) in CG + GG genotype (4.78 +- 0.42) were statistically higher than in CC genotype (3.93 +- 0.36) (p = 0.0000).	cysteinylglycine	58-60	interleukin 6	Homo sapiens	35-39
25869012-5	2016	For example, variability in CG-137 methylation contributes 25% to variance of growth response to GH.	cysteinylglycine	28-30	growth hormone 1	Homo sapiens	97-99
27797266-8	2016	CONCLUSIONS: Detecting a methylation at cg 16941656 of FRY in bile has high specificity, with an acceptable positive likelihood rate, and may therefore be helpful in distinguishing pancreatic cancer from benign strictures.	cysteinylglycine	40-42	FRY microtubule binding protein	Homo sapiens	55-58
27076938-8	2016	The frequencies of the CG and CG + GG genotype of rs12026 (PON2) conferred risk factors for NIHL with adjusted OR values of 2.62 (95% CI, 1.69-4.06) and 2.48 (95% CI, 1.63-3.78), respectively.	cysteinylglycine	23-25	paraoxonase 2	Homo sapiens	59-63
27026921-10	2016	Our study reveals an association between OGG1 Ser326Cys polymorphism and cancer susceptibility of the upper aero-digestive and gastrointestinal tract (CG + GG vs CC; odds ratio, OR 1.22; 95 % CI 1.05-1.41; GG vs CG + CC; OR 1.36; 95 % CI 1.09-1.70; GG vs CC; OR 1.46; 95 % CI 1.12-1.92).	cysteinylglycine	151-153	8-oxoguanine DNA glycosylase	Homo sapiens	41-45
27026921-10	2016	Our study reveals an association between OGG1 Ser326Cys polymorphism and cancer susceptibility of the upper aero-digestive and gastrointestinal tract (CG + GG vs CC; odds ratio, OR 1.22; 95 % CI 1.05-1.41; GG vs CG + CC; OR 1.36; 95 % CI 1.09-1.70; GG vs CC; OR 1.46; 95 % CI 1.12-1.92).	cysteinylglycine	212-214	8-oxoguanine DNA glycosylase	Homo sapiens	41-45
27386434-7	2016	However, after multiple comparison adjustment, this relationship remained significant only for CG+ GG genotypes of ZNF259 polymorphism.	cysteinylglycine	95-97	ZPR1 zinc finger	Homo sapiens	115-121
26365480-5	2015	RESULTS: The frequency of CG+GG genotype in the GDF15 H6D polymorphism was significantly increased in CRC patients when compared with controls [odds ratio (OR), 1.543; 95% confidence interval (95% CI), 1.138-2.094, P=0.005].	cysteinylglycine	26-28	growth differentiation factor 15	Homo sapiens	48-53
26884762-9	2016	The carriers of the G allele (CG or GG) of rs9794 were also significantly associated with decreased level of CRP, regression coefficients was -0.219, and standard error was 0.114 (p = 0.012).	cysteinylglycine	30-32	C-reactive protein	Homo sapiens	109-112
26169021-6	2015	RESULTS: We found that the IL-6 -174C/G polymorphism might be associated with decreased risk of TB (C vs. G: OR=0.77, 95% CI=0.64-0.91; CG vs. GG: OR=0.72, 95% CI=0.57-0.90; CC+CG vs. GG: OR=0.71, 95% CI=0.57-0.88).	cysteinylglycine	136-138	interleukin 6	Homo sapiens	27-31
26169021-6	2015	RESULTS: We found that the IL-6 -174C/G polymorphism might be associated with decreased risk of TB (C vs. G: OR=0.77, 95% CI=0.64-0.91; CG vs. GG: OR=0.72, 95% CI=0.57-0.90; CC+CG vs. GG: OR=0.71, 95% CI=0.57-0.88).	cysteinylglycine	177-179	interleukin 6	Homo sapiens	27-31
26169021-8	2015	Moreover, the IL-6 -174 C/G polymorphism was also associated with decreased risk of TB in Asians (C vs. G: OR=0.71, 95% CI=0.54-0.93; CG vs. GG: OR=0.61, 95% CI=0.44-0.85; CC+CG vs. GG: OR=0.63, 95% CI=0.46-0.86).	cysteinylglycine	134-136	interleukin 6	Homo sapiens	14-18
26169021-8	2015	Moreover, the IL-6 -174 C/G polymorphism was also associated with decreased risk of TB in Asians (C vs. G: OR=0.71, 95% CI=0.54-0.93; CG vs. GG: OR=0.61, 95% CI=0.44-0.85; CC+CG vs. GG: OR=0.63, 95% CI=0.46-0.86).	cysteinylglycine	175-177	interleukin 6	Homo sapiens	14-18
26862480-7	2016	RESULTS: For the rs2910164 polymorphism of miR-146a, significantly increased risks for HCC were observed when all studies were pooled under two models (CG vs CC: OR = 1.11, 95% CI = 1.02-1.21, P = 0.021; GG + CG vs CC: OR = 1.11, 95% CI = 1.01-1.22, P = 0.035).	cysteinylglycine	152-154	microRNA 146a	Homo sapiens	43-51
26862480-7	2016	RESULTS: For the rs2910164 polymorphism of miR-146a, significantly increased risks for HCC were observed when all studies were pooled under two models (CG vs CC: OR = 1.11, 95% CI = 1.02-1.21, P = 0.021; GG + CG vs CC: OR = 1.11, 95% CI = 1.01-1.22, P = 0.035).	cysteinylglycine	209-211	microRNA 146a	Homo sapiens	43-51
26369868-5	2015	Next, we examined its antagonistic activity using in vitro cell models, and the results showed that CG-86 could effectively inhibit growth hormone receptor-mediated signalling and effectively inhibit growth hormone-induced Ba/F3-GHR638 proliferation.	cysteinylglycine	100-102	growth hormone receptor	Homo sapiens	132-155
26369868-5	2015	Next, we examined its antagonistic activity using in vitro cell models, and the results showed that CG-86 could effectively inhibit growth hormone receptor-mediated signalling and effectively inhibit growth hormone-induced Ba/F3-GHR638 proliferation.	cysteinylglycine	100-102	growth hormone 1	Homo sapiens	132-146
26270612-3	2015	Cell binding by using glycosylation mutants reveals binding of the N-terminal domain of chicken galectin-8 (CG-8N) to alpha-2,3-sialylated and galactose-terminated glycan chains.	cysteinylglycine	108-110	galectin 8	Gallus gallus	96-106
26399685-9	2015	We obtained similar results when investigated human tissues; the CG pairs in the P2RX7 CpG islands showed hypermethylation and hypomethylation patterns in human normal and cancer tissues, respectively.	cysteinylglycine	65-67	purinergic receptor P2X 7	Homo sapiens	81-86
26346467-10	2015	The IL-18 -137 G/C polymorphism was significantly associated with an increased risk of RPL under a recessive genetic model (CC vs. GG + CG: odds ratio = 1.56, 95% confidence interval = 1.13 ~ 2.15).	cysteinylglycine	136-138	interleukin 18	Homo sapiens	4-9
26617878-5	2015	Regression analyses indicated a noticeable effect of CG on VEGF expression, the higher the CG was, the lower the VEGF protein expression was (P < 0.05).	cysteinylglycine	53-55	vascular endothelial growth factor A	Homo sapiens	59-63
26379412-8	2015	De novo NAFLD was more frequent in PNPLA3 GG carriers (0.33 vs 0.10 for GG vs CC + CG carriers, P = 0.018), while the genetic impact on NAFLD susceptibility was insignificant when categorized by the TM6SF2 polymorphism (0.19 in CC vs 0.14 in CT + TT carriers, P = 0.883).	cysteinylglycine	83-85	patatin like phospholipase domain containing 3	Homo sapiens	35-41
26370976-5	2015	We found an association with elevated glucose levels (odds ratio (OR) = 2.9; p = 0.013) in carrying the AA genotype of rs1884051 in the ESR1 gene compared with the GG genotype, and the CC genotype of rs328 in the LPL gene was associated with MetS compared to the CG or GG genotype (OR = 2.8; p = 0.04).	cysteinylglycine	263-265	estrogen receptor 1	Homo sapiens	136-140
25755069-2	2015	The screen demonstrated that loss of GCN5 or deletion of components of the Gcn5 histone acetyltransferase (HAT) complex, SAGA, sensitizes yeast to CG-1521-induced cell death.	cysteinylglycine	147-149	lysine acetyltransferase 2A	Homo sapiens	37-41
25755069-2	2015	The screen demonstrated that loss of GCN5 or deletion of components of the Gcn5 histone acetyltransferase (HAT) complex, SAGA, sensitizes yeast to CG-1521-induced cell death.	cysteinylglycine	147-149	lysine acetyltransferase 2A	Homo sapiens	75-79
25755069-5	2015	In human cell lines, siRNA mediated knockdown of GCN5 or PCAF, or chemical inhibition of GCN5 enzymatic activity, increases the sensitivity to CG-1521 and SAHA.	cysteinylglycine	143-145	lysine acetyltransferase 2A	Homo sapiens	49-53
26617878-5	2015	Regression analyses indicated a noticeable effect of CG on VEGF expression, the higher the CG was, the lower the VEGF protein expression was (P < 0.05).	cysteinylglycine	53-55	vascular endothelial growth factor A	Homo sapiens	113-117
25755069-5	2015	In human cell lines, siRNA mediated knockdown of GCN5 or PCAF, or chemical inhibition of GCN5 enzymatic activity, increases the sensitivity to CG-1521 and SAHA.	cysteinylglycine	143-145	lysine acetyltransferase 2B	Homo sapiens	57-61
26402809-8	2015	Significantly increased PTC susceptibility was also associated with the TP-53 Arg72Pro CC and CG/CC genotypes compared with the GG genotype (CC vs GG: adjusted OR = 2.04, 95%CI = 1.54-2.70; CG/CC vs GG: adjusted OR = 1.35, 95%CI = 1.11-1.67, respectively).	cysteinylglycine	190-192	tumor protein p53	Homo sapiens	72-77
25755069-5	2015	In human cell lines, siRNA mediated knockdown of GCN5 or PCAF, or chemical inhibition of GCN5 enzymatic activity, increases the sensitivity to CG-1521 and SAHA.	cysteinylglycine	143-145	lysine acetyltransferase 2A	Homo sapiens	89-93
26370461-7	2015	The distribution of SLC22A5 genotypes in infertile men was as follows: CC - 29.6%, CG - 53.9%, GG - 16.5% and in fertile men: CC - 32.0%, CG - 50.0%, GG - 18.0%, and was comparable in both evaluated groups.	cysteinylglycine	83-85	solute carrier family 22 member 5	Homo sapiens	20-27
25944162-7	2015	In multivariate logistic regression analysis, TNM stage (p = 0.001), recipient SMO rs3824 genotype (CG vs. CC/GG p = 0.001), and histologic grade (p = 0.019) were identified as independent risk factors of HCC recurrence.	cysteinylglycine	100-102	smoothened, frizzled class receptor	Homo sapiens	79-82
25736215-5	2015	In RET S904S, frequency of variant alleles (CG + GG) in cases was 56% versus 44% in controls (P < 0.05).	cysteinylglycine	44-46	ret proto-oncogene	Homo sapiens	3-6
26550136-6	2015	When subgroup analysis was performed based on ethnicity and the epsilon 4 allele of apolipoprotein E (APOEepsilon4) carriers status, significant associations were demonstrated (CC versus CG+GG: OR=1.37, 95% CI=1.04-1.82, P=0.03<0.05 and CC versus CG: OR=1.49, 95% CI=1.11-2.01, P=0.01<0.05) for APOEepsilon4 carriers status.	cysteinylglycine	187-189	apolipoprotein E	Homo sapiens	84-100
26550136-6	2015	When subgroup analysis was performed based on ethnicity and the epsilon 4 allele of apolipoprotein E (APOEepsilon4) carriers status, significant associations were demonstrated (CC versus CG+GG: OR=1.37, 95% CI=1.04-1.82, P=0.03<0.05 and CC versus CG: OR=1.49, 95% CI=1.11-2.01, P=0.01<0.05) for APOEepsilon4 carriers status.	cysteinylglycine	250-252	apolipoprotein E	Homo sapiens	84-100
26171202-6	2015	Overall, the results showed that the pri-miR-124-1 rs531564 polymorphism was significantly associated with a reduced cancer risk (G vs. C: OR, 0.86; 95% CI, 0.77-0.96; GG vs. CC: OR, 0.52; 95% CI, 0.34-0.79; GG vs. CG/CC: OR, 0.54; 95% CI, 0.36-0.81).	cysteinylglycine	215-217	microRNA 124-1	Homo sapiens	41-50
25981075-9	2015	Yield of de novo synthesized and preformed milk fatty acids increased with CG.	cysteinylglycine	75-77	Weaning weight-maternal milk	Bos taurus	43-47
25981075-11	2015	Compared with SH, the CG treatment increased energy-corrected milk in higher-producing cows with a lesser response to CG as milk yield decreased.	cysteinylglycine	22-24	Weaning weight-maternal milk	Bos taurus	62-66
25981075-11	2015	Compared with SH, the CG treatment increased energy-corrected milk in higher-producing cows with a lesser response to CG as milk yield decreased.	cysteinylglycine	22-24	Weaning weight-maternal milk	Bos taurus	124-128
26143914-5	2015	Two box A domains of HMGB1 collaborate in an unusual configuration in which the Phe37 residues of both domains stack together and intercalate the same CG base pair, generating highly kinked DNA.	cysteinylglycine	151-153	high mobility group box 1	Homo sapiens	21-26
26109393-13	2015	CG + GG genotype was associated with high HMGB1 levels compared with the genotype CC at 4 h (p = 0.023), and 24 h (p = 0.015) after CPB.	cysteinylglycine	0-2	high mobility group box 1	Homo sapiens	42-47
26228366-10	2015	Moreover, Western blot and immunohistochemistry analysis showed that CPE protein level was significantly lower in CGS group than in the control group.	cysteinylglycine	114-117	carboxypeptidase E	Homo sapiens	69-72
25691252-7	2015	Similarly, variant genotype GG (OR = 2.58; p = 0.003) and G allele carrier (CG + GG) (OR = 1.50; p = 0.043) of DR4 209 conferred increased risk.	cysteinylglycine	76-78	TNF receptor superfamily member 10a	Homo sapiens	111-114
25796172-0	2015	The calmodulin inhibitor CGS 9343B inhibits voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells.	cysteinylglycine	25-28	calmodulin	Oryctolagus cuniculus	4-14
25911169-8	2015	Similarly, the A2AAR selective agonist CGS-21680-induced increase in coronary flow was significantly blunted by Nox2 inhibition in both WT and A2BAR KO, while the A2BAR selective agonist BAY 60-6583-induced increase in coronary flow was not affected by Nox2 inhibition in WT.	cysteinylglycine	39-42	adenosine A2a receptor	Mus musculus	15-20
26309550-8	2015	RESULTS: Overall, hOGG1 Ser326Cys polymorphism was in relation with increased risk for HCC under the following genetic models: GG versus CC: OR=2.51, 95% CI=1.67-3.78; GG versus CG + CC: OR=2.27, 95% CI=1.57-3.30; GG + CG versus CC: OR=1.13, 95% CI=1.03-1.24.	cysteinylglycine	178-180	8-oxoguanine DNA glycosylase	Homo sapiens	18-23
26309550-8	2015	RESULTS: Overall, hOGG1 Ser326Cys polymorphism was in relation with increased risk for HCC under the following genetic models: GG versus CC: OR=2.51, 95% CI=1.67-3.78; GG versus CG + CC: OR=2.27, 95% CI=1.57-3.30; GG + CG versus CC: OR=1.13, 95% CI=1.03-1.24.	cysteinylglycine	219-221	8-oxoguanine DNA glycosylase	Homo sapiens	18-23
26309585-7	2015	For LOX-1 G501C polymorphism, significantly increased CAD risk was also associated with variant genotype (GG vs. CC: OR = 1.42, 95% CI 1.07-1.87; CG vs. CC: OR = 1.28, 95% CI 1.04-1.56; and dominant model: OR = 1.30, 95% CI 1.07-1.58).	cysteinylglycine	146-148	oxidized low density lipoprotein receptor 1	Homo sapiens	4-9
26309626-8	2015	MIF-173G/C polymorphism was associated with a significantly increased risk of IBD when compared with CG and GG genotypes (OR=1.43; 95% CI 1.08-1.90; I(2) =0%).	cysteinylglycine	101-103	macrophage migration inhibitory factor	Homo sapiens	0-3
26032981-5	2015	We show that DNMT1 and DNMT3a/3b activities work complementarily and simultaneously to establish symmetric CG methylation and CHH (H = A, T or C) methylation.	cysteinylglycine	107-109	DNA methyltransferase (cytosine-5) 1	Mus musculus	13-18
26032981-5	2015	We show that DNMT1 and DNMT3a/3b activities work complementarily and simultaneously to establish symmetric CG methylation and CHH (H = A, T or C) methylation.	cysteinylglycine	107-109	DNA methyltransferase 3A	Mus musculus	23-31
25835289-7	2015	RESULTS: Although the d3 polymorphism of the GHR contributed 19% to the variance of the IGF-1 response, CG-137 methylation in the IGF-1 promoter contributed 30%, the combined contribution of the two factors totaling 43%.	cysteinylglycine	104-106	insulin like growth factor 1	Homo sapiens	130-135
25911169-8	2015	Similarly, the A2AAR selective agonist CGS-21680-induced increase in coronary flow was significantly blunted by Nox2 inhibition in both WT and A2BAR KO, while the A2BAR selective agonist BAY 60-6583-induced increase in coronary flow was not affected by Nox2 inhibition in WT.	cysteinylglycine	39-42	cytochrome b-245, beta polypeptide	Mus musculus	112-116
25911169-8	2015	Similarly, the A2AAR selective agonist CGS-21680-induced increase in coronary flow was significantly blunted by Nox2 inhibition in both WT and A2BAR KO, while the A2BAR selective agonist BAY 60-6583-induced increase in coronary flow was not affected by Nox2 inhibition in WT.	cysteinylglycine	39-42	adenosine A2b receptor	Mus musculus	143-148
25911169-8	2015	Similarly, the A2AAR selective agonist CGS-21680-induced increase in coronary flow was significantly blunted by Nox2 inhibition in both WT and A2BAR KO, while the A2BAR selective agonist BAY 60-6583-induced increase in coronary flow was not affected by Nox2 inhibition in WT.	cysteinylglycine	39-42	cytochrome b-245, beta polypeptide	Mus musculus	253-257
26214637-10	2015	Similarly, CC genotpe of rs2910164 was found to be inversely related to susceptibility of oral SCC (CC+CG vs. GG: OR=0.726, 95% CI=0.607-0.869, p<0.001).	cysteinylglycine	103-105	serpin family B member 3	Homo sapiens	95-98
25801076-7	2015	When stratifying for obesity, PNPLA3 was associated with NASH in non-obese patients only (12.0% in CC vs. 18.3% in CG vs. 27.3% in GG, P = 0.01), including after correction for metabolic confounders (OR 2.06, 95% CI 1.26-3.36, P = 0.004).	cysteinylglycine	115-117	patatin like phospholipase domain containing 3	Homo sapiens	30-36
25716890-11	2015	Biochemical characterization of the in vitro purified hexameric AtLAP1 enzyme revealed a Km for Cys-Gly of 1.3 mM that was physiologically relevant and indicated that AtLAP1 represents a cytosolic Cys-Gly peptidase activity of A. thaliana.	cysteinylglycine	96-103	Cytosol aminopeptidase family protein	Arabidopsis thaliana	64-70
25716890-11	2015	Biochemical characterization of the in vitro purified hexameric AtLAP1 enzyme revealed a Km for Cys-Gly of 1.3 mM that was physiologically relevant and indicated that AtLAP1 represents a cytosolic Cys-Gly peptidase activity of A. thaliana.	cysteinylglycine	96-103	Cytosol aminopeptidase family protein	Arabidopsis thaliana	167-173
25633564-6	2015	Apomorphine, benzamil, etoposide, CGS-15943, kenpaullone, and rutaecarpine (all at 10 mumol/L) significantly inhibited hepcidin mRNA expression by Hep3B cells without affecting cell viability.	cysteinylglycine	34-37	hepcidin antimicrobial peptide	Homo sapiens	119-127
25768087-8	2015	When replicated in the KOALA study, ADAM33 rs528557 showed a negative association of the CG/GG-genotype with progression of recurrent wheeze into childhood asthma (0.50 (0.26-0.97) p = 0.04) and no association with preschool wheeze.	cysteinylglycine	89-91	ADAM metallopeptidase domain 33	Homo sapiens	36-42
25081498-8	2015	Serum IL-6 levels in G carries (CG + GG) (195.1 +- 11.8 pg/ml) elevated significantly compared to CC homozygotes (167.7 +- 6.7 pg/ml) in EV71-infected patients (p<0.001), but no significant differences were observed in CSF IL-6 levels among different genotypes in patients with EV71 encephalitis.	cysteinylglycine	32-34	interleukin 6	Homo sapiens	6-10
25638528-11	2015	A notable exception was the hypomethylation of a CG site in the promoter region of the cytoskeleton-regulating gene RAC1 in LDGs.	cysteinylglycine	49-51	Rac family small GTPase 1	Homo sapiens	116-120
25875799-4	2015	In branch duct IPMNs, VEGF +405C/C was significantly associated with malignant transformation (CC vs GG: OR, 4.0; P = 0.03; CC vs CG + GG: OR, 3.3; P = 0.04), and there was a trend of VEGF +405C/C associated with malignant transformation of gastric-type IPMNs (CC vs GG: OR, 3.0; P = 0.07).	cysteinylglycine	130-132	vascular endothelial growth factor A	Homo sapiens	22-26
25684209-4	2015	MBD7 preferentially binds to highly methylated, CG-dense regions and physically associates with other anti-silencing factors, including the histone acetyltransferase IDM1 and the alpha-crystallin domain proteins IDM2 and IDM3.	cysteinylglycine	48-50	methyl-CPG-binding domain 7	Arabidopsis thaliana	0-4
25768087-10	2015	The replication of the negative association of the CG/GG-genotype of rs528557 ADAM33 with childhood asthma in an independent birth cohort study confirms that a compromised ADAM33 gene may be implicated in the progression of wheeze into childhood asthma.	cysteinylglycine	51-53	ADAM metallopeptidase domain 33	Homo sapiens	78-84
25768087-10	2015	The replication of the negative association of the CG/GG-genotype of rs528557 ADAM33 with childhood asthma in an independent birth cohort study confirms that a compromised ADAM33 gene may be implicated in the progression of wheeze into childhood asthma.	cysteinylglycine	51-53	ADAM metallopeptidase domain 33	Homo sapiens	172-178
25639450-10	2015	The MMP-9 1721 C/G polymorphism was associated with a protective effect in both men and women groups (CG+GG vs. CC: P=0.04 and P=0.0002, respectively).	cysteinylglycine	102-104	matrix metallopeptidase 9	Homo sapiens	4-9
25789079-8	2015	The highest association was for CG-137 methylation, which contributed 13% to the variance of height and 10% to serum IGF1.	cysteinylglycine	32-34	insulin like growth factor 1	Homo sapiens	117-121
25945528-5	2015	RESULTS: APOE E3/E3 was more prevalent (SG=74.6%; CG=77.4%), with no difference between both groups (P=0.667).	cysteinylglycine	50-52	apolipoprotein E	Homo sapiens	9-13
24620780-10	2015	In PBC liver, OCT1 protein levels were lower in patients with minor (CG/GG at rs683369 and/or CC at rs622342) than major (CC at rs683369 and AA at rs622342) genotypes of the OCT1 gene.	cysteinylglycine	69-71	solute carrier family 22 member 1	Homo sapiens	14-18
26225711-5	2015	RESULTS: A total of nine studies including 5,102 cases and 6,326 controls based on the search criteria were included and significant associations were found between ERCC5 rs17655 polymorphism CG vs GG overall (OR=1.29, 95% CI=1.18~1.40) and in the dominant model (OR=1.23, 95% CI=1.13~1.33).	cysteinylglycine	192-194	ERCC excision repair 5, endonuclease	Homo sapiens	165-170
25973100-4	2015	In the Cox proportional hazards model, we observed that individuals carrying CG+GG genotype of STAT3 rs4796793 was associated with reduced risk of death from breast cancer when compared with CC genotype (HR = 0.43, 95% CI = 0.20-0.93).	cysteinylglycine	77-79	signal transducer and activator of transcription 3	Homo sapiens	95-100
25451439-8	2015	The antioxidative enzyme GST was significantly elevated in both patients and controls (BD: M 298.24, SD 133.02; CG: M 307.27 SD 118.18).	cysteinylglycine	112-114	glutathione S-transferase kappa 1	Homo sapiens	25-28
25713769-7	2015	RESULTS: PNPLA3 genotypes were CC, CG, and GG for 118, 72, and 41 patients, respectively.	cysteinylglycine	35-37	patatin like phospholipase domain containing 3	Homo sapiens	9-15
25488073-8	2015	A CC genotype was associated with higher levels of plasma VEGFA at baseline (107.6 versus 57.50 pg/mL in heterozygotes (CG) and 52.75 pg/mL in GG patients, P = 0.035 and P = 0.028 respectively).	cysteinylglycine	120-122	vascular endothelial growth factor A	Homo sapiens	58-63
25450314-1	2015	Several psychiatric disorders have been associated with CpG methylation changes in CG rich promoters of the brain-derived neurotrophic factor (BDNF) mainly by extracting DNA from peripheral blood cells.	cysteinylglycine	83-85	brain derived neurotrophic factor	Homo sapiens	108-141
25450314-1	2015	Several psychiatric disorders have been associated with CpG methylation changes in CG rich promoters of the brain-derived neurotrophic factor (BDNF) mainly by extracting DNA from peripheral blood cells.	cysteinylglycine	83-85	brain derived neurotrophic factor	Homo sapiens	143-147
26731990-7	2015	CONCLUSIONS: The article provides evidence that GG genotype and G carrier (CG+GG) genotypes of the rs4640525 polymorphism in the APPL1 gene may be suitable susceptibility biomarkers for NAFLD.	cysteinylglycine	75-77	adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1	Homo sapiens	129-134
25451162-3	2015	We identified 2984 CG sites across the genome with unique loss of DNA methylation in double negative T cells, and showed significant reduction in mRNA expression of DNA methyltransferases DNMT1, DNMT3A, and DNMT3B.	cysteinylglycine	19-21	DNA methyltransferase 1	Homo sapiens	188-193
25451162-3	2015	We identified 2984 CG sites across the genome with unique loss of DNA methylation in double negative T cells, and showed significant reduction in mRNA expression of DNA methyltransferases DNMT1, DNMT3A, and DNMT3B.	cysteinylglycine	19-21	DNA methyltransferase 3 alpha	Homo sapiens	195-201
25451162-3	2015	We identified 2984 CG sites across the genome with unique loss of DNA methylation in double negative T cells, and showed significant reduction in mRNA expression of DNA methyltransferases DNMT1, DNMT3A, and DNMT3B.	cysteinylglycine	19-21	DNA methyltransferase 3 beta	Homo sapiens	207-213
25702660-11	2015	CONCLUSIONS: In conclusion, both the CG carriers/G allele carriers of rs2267437 (XRCC6) and the haplotype AT/CC established by the SNPs of XRCC5 are associated with ESCC susceptibility.	cysteinylglycine	37-39	X-ray repair cross complementing 6	Homo sapiens	81-86
25695131-8	2015	In the human genome, ~ 11% of GATC sites overlap with CGs (e.g., CGAT(m)CG); therefore, the methylated status of these sites can be perpetuated by human DNMT1.	cysteinylglycine	54-56	DNA methyltransferase 1	Homo sapiens	153-158
26664829-12	2015	IL6 G-174C GG genotype (2.23 +- 0.14 pg/mL) was 19% greater than CG or CC genotypes.	cysteinylglycine	65-67	interleukin 6	Homo sapiens	0-3
25702660-11	2015	CONCLUSIONS: In conclusion, both the CG carriers/G allele carriers of rs2267437 (XRCC6) and the haplotype AT/CC established by the SNPs of XRCC5 are associated with ESCC susceptibility.	cysteinylglycine	37-39	X-ray repair cross complementing 5	Homo sapiens	139-144
25565272-5	2014	By contrast, the rs11515*CG+GG of CDKN2A gene was more frequent in the controls (32.65%) than in patients (15.56%), reducing the risk for s-MTC (OR=0.174; 95% CI=0.048-0.627; P=0.0075).	cysteinylglycine	25-27	cyclin dependent kinase inhibitor 2A	Homo sapiens	34-40
25088792-5	2014	RESULTS: Variant genotype (CC vs CG+GG) (p<0.001: OR=2.22: 95% CI=1.60-3.10) of 420C/G resistin gene polymorphism was less frequently observed in control population.	cysteinylglycine	33-35	resistin	Homo sapiens	90-98
25427234-1	2014	Dug1p, a M20 family metallopeptidase and human orthologue of carnosinase, hydrolyzes Cys-Gly dipeptide, the last step of glutathione (GSH) degradation in Saccharomyces cerevisiae.	cysteinylglycine	85-92	metallodipeptidase	Saccharomyces cerevisiae S288C	0-5
24770678-6	2014	RESULTS: In the training group, only the rs4919510 SNP of the mir-608 gene was significantly associated with clinical outcome (CG vs. GG, hazard ratio [HR] 0.47, 95 % confidence interval [CI] 0.27-0.82, P = 0.008 for death, HR 0.47, 95 % CI 0.29-0.77, P = 0.002 for recurrence).	cysteinylglycine	127-129	microRNA 608	Homo sapiens	62-69
24477600-5	2014	The barrier-protective effect of adenosine in response to thrombin was recapitulated by the A2A specific agonist, CGS 21680, and abrogated both by the siRNA knockdown of the A2A receptor and by the A2A -specific antagonists, ZM-241385 and SCH-58261.	cysteinylglycine	114-117	coagulation factor II, thrombin	Homo sapiens	58-66
25546664-8	2014	With respect to miR-146a rs2910164 polymorphism, statistical significant increased HCC risk was found when all studies were pooled into the meta-analysis (GG+CG vs CC: OR = 1.097, 95% CI 1.005-1.197, P = 0.037).	cysteinylglycine	158-160	microRNA 146a	Homo sapiens	16-24
25277193-5	2014	EMSA assays confirmed that purified USF1 binds better toward the unmethylated than the methylated CG-containing USF1 consensus probe.	cysteinylglycine	98-100	upstream transcription factor 1	Homo sapiens	36-40
25277193-5	2014	EMSA assays confirmed that purified USF1 binds better toward the unmethylated than the methylated CG-containing USF1 consensus probe.	cysteinylglycine	98-100	upstream transcription factor 1	Homo sapiens	112-116
23075575-6	2014	In addition, interleukin-15 (IL-15) and intercellular adhesion molecule-1 (ICAM-1) were significantly increased in CG-inhaled animals.	cysteinylglycine	115-117	interleukin 15	Rattus norvegicus	13-27
23075575-6	2014	In addition, interleukin-15 (IL-15) and intercellular adhesion molecule-1 (ICAM-1) were significantly increased in CG-inhaled animals.	cysteinylglycine	115-117	interleukin 15	Rattus norvegicus	29-34
23075575-6	2014	In addition, interleukin-15 (IL-15) and intercellular adhesion molecule-1 (ICAM-1) were significantly increased in CG-inhaled animals.	cysteinylglycine	115-117	intercellular adhesion molecule 1	Rattus norvegicus	40-73
23075575-6	2014	In addition, interleukin-15 (IL-15) and intercellular adhesion molecule-1 (ICAM-1) were significantly increased in CG-inhaled animals.	cysteinylglycine	115-117	intercellular adhesion molecule 1	Rattus norvegicus	75-81
23075575-7	2014	Ulinastatin administration at 1 h postexposure significantly reduced the intensity of all the pathological changes in the lungs of these CG-exposed animals.	cysteinylglycine	137-139	alpha-1-microglobulin/bikunin precursor	Rattus norvegicus	0-11
23075575-10	2014	Thus, our data suggest that ulinastatin can be used as an effective drug for the treatment of CG-induced ALI.	cysteinylglycine	94-96	alpha-1-microglobulin/bikunin precursor	Rattus norvegicus	28-39
23075575-11	2014	The serum levels of IL-15 and ICAM-1 can be used as the markers of lung injury after exposure to CG and may also serve as useful therapeutic targets at an early stage.	cysteinylglycine	97-99	interleukin 15	Rattus norvegicus	20-25
23075575-11	2014	The serum levels of IL-15 and ICAM-1 can be used as the markers of lung injury after exposure to CG and may also serve as useful therapeutic targets at an early stage.	cysteinylglycine	97-99	intercellular adhesion molecule 1	Rattus norvegicus	30-36
25356148-8	2014	Increased IL-6 levels were correlated with the IL-6 -634G allele carriers (CG+GG genotypes).	cysteinylglycine	75-77	interleukin 6	Homo sapiens	10-14
25356148-8	2014	Increased IL-6 levels were correlated with the IL-6 -634G allele carriers (CG+GG genotypes).	cysteinylglycine	75-77	interleukin 6	Homo sapiens	47-51
24952884-5	2014	In subgroup meta-analysis, rs2910164 in miR-146a and large-artery atherosclerosis, rather than small-vessel disease, showed the significant association under the dominant model (CC vs CG+GG, OR 1.694; 95 % CI 1.199-2.395 p = 0.003).	cysteinylglycine	184-186	microRNA 146a	Homo sapiens	40-48
24992162-8	2014	RESULTS: Our results indicated that the GG genotype and G carrier (CG+GG) of rs2228314 G>C polymorphism in the SREBP-2 gene were strongly associated with susceptibility to NAFLD (both p<0.001).	cysteinylglycine	67-69	sterol regulatory element binding transcription factor 2	Homo sapiens	114-121
24992162-11	2014	CONCLUSION: The results of this study provide evidence that the GG genotype and G carrier (CG+GG) of rs2228314 G>C polymorphism in the SREBP-2 gene may increase the risk of NAFLD.	cysteinylglycine	91-93	sterol regulatory element binding transcription factor 2	Homo sapiens	138-145
24361450-5	2014	A lower BDNF concentration (20 ng/ml) was only effective to inhibit LTD if A(2A)Rs were activated by a selective agonist, CGS 21680 (10 nM), or if the extracellular adenosine level was increased by 5-iodotubercidin (100 nM).	cysteinylglycine	122-125	brain-derived neurotrophic factor	Rattus norvegicus	8-12
24884070-3	2014	At 3 and 10 nM, the A2AR agonist CGS-21680 enhanced [(3)H]-GABA release induced by high K(+) (20 mM) and the effect of 3 nM CGS-21680 was prevented by the A2AR antagonist ZM-241385 (100 nM).	cysteinylglycine	33-36	adenosine A2a receptor	Rattus norvegicus	20-24
24884070-3	2014	At 3 and 10 nM, the A2AR agonist CGS-21680 enhanced [(3)H]-GABA release induced by high K(+) (20 mM) and the effect of 3 nM CGS-21680 was prevented by the A2AR antagonist ZM-241385 (100 nM).	cysteinylglycine	33-36	adenosine A2a receptor	Rattus norvegicus	155-159
24884070-3	2014	At 3 and 10 nM, the A2AR agonist CGS-21680 enhanced [(3)H]-GABA release induced by high K(+) (20 mM) and the effect of 3 nM CGS-21680 was prevented by the A2AR antagonist ZM-241385 (100 nM).	cysteinylglycine	124-127	adenosine A2a receptor	Rattus norvegicus	20-24
24884070-3	2014	At 3 and 10 nM, the A2AR agonist CGS-21680 enhanced [(3)H]-GABA release induced by high K(+) (20 mM) and the effect of 3 nM CGS-21680 was prevented by the A2AR antagonist ZM-241385 (100 nM).	cysteinylglycine	124-127	adenosine A2a receptor	Rattus norvegicus	155-159
24912137-8	2014	Results show that the adenosine A2a receptor agonist, CGS 21680, increases neurotransmitter release, in particular, glutamate and noradrenaline and such response is mediated by protein kinase A activation, which in turn increased synapsin I phosphorylation.	cysteinylglycine	54-57	adenosine A2a receptor	Rattus norvegicus	22-44
24912137-8	2014	Results show that the adenosine A2a receptor agonist, CGS 21680, increases neurotransmitter release, in particular, glutamate and noradrenaline and such response is mediated by protein kinase A activation, which in turn increased synapsin I phosphorylation.	cysteinylglycine	54-57	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	177-193
24912137-8	2014	Results show that the adenosine A2a receptor agonist, CGS 21680, increases neurotransmitter release, in particular, glutamate and noradrenaline and such response is mediated by protein kinase A activation, which in turn increased synapsin I phosphorylation.	cysteinylglycine	54-57	synapsin I	Rattus norvegicus	230-240
25002488-2	2014	In the dicot model plant Arabidopsis thaliana, methyltransferase 1 (MET1), a principal CG methylase, functions to maintain (m)CG during DNA replication, with its null mutation resulting in global hypomethylation and pleiotropic developmental defects.	cysteinylglycine	87-89	methyltransferase 1	Arabidopsis thaliana	47-66
25002488-2	2014	In the dicot model plant Arabidopsis thaliana, methyltransferase 1 (MET1), a principal CG methylase, functions to maintain (m)CG during DNA replication, with its null mutation resulting in global hypomethylation and pleiotropic developmental defects.	cysteinylglycine	87-89	methyltransferase 1	Arabidopsis thaliana	68-72
24556216-7	2014	Only variant rs236918 in the PCSK7 gene (proprotein convertase subtilisin/kexin type 7) was associated with cirrhosis or advanced fibrosis (P = 1.02 x 10(-5)) in the German cohort with genotypic odds ratios of 3.56 (95% CI 1.29-9.77) for CG heterozygotes and 5.38 (95% CI 2.39-12.10) for C allele carriers.	cysteinylglycine	238-240	proprotein convertase subtilisin/kexin type 7	Homo sapiens	29-34
24556216-7	2014	Only variant rs236918 in the PCSK7 gene (proprotein convertase subtilisin/kexin type 7) was associated with cirrhosis or advanced fibrosis (P = 1.02 x 10(-5)) in the German cohort with genotypic odds ratios of 3.56 (95% CI 1.29-9.77) for CG heterozygotes and 5.38 (95% CI 2.39-12.10) for C allele carriers.	cysteinylglycine	238-240	proprotein convertase subtilisin/kexin type 7	Homo sapiens	41-86
24922697-6	2014	The hOGG1 Ser326Cys polymorphism (CG or GG vs. CC genotypes) was shown as a protective factor against UADT cancer in moderate smokers (p=0.031).	cysteinylglycine	34-36	8-oxoguanine DNA glycosylase	Homo sapiens	4-9
24390153-4	2014	Objective was to investigate the impact of an acute levodopa application with and without catechol-O-methyltransferase inhibitor on cysteine- and cysteinyl-glycine plasma levels.	cysteinylglycine	146-163	catechol-O-methyltransferase	Homo sapiens	90-118
24685936-10	2014	FRAP was increased (p<0.05) in the NTFG (4,651 +- 192.5 mmol/mL) and the TFG (4,743 +- 116.7 mmol/mL) when compared with the CG (1,844 +- 343.8 mmol/mL).	cysteinylglycine	128-130	mechanistic target of rapamycin kinase	Homo sapiens	0-4
24521981-4	2014	We demonstrate that caffeine and CGS 15943 block proliferation in HCC and PDAC cell lines by inhibiting the PI3K/Akt pathway.	cysteinylglycine	33-36	AKT serine/threonine kinase 1	Homo sapiens	113-116
24889129-5	2014	The histological analysis showed that both CGS-21680 and dexamethasone produced a marked reduction of inflammatory cell infiltrate, which correlated with diminished myeloperoxidase (MPO) activity in skin homogenates.	cysteinylglycine	43-46	myeloperoxidase	Mus musculus	165-180
24889129-5	2014	The histological analysis showed that both CGS-21680 and dexamethasone produced a marked reduction of inflammatory cell infiltrate, which correlated with diminished myeloperoxidase (MPO) activity in skin homogenates.	cysteinylglycine	43-46	myeloperoxidase	Mus musculus	182-185
24893910-9	2014	We also encountered four hypermethylated CG sites in the Glra1 PR, as well as three in the risperidone group and another in the haloperidol group, when compared to non-treated rats.	cysteinylglycine	41-43	glycine receptor, alpha 1	Rattus norvegicus	57-62
24971745-6	2014	Detailed analyses of specific genes at intermediate levels of the tree suggest that Vacuolar ATPase and lysosomal genes involved in vacuolar biogenesis play an evolutionarily conserved role in CG endocytosis.	cysteinylglycine	193-195	Vacuolar H[+] ATPase 68 kDa subunit 2	Drosophila melanogaster	84-99
24755421-7	2014	We found that CG-172 can activate JAK2, AKT, ERK1/2 and STAT1/3 but not STAT5.	cysteinylglycine	14-16	Janus kinase 2	Rattus norvegicus	34-38
24755421-7	2014	We found that CG-172 can activate JAK2, AKT, ERK1/2 and STAT1/3 but not STAT5.	cysteinylglycine	14-16	AKT serine/threonine kinase 1	Rattus norvegicus	40-43
24755421-7	2014	We found that CG-172 can activate JAK2, AKT, ERK1/2 and STAT1/3 but not STAT5.	cysteinylglycine	14-16	mitogen activated protein kinase 3	Rattus norvegicus	45-51
24755421-7	2014	We found that CG-172 can activate JAK2, AKT, ERK1/2 and STAT1/3 but not STAT5.	cysteinylglycine	14-16	signal transducer and activator of transcription 1	Rattus norvegicus	56-63
24755421-8	2014	The phosphorylation kinetics of STAT1/3, AKT and ERK1/2 induced by either GH or CG-172 were analysed in dose-response and time course experiments.	cysteinylglycine	80-82	signal transducer and activator of transcription 1	Rattus norvegicus	32-39
24755421-8	2014	The phosphorylation kinetics of STAT1/3, AKT and ERK1/2 induced by either GH or CG-172 were analysed in dose-response and time course experiments.	cysteinylglycine	80-82	AKT serine/threonine kinase 1	Rattus norvegicus	41-44
24755421-8	2014	The phosphorylation kinetics of STAT1/3, AKT and ERK1/2 induced by either GH or CG-172 were analysed in dose-response and time course experiments.	cysteinylglycine	80-82	mitogen activated protein kinase 3	Rattus norvegicus	49-55
24408019-7	2014	Overall, a significant association between IL6 -634C/G polymorphism and LC susceptibility was observed for GG + CG vs. CC (OR = 1.33, 95% CI 1.20-1.47, P < 0.00001).	cysteinylglycine	112-114	interleukin 6	Homo sapiens	43-46
24318992-7	2014	The combined results showed that association between IL-6-174 G/C polymorphism and risk of HCC was significant under additive model (CC vs. GG: OR 0.36; 95% CI, 0.16, 0.85) and recessive model (GG+CG vs. CC: OR 2.82; 95% CI 1.26, 6.28).	cysteinylglycine	197-199	interleukin 6	Homo sapiens	53-57
24668745-6	2014	In contrast with NUC1, disruption of NUC2 induces CG hypermethylation of rDNA and NOR association with the nucleolus.	cysteinylglycine	50-52	nucleolin like 2	Arabidopsis thaliana	37-41
24626403-2	2014	After the NIR CuInS2 QDs conjugated with the MUC1 aptamer-(CGA)7, DNR can intercalate into the double-stranded CG sequence of the MUC1-QDs.	cysteinylglycine	59-61	mucin 1, cell surface associated	Homo sapiens	45-49
24626403-2	2014	After the NIR CuInS2 QDs conjugated with the MUC1 aptamer-(CGA)7, DNR can intercalate into the double-stranded CG sequence of the MUC1-QDs.	cysteinylglycine	59-61	mucin 1, cell surface associated	Homo sapiens	130-134
24630728-1	2014	Dnmt1 epigenetically propagates symmetrical CG methylation in many eukaryotes.	cysteinylglycine	44-46	DNA methyltransferase 1	Homo sapiens	0-5
24552127-5	2014	After analysis by sex and adjustment for conventional risk factors, the beta1 -AR Gly389 homozygote conferred about a 3-fold risk of OH and independently predicted a 6.5 mm Hg greater orthostatic SBP decrease (GG -8.9+-13 mm Hg vs CC+CG -2.4+-12 mm Hg, P<.001) only in female hypertensive patients.	cysteinylglycine	234-236	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	72-77
24411479-2	2014	Defining its Cys-Gly binding site is extremely important not only in defining the physiological function of GGT, but also in designing specific and effective inhibitors for pharmaceutical purposes.	cysteinylglycine	13-20	gamma-glutamyltransferase 2, pseudogene	Homo sapiens	108-111
24411479-10	2014	Ion-spray mass analysis of the inhibited E. coli GGT confirmed the formation of a 1:1 covalent adduct with the catalytic subunit (small subunit) with concomitant loss of phenoxide, leaving the peptidyl moiety that presumably occupies the Cys-Gly binding site.	cysteinylglycine	238-245	gamma-glutamyltransferase 2, pseudogene	Homo sapiens	49-52
24411479-11	2014	The peptidyl phosphonate inhibitors are highly useful as a ligand for X-ray structural analysis of GGT for defining hitherto unidentified Cys-Gly binding site to design specific inhibitors.	cysteinylglycine	138-145	gamma-glutamyltransferase 2, pseudogene	Homo sapiens	99-102
24761851-3	2014	In SiHa, we identified 2 CG sites methylated from all of 12CpG sites of the hRFT2 gene.	cysteinylglycine	25-27	solute carrier family 52 member 3	Homo sapiens	76-81
24433488-15	2014	CGS varied depending on the location of the mutation within the RyR1 gene.	cysteinylglycine	0-3	ryanodine receptor 1	Homo sapiens	64-68
24391010-6	2013	Statistically significant differences were observed between cases and controls in distribution of genotypes or alleles at PTEN rs701848 T/C and rs2735343 C/G, with either haplotype TG or CG possessing notably higher proportion in cases than in the controls.	cysteinylglycine	187-189	phosphatase and tensin homolog	Homo sapiens	122-126
24265036-7	2014	The ESR1 PvuII XbaI CG haplotype was associated with the time to the occurrence of hot flashes during the complete time on tamoxifen (CG/CG vs. CG/other + other/other: adjusted hazard ratio 0.49, 95 % CI 0.25-0.97; p = 0.04).	cysteinylglycine	20-22	estrogen receptor 1	Homo sapiens	4-8
24265036-7	2014	The ESR1 PvuII XbaI CG haplotype was associated with the time to the occurrence of hot flashes during the complete time on tamoxifen (CG/CG vs. CG/other + other/other: adjusted hazard ratio 0.49, 95 % CI 0.25-0.97; p = 0.04).	cysteinylglycine	134-136	estrogen receptor 1	Homo sapiens	4-8
24265036-7	2014	The ESR1 PvuII XbaI CG haplotype was associated with the time to the occurrence of hot flashes during the complete time on tamoxifen (CG/CG vs. CG/other + other/other: adjusted hazard ratio 0.49, 95 % CI 0.25-0.97; p = 0.04).	cysteinylglycine	134-136	estrogen receptor 1	Homo sapiens	4-8
25482940-8	2014	Moreover, patients carrying the MDM2 c.-461 > G -c.14 + 309T > G CG/CT diplotype exhibited higher toxicities than those carrying CG/CG.	cysteinylglycine	71-73	MDM2 proto-oncogene	Homo sapiens	32-36
23982872-7	2014	In the subgroup analysis by cancer type, we observed that the PIN1 rs2233678 polymorphism was significantly associated with decreased breast cancer risk (C-allele vs. G-allele: OR = 0.73, 95% CI: 0.60-0.89; CC+CG vs. GG: OR = 0.71, 95% CI 0.57-0.89).	cysteinylglycine	210-212	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	62-66
24279389-12	2013	These results suggest that gamma irradiation induced DNA hypomethylation preferentially at non-CG sites of transcriptionally inactive repeats in a locus-specific manner, which depends on CMT3 activity.	cysteinylglycine	95-97	chromomethylase 3	Arabidopsis thaliana	187-191
24968778-4	2014	The A2A agonist CGS 21680 with atypical antipsychotic properties may at least in part act by increasing beta-arrestin2 signaling over the D2 protomer in the A2A-D2 heteroreceptor complex in the ventral striatum.	cysteinylglycine	16-19	arrestin beta 2	Homo sapiens	104-118
23793976-6	2013	Six weeks after implantation, LDI showed that mice who received CGS with 1 mug/cm(2) bFGF had the greatest mean blood flow, and these mice had the heaviest resected specimens, which contained the most newly formed adipose tissue.	cysteinylglycine	64-67	fibroblast growth factor 2	Mus musculus	85-89
23794133-6	2013	The frequencies of CC, CG, and GG genotypes of CYP1B1 C4326G in cases and controls were 66.0, 26.8, 7.2% and 75.2, 21.6, and 3.2%, respectively, and there was a significant difference between the two groups (P = 0.034).	cysteinylglycine	23-25	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	47-53
23860373-4	2013	In nonischemic piglets, direct infusion of the selective A2A receptor agonist CGS 21680 through microdialysis probes into putamen increased phosphorylation of N-methyl-D-aspartic acid (NMDA) receptor NR1 subunit and Na(+),K(+)-ATPase selectively at protein kinase A (PKA)-sensitive sites.	cysteinylglycine	78-81	glutamate ionotropic receptor NMDA type subunit 1	Homo sapiens	200-203
23849964-8	2013	RESULTS: Twelve and 24-hour post-PCI Creatine Kinase Muscle and Brain (CK-MB) elevation >3x occurred more frequently in the CG than in the RG and in the AG (at 24-h: 25.0 vs 7.1; p=0.003 and 25.0 vs 6.1; p=0.001).	cysteinylglycine	127-129	creatine kinase, M-type	Homo sapiens	37-69
24497707-8	2013	For the Pro12Ala polymorphism of PPARgamma gene, genotypic distributions and allelic frequencies were, 0.813 for CC, 0.181 for CG and 0.06 for GG and 0.903 for C and 0.097 for G respectively.	cysteinylglycine	127-129	peroxisome proliferator activated receptor gamma	Homo sapiens	33-42
23859071-3	2013	Recipient PNPLA-3 genotype was independently associated with obesity (BMI > 30) at 3 years posttransplant (genotype CC 33.7%, CG 48.3% and GG 82.4%, p = 0.002), with an odds ratio (OR 2.54, CI 1.38-4.66, p = 0.003), associated with the G allele.	cysteinylglycine	129-131	patatin like phospholipase domain containing 3	Homo sapiens	10-17
23587453-7	2013	The highly selective A2AR agonist CGS 21680 significantly improved vascular reactivity, hemodynamic parameters, and animal survival, whereas the specific antagonist SCH58261 further decreased the shock-induced reduction in vascular reactivity and hemodynamic parameters.	cysteinylglycine	34-37	adenosine A2a receptor	Rattus norvegicus	21-25
23301633-0	2013	The adenosine A2A receptor agonist CGS 21680 decreases ethanol self-administration in both non-dependent and dependent animals.	cysteinylglycine	35-38	adenosine A2a receptor	Mus musculus	4-26
23301633-3	2013	Here, we investigated whether the A2AR agonist CGS 21680 can reduce ethanol operant self-administration in both non-dependent and ethanol-dependent Wistar rats.	cysteinylglycine	47-50	adenosine A2a receptor	Rattus norvegicus	34-38
23301633-10	2013	In conclusion, our findings demonstrated the effectiveness of the A2AR agonist CGS 21680 in a preclinical model of alcohol addiction and suggested that the adenosinergic pathway is a promising target to treat alcohol addiction.	cysteinylglycine	79-82	adenosine A2a receptor	Mus musculus	66-70
23820669-9	2013	A switch towards up-regulation of physiological growth signalling was observed: the ratio of p-Akt/t-Akt was 2-fold higher in GT vs CG, P < 0.05 while p-JNK/t-JNK was 2.5-fold lower (P < 0.05) in GT vs CG, in pre-HTx samples.	cysteinylglycine	132-134	AKT serine/threonine kinase 1	Homo sapiens	95-98
23820669-9	2013	A switch towards up-regulation of physiological growth signalling was observed: the ratio of p-Akt/t-Akt was 2-fold higher in GT vs CG, P < 0.05 while p-JNK/t-JNK was 2.5-fold lower (P < 0.05) in GT vs CG, in pre-HTx samples.	cysteinylglycine	132-134	AKT serine/threonine kinase 1	Homo sapiens	101-104
24191238-0	2013	Effect of Nrf2 activators on release of glutathione, cysteinylglycine and homocysteine by human U373 astroglial cells.	cysteinylglycine	53-69	NFE2 like bZIP transcription factor 2	Homo sapiens	10-14
23239496-4	2013	We found that SNO uptake and NO-dependent actions, such as the activation of soluble guanylyl cyclase (sGC), the augmentation of sGC-dependent filamentous actin (F-actin) polymerization, phagocytosis, and the inhibition of NF-kappaB activation, were significantly augmented by the addition of Cys-Gly in a manner dependent on PEPT2 transport.	cysteinylglycine	293-300	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	129-132
23807313-5	2013	We found 3 contexts (CG, CNG, and CNN) of methylated cytosines in the regulatory region of Solanum lycopersicum Asr2 but only one context (CG) in the gene body.	cysteinylglycine	21-23	abscisic stress-ripening protein 2	Solanum lycopersicum	112-116
23614786-6	2013	The presence of Rep suppressed TGS of an Arabidopsis thaliana transgene and of host loci whose expression was strongly controlled by CG methylation.	cysteinylglycine	133-135	Rab escort protein	Arabidopsis thaliana	16-19
23614786-7	2013	Bisulfite sequencing analyses showed that the expression of Rep caused a substantial reduction in the levels of DNA methylation at CG sites.	cysteinylglycine	131-133	Rab escort protein	Arabidopsis thaliana	60-63
23504554-5	2013	The gene-gene interaction of miR-34b/c rs4938723 and TP-53 Arg72-Pro showed that the combined genotypes of rs4938723CT/CC and TP-53CG/CC increased the risk of NPC (rs4938723CT/CC + TP-53CG/CC vs. rs4938723 TT+TP-53 CG/CC: OR=1.58, 95 % CI 1.04-2.42, p=0.03).	cysteinylglycine	131-133	microRNA 34b	Homo sapiens	29-36
23504554-5	2013	The gene-gene interaction of miR-34b/c rs4938723 and TP-53 Arg72-Pro showed that the combined genotypes of rs4938723CT/CC and TP-53CG/CC increased the risk of NPC (rs4938723CT/CC + TP-53CG/CC vs. rs4938723 TT+TP-53 CG/CC: OR=1.58, 95 % CI 1.04-2.42, p=0.03).	cysteinylglycine	131-133	tumor protein p53	Homo sapiens	53-58
23374503-7	2013	RESULTS: Grade >=3 RP was experienced by 13% of those with CG/GG and 29% of those with CC genotype of HSPB1 rs2868371 in the training data set (P=.028); corresponding rates in the validation data set were 2% CG/GG and 14% CC (P=.02).	cysteinylglycine	211-213	heat shock protein family B (small) member 1	Homo sapiens	105-110
23374503-8	2013	Univariate and multivariate analysis confirmed the association of CC of HSPB1 rs2868371 with higher risk of grade >=3 RP than CG/GG after adjustment for sex, age, performance status, and lung mean dose.	cysteinylglycine	129-131	heat shock protein family B (small) member 1	Homo sapiens	72-77
23603420-6	2013	Significant associations were observed for the dominant model in two ACE tag SNPs influencing serum ACE concentrations (rs8066114 polymorphism: GG+CG vs. CC; rs4461142 polymorphism: TT+CT vs. CC).	cysteinylglycine	147-149	angiotensin I converting enzyme	Homo sapiens	69-72
23603420-6	2013	Significant associations were observed for the dominant model in two ACE tag SNPs influencing serum ACE concentrations (rs8066114 polymorphism: GG+CG vs. CC; rs4461142 polymorphism: TT+CT vs. CC).	cysteinylglycine	147-149	angiotensin I converting enzyme	Homo sapiens	100-103
23857790-7	2013	The most hypomethylated CG site is located in the promoter of SSTR4 (somatostatin receptor 4) and the most hypermethylated CG site is GABRP (gamma-aminobutyric acid A receptor).	cysteinylglycine	24-26	somatostatin receptor 4	Homo sapiens	62-67
23857790-7	2013	The most hypomethylated CG site is located in the promoter of SSTR4 (somatostatin receptor 4) and the most hypermethylated CG site is GABRP (gamma-aminobutyric acid A receptor).	cysteinylglycine	24-26	somatostatin receptor 4	Homo sapiens	69-92
23857790-7	2013	The most hypomethylated CG site is located in the promoter of SSTR4 (somatostatin receptor 4) and the most hypermethylated CG site is GABRP (gamma-aminobutyric acid A receptor).	cysteinylglycine	123-125	gamma-aminobutyric acid type A receptor subunit pi	Homo sapiens	134-139
23318131-7	2013	For 5HTR1A, patients homozygous for the -1019 G allele presented higher Beck Depression Inventory scores relative to the CG/CC group, indicating a major effect of this SNP on depression.	cysteinylglycine	121-123	5-hydroxytryptamine receptor 1A	Homo sapiens	0-10
23255614-8	2013	The GSH precursor dipeptide, cysteinyl glycine (cysgly), and the glutamate derivative N-acetyl glutamate (NAG), inhibited uptake of PAH when present in the medium and trans-stimulated uptake of PAH from the intracellular side, indicating that they are hitherto unrecognized transported substrates of OAT1.	cysteinylglycine	29-46	solute carrier family 22 member 6	Homo sapiens	300-304
23255614-12	2013	However, OAT1 could support intracellular GSH synthesis by taking up cysteinyl glycine.	cysteinylglycine	69-86	solute carrier family 22 member 6	Homo sapiens	9-13
23203508-3	2013	The latter dipeptide is a substrate of leucyl aminopeptidase, which hydrolyzes cysteinylglycine to glycine and cysteine that can be easily measured spectrophotometrically.	cysteinylglycine	79-95	leucine aminopeptidase 3	Homo sapiens	39-60
23898084-7	2013	Moreover, a multivariate analysis showed that the CC genotype of miR-146a rs2910164 was associated with worse relapse-free and disease-specific survival compared to the CG or GG genotype in a recessive model of the C allele, adjusted for patient and tumor characteristics (hazard ratio=2.120 and 2.349, p=0.005 and 0.007, respectively).	cysteinylglycine	169-171	microRNA 146a	Homo sapiens	65-73
23726031-2	2013	We synthesized rhodanine derivatives, CG-707 and BR-1, which inhibited PRL-3 enzymatic activity with IC50 values of 0.8 muM and 1.1 muM, respectively.	cysteinylglycine	38-40	protein tyrosine phosphatase 4A3	Homo sapiens	71-76
23726031-2	2013	We synthesized rhodanine derivatives, CG-707 and BR-1, which inhibited PRL-3 enzymatic activity with IC50 values of 0.8 muM and 1.1 muM, respectively.	cysteinylglycine	38-40	latexin	Homo sapiens	120-123
23726031-2	2013	We synthesized rhodanine derivatives, CG-707 and BR-1, which inhibited PRL-3 enzymatic activity with IC50 values of 0.8 muM and 1.1 muM, respectively.	cysteinylglycine	38-40	latexin	Homo sapiens	132-135
23179048-3	2013	Also, the nitric oxide synthase (NOS) inhibitor, L-NAME, was used in co-incubation with CGS-21680.	cysteinylglycine	88-91	nitric oxide synthase 2	Homo sapiens	10-31
23349051-8	2013	We tested an ADORA2A-specific agonist, CGS-21680 hydrochloride, in LPS plus oxygen-exposed WT and ADORA2A(-/-) mice.	cysteinylglycine	39-42	adenosine A2a receptor	Mus musculus	13-20
23637617-8	2013	Lack of Dnmt3a or Dnmt3L resulted in a global reduction in both CG and non-CG methylation, showing that non-CG methylation depends on the Dnmt3a-Dnmt3L complex.	cysteinylglycine	64-66	DNA methyltransferase 3A	Mus musculus	8-14
23637617-8	2013	Lack of Dnmt3a or Dnmt3L resulted in a global reduction in both CG and non-CG methylation, showing that non-CG methylation depends on the Dnmt3a-Dnmt3L complex.	cysteinylglycine	64-66	DNA (cytosine-5-)-methyltransferase 3-like	Mus musculus	18-24
23637617-8	2013	Lack of Dnmt3a or Dnmt3L resulted in a global reduction in both CG and non-CG methylation, showing that non-CG methylation depends on the Dnmt3a-Dnmt3L complex.	cysteinylglycine	64-66	DNA methyltransferase 3A	Mus musculus	138-144
23637617-8	2013	Lack of Dnmt3a or Dnmt3L resulted in a global reduction in both CG and non-CG methylation, showing that non-CG methylation depends on the Dnmt3a-Dnmt3L complex.	cysteinylglycine	64-66	DNA (cytosine-5-)-methyltransferase 3-like	Mus musculus	145-151
23637617-11	2013	Dnmt1 may act on CG sites that remain hemimethylated in the de novo methylation process.	cysteinylglycine	17-19	DNA methyltransferase (cytosine-5) 1	Mus musculus	0-5
23283737-4	2013	In Eca109, we identified 6 CG sites methylated from all of 22 CpG sites of LMP7 gene.	cysteinylglycine	27-29	proteasome 20S subunit beta 8	Homo sapiens	75-79
23318391-9	2013	Similar advantage was observed in the dosimetry of contralateral breast where the percent maximum dose for CG-Darc, 3D CRT, and RapidArc were 3.9%, 6.3%, and 5.8% for group A and 4.3%, 9.2%, and 6.3% for group B, respectively (p < 0.05).	cysteinylglycine	107-109	atypical chemokine receptor 1 (Duffy blood group)	Homo sapiens	110-114
22847551-6	2013	Extracellular levels of cysteinylglycine decreased in response to all concentrations of IL-1beta and TNF-alpha.	cysteinylglycine	24-40	interleukin 1 beta	Homo sapiens	88-96
23152114-7	2013	CGS-21680 (10(-6) M)-induced relaxation was higher in sEH(-/-) (+37.4 +- 5.4%) vs. sEH(+/+) (+2.14 +- 2.8%).	cysteinylglycine	0-3	epoxide hydrolase 2, cytoplasmic	Mus musculus	54-57
22847551-6	2013	Extracellular levels of cysteinylglycine decreased in response to all concentrations of IL-1beta and TNF-alpha.	cysteinylglycine	24-40	tumor necrosis factor	Homo sapiens	101-110
22989351-6	2013	However, the development of advanced fibrosis (F3-4) was significantly faster in patients with YKL-40-G-allele: t(CC) = 4.6 versus t(CG/GG) = 2.4 years; P = 0.006.	cysteinylglycine	133-135	chitinase 3 like 1	Homo sapiens	95-101
22989351-8	2013	ACR-occurrence was associated with YKL-40-genotypes (ACR: CC = 60.4%, CG = 25.0% and GG = 14.6% vs non-ACR: CC = 74.2%, CG = 23.8% and GG = 2.0%; P = 0.009) and with gender compatibility between donor and recipient (P = 0.012).	cysteinylglycine	70-72	chitinase 3 like 1	Homo sapiens	35-41
22989351-8	2013	ACR-occurrence was associated with YKL-40-genotypes (ACR: CC = 60.4%, CG = 25.0% and GG = 14.6% vs non-ACR: CC = 74.2%, CG = 23.8% and GG = 2.0%; P = 0.009) and with gender compatibility between donor and recipient (P = 0.012).	cysteinylglycine	120-122	chitinase 3 like 1	Homo sapiens	35-41
22933274-9	2012	Competitive Env binding studies revealed three MAb competition groups: CG-I, CG-II, and CG-III.	cysteinylglycine	71-73	endogenous retrovirus group W member 1, envelope	Homo sapiens	12-15
22480748-5	2012	RESULTS: In RA, the TRAILR1 CC genotype was associated with a better response after 3 and 6 months of anti-TNFalpha treatment (CC: 91.7% vs. CG/GG: 62.2%; P=0.019, and CC: 82.6% vs. CG/GG: 56.1%; P=0.019, respectively).	cysteinylglycine	141-143	TNF receptor superfamily member 10a	Homo sapiens	20-27
22480748-5	2012	RESULTS: In RA, the TRAILR1 CC genotype was associated with a better response after 3 and 6 months of anti-TNFalpha treatment (CC: 91.7% vs. CG/GG: 62.2%; P=0.019, and CC: 82.6% vs. CG/GG: 56.1%; P=0.019, respectively).	cysteinylglycine	141-143	tumor necrosis factor	Homo sapiens	107-115
22480748-5	2012	RESULTS: In RA, the TRAILR1 CC genotype was associated with a better response after 3 and 6 months of anti-TNFalpha treatment (CC: 91.7% vs. CG/GG: 62.2%; P=0.019, and CC: 82.6% vs. CG/GG: 56.1%; P=0.019, respectively).	cysteinylglycine	182-184	TNF receptor superfamily member 10a	Homo sapiens	20-27
22480748-8	2012	In PsA, TRAILR1 CC genotype was only associated with EULAR response to infliximab at 6 months (CC: 71.4% vs CG/GG: 50%P=0.048).	cysteinylglycine	108-110	TNF receptor superfamily member 10a	Homo sapiens	8-15
22810848-10	2012	The volume of Lb was significantly reduced and mRNA levels of ABCA3 transporter tended to be lower in TG versus CG.	cysteinylglycine	112-114	ATP-binding cassette, sub-family A (ABC1), member 3	Mus musculus	62-67
24522021-8	2013	On the other hand analysis of MTHFR*ADRA2A (C677T*C-1291G) interaction revealed significant association between ADRA2A CC+CG genotype in the MTHFR TC+TT carriers (p=0.008).	cysteinylglycine	122-124	methylenetetrahydrofolate reductase	Homo sapiens	30-35
24522021-8	2013	On the other hand analysis of MTHFR*ADRA2A (C677T*C-1291G) interaction revealed significant association between ADRA2A CC+CG genotype in the MTHFR TC+TT carriers (p=0.008).	cysteinylglycine	122-124	adrenoceptor alpha 2A	Homo sapiens	36-42
24522021-8	2013	On the other hand analysis of MTHFR*ADRA2A (C677T*C-1291G) interaction revealed significant association between ADRA2A CC+CG genotype in the MTHFR TC+TT carriers (p=0.008).	cysteinylglycine	122-124	adrenoceptor alpha 2A	Homo sapiens	112-118
24522021-8	2013	On the other hand analysis of MTHFR*ADRA2A (C677T*C-1291G) interaction revealed significant association between ADRA2A CC+CG genotype in the MTHFR TC+TT carriers (p=0.008).	cysteinylglycine	122-124	methylenetetrahydrofolate reductase	Homo sapiens	141-146
23805714-8	2013	In erythrocyte membranes, DM2 disturbs ACSS functions at the level of the catalytic component and its responsiveness to hormone action at the level of interactions between CG, and AC.	cysteinylglycine	172-174	immunoglobulin heavy diversity 1-14 (non-functional)	Homo sapiens	26-29
22879591-5	2012	We further confirmed that, in vivo, CG was required for the extracellular release of AnxA1 and CRAMP in a subcutaneous air pouch model.	cysteinylglycine	36-38	annexin A1	Homo sapiens	85-90
22879591-5	2012	We further confirmed that, in vivo, CG was required for the extracellular release of AnxA1 and CRAMP in a subcutaneous air pouch model.	cysteinylglycine	36-38	cathelicidin antimicrobial peptide	Homo sapiens	95-100
22879591-6	2012	In vitro, CG efficiently cleaved AnxA1, releasing the active N-terminal peptide Ac2-26, and processed CRAMP in limited fashion.	cysteinylglycine	10-12	annexin A1	Homo sapiens	33-38
22879591-6	2012	In vitro, CG efficiently cleaved AnxA1, releasing the active N-terminal peptide Ac2-26, and processed CRAMP in limited fashion.	cysteinylglycine	10-12	cathelicidin antimicrobial peptide	Homo sapiens	102-107
22587613-1	2012	Arabidopsis METHYLTRANSFERASE 1 (MET1) controls faithful maintenance of cytosine methylation at CG sites in repetitive regions and central body regions of active genes.	cysteinylglycine	96-98	methyltransferase 1	Arabidopsis thaliana	12-31
22998978-7	2012	In the group treated with EZE the subjects carrying the G allele of the g.1679 C > G silent polymorphism of NPC1L1 gene showed a higher response to EZE than homozygous for the common allele (GG + CG: LDL-C -29.4+-5.0%, CC -23.6+-6.5%, P <0.001).	cysteinylglycine	199-201	NPC1 like intracellular cholesterol transporter 1	Homo sapiens	111-117
22836044-6	2012	Logistic regression analyses, adjusted for age and gender, further showed a significant association between EBI3 rs428253 and protective effects against AR (P=0.015, OR=0.624 for CG/CC).	cysteinylglycine	179-181	Epstein-Barr virus induced 3	Homo sapiens	108-112
22587613-1	2012	Arabidopsis METHYLTRANSFERASE 1 (MET1) controls faithful maintenance of cytosine methylation at CG sites in repetitive regions and central body regions of active genes.	cysteinylglycine	96-98	methyltransferase 1	Arabidopsis thaliana	33-37
22901274-11	2012	Moreover, the concentrations of TNF-alpha and IL-6 in cell culture supernatants were also significantly higher in the subjects with rs4755453GG genotype than in subjects with CG and CC genotype.	cysteinylglycine	175-177	tumor necrosis factor	Homo sapiens	32-41
22901274-11	2012	Moreover, the concentrations of TNF-alpha and IL-6 in cell culture supernatants were also significantly higher in the subjects with rs4755453GG genotype than in subjects with CG and CC genotype.	cysteinylglycine	175-177	interleukin 6	Homo sapiens	46-50
22607186-1	2012	The present study reports on a thermogelling poly(ethylene glycol)-poly(L-alanine-co-L-phenyl alanine) grafted chitosan (CS-g-(PAF-PEG)) system, focusing on phase diagram, transition mechanism, and in vivo gel duration.	cysteinylglycine	121-125	PCNA clamp associated factor	Rattus norvegicus	127-130
22453052-7	2012	Biliary excretion of DNP-SG+DNP-CG was decreased in GLP-2 rats with respect to controls.	cysteinylglycine	32-34	mast cell protease 10	Rattus norvegicus	52-57
22523074-6	2012	We found that human CG (HCG)-induced HLHCGR internalization, cAMP accumulation and ARF6 activation were inhibited by Gallein (betagamma inhibitor), Wortmannin (PI 3-kinase inhibitor), SecinH3 (cytohesin ARF GEF inhibitor), QS11 (an ARF GAP inhibitor), an ARF6 inhibitory peptide and ARF6 siRNA.	cysteinylglycine	20-22	ADP ribosylation factor 6	Homo sapiens	83-87
22523074-6	2012	We found that human CG (HCG)-induced HLHCGR internalization, cAMP accumulation and ARF6 activation were inhibited by Gallein (betagamma inhibitor), Wortmannin (PI 3-kinase inhibitor), SecinH3 (cytohesin ARF GEF inhibitor), QS11 (an ARF GAP inhibitor), an ARF6 inhibitory peptide and ARF6 siRNA.	cysteinylglycine	20-22	Rho/Rac guanine nucleotide exchange factor 2	Homo sapiens	207-210
22523074-6	2012	We found that human CG (HCG)-induced HLHCGR internalization, cAMP accumulation and ARF6 activation were inhibited by Gallein (betagamma inhibitor), Wortmannin (PI 3-kinase inhibitor), SecinH3 (cytohesin ARF GEF inhibitor), QS11 (an ARF GAP inhibitor), an ARF6 inhibitory peptide and ARF6 siRNA.	cysteinylglycine	20-22	ADP ribosylation factor 6	Homo sapiens	255-259
22523074-6	2012	We found that human CG (HCG)-induced HLHCGR internalization, cAMP accumulation and ARF6 activation were inhibited by Gallein (betagamma inhibitor), Wortmannin (PI 3-kinase inhibitor), SecinH3 (cytohesin ARF GEF inhibitor), QS11 (an ARF GAP inhibitor), an ARF6 inhibitory peptide and ARF6 siRNA.	cysteinylglycine	20-22	ADP ribosylation factor 6	Homo sapiens	255-259
21792899-4	2012	TLR3 rs11721827 was associated with rectal cancer (odds ratio [OR] 1.27, 95% confidence interval [CI] 1.02, 1.58 for AC/CC vs. AA genotype, Wald p = 0.035; adjusted p = 0.126); TLR3 rs3775292 and TLR4 rs11536898 were associated with colon cancer (OR 0.68, 95% CI 0.49, 0.95 for GG vs. CC/CG and OR 0.50.	cysteinylglycine	288-290	toll like receptor 3	Homo sapiens	0-4
22707942-6	2012	Methylation at two residues in the CpG island itself (cg 25769822 and cg05016953) was associated with total SLC6A4 expression.	cysteinylglycine	54-56	solute carrier family 6 member 4	Homo sapiens	108-114
22607186-5	2012	As the temperature increased, deprotonation of the chitosan and dehydration of the PEG were suggested, whereas the alpha-helical secondary structure of PAF was slightly changed in the sol-to-gel transition temperature range of 10-50  C. A gel was formed in situ after injecting the CS-g-(PAF-PEG) aqueous solution into the subcutaneous layer of rats.	cysteinylglycine	282-286	PCNA clamp associated factor	Rattus norvegicus	152-155
22502642-8	2012	Treatment of chondrocytes with the HA-blocking peptide Pep-1 and/or a specific A(2A)R agonist (CGS-21680) significantly reduced all of the inflammatory parameters upregulated by IL-1beta.	cysteinylglycine	95-98	interleukin 1 beta	Mus musculus	178-186
22565176-8	2012	Cystatin C has a strong association with MDRD (r = 0.8086) and CG (r = 0.7915) and a low one with creatinine clearance (r = 0.1044).	cysteinylglycine	63-65	cystatin C	Homo sapiens	0-10
23044206-7	2012	However, after adjusting by multivariate logistic regression, the odds ratio (OR) of HCC for the G allele (CG + GG genotypes) carriers was 1.31 (95% confidence interval (CI): 1.00 - 1.71) compared with the CC genotype.	cysteinylglycine	107-109	HCC	Homo sapiens	85-88
21968632-6	2012	days in six patients in each group and all recovered completely by 3 months p.o., except one patient with HB 2 in CG.	cysteinylglycine	114-116	keratin 82	Homo sapiens	106-110
22277648-8	2012	In vitro reconstitution assays revealed that Dug2p and Dug3p were required together for the cleavage of glutathione into glutamate and Cys-Gly.	cysteinylglycine	135-142	glutamine amidotransferase subunit DUG2	Saccharomyces cerevisiae S288C	45-50
22512782-10	2012	By contrast, a CRP4-GFP fusion gene under the control of a CRP4 promoter fragment acquires CG and non-CG methylation in the CRP coding region in leaves similar to the silent endogenous CRP4 gene.	cysteinylglycine	91-93	ECA1 gametogenesis related family protein	Arabidopsis thaliana	15-19
22512782-10	2012	By contrast, a CRP4-GFP fusion gene under the control of a CRP4 promoter fragment acquires CG and non-CG methylation in the CRP coding region in leaves similar to the silent endogenous CRP4 gene.	cysteinylglycine	91-93	ECA1 gametogenesis related family protein	Arabidopsis thaliana	59-63
22512782-10	2012	By contrast, a CRP4-GFP fusion gene under the control of a CRP4 promoter fragment acquires CG and non-CG methylation in the CRP coding region in leaves similar to the silent endogenous CRP4 gene.	cysteinylglycine	91-93	ECA1 gametogenesis related family protein	Arabidopsis thaliana	59-63
22221294-5	2012	MBL2 C(-290)G-G161A C-G haplotype was overrepresented in LC group in 5-year-olds (P = 0.01), while the opposite association was observed in 13-year-olds, where C-G was overrepresented in HC group (P = 0.028).	cysteinylglycine	20-23	mannose binding lectin 2	Homo sapiens	0-4
22262850-5	2012	Herein, we describe the preparation and characterization of an oligodeoxynucleotide containing a CPD of a T(m)CG site, one of the major sites of C methylation and C-to-T mutations found in the p53 gene of basal and squamous cell cancers.	cysteinylglycine	110-112	tumor protein p53	Homo sapiens	193-196
22277648-8	2012	In vitro reconstitution assays revealed that Dug2p and Dug3p were required together for the cleavage of glutathione into glutamate and Cys-Gly.	cysteinylglycine	135-142	glutamine amidotransferase subunit DUG3	Saccharomyces cerevisiae S288C	55-60
21833041-8	2011	The minor G allele of SNP rs1800796 was associated with lower plasma IL6 (geometric mean (95% CI) = 0.46 (0.41-0.51) ng/l for CG and 0.49 (0.39-0.62) ng/l for GG vs. 0.53 (0.50-0.57) ng/l for CC, P = 0.005).	cysteinylglycine	126-128	interleukin 6	Homo sapiens	69-72
22159450-6	2012	In contrast, CG-1521             significantly induces the expression of several p53 target genes associated with             apoptosis including Bnip3/Bnip3L, p21/p21B and Gdf15.	cysteinylglycine	13-15	tumor protein p53	Homo sapiens	81-84
22159450-6	2012	In contrast, CG-1521             significantly induces the expression of several p53 target genes associated with             apoptosis including Bnip3/Bnip3L, p21/p21B and Gdf15.	cysteinylglycine	13-15	BCL2 interacting protein 3	Homo sapiens	146-151
22159450-6	2012	In contrast, CG-1521             significantly induces the expression of several p53 target genes associated with             apoptosis including Bnip3/Bnip3L, p21/p21B and Gdf15.	cysteinylglycine	13-15	BCL2 interacting protein 3 like	Homo sapiens	152-158
22159450-6	2012	In contrast, CG-1521             significantly induces the expression of several p53 target genes associated with             apoptosis including Bnip3/Bnip3L, p21/p21B and Gdf15.	cysteinylglycine	13-15	H3 histone pseudogene 16	Homo sapiens	160-163
22159450-6	2012	In contrast, CG-1521             significantly induces the expression of several p53 target genes associated with             apoptosis including Bnip3/Bnip3L, p21/p21B and Gdf15.	cysteinylglycine	13-15	growth differentiation factor 15	Homo sapiens	173-178
22113418-5	2012	The rs266729 SNP was strongly associated with cord blood adiponectin; neonates with rs266729 GG had the highest adiponectin (CC: 34.1+-20.2 versus CG: 44.3+-26.1 versus GG: 54.1+-36.7 mug ml(-1), P=2.80 x 10(-9), adjusted P=1.68 x 10(-8)).	cysteinylglycine	147-149	adiponectin, C1Q and collagen domain containing	Homo sapiens	57-68
22153617-6	2012	Bisulfite sequencing revealed 8 methylated CG sites at the promoter region of CRABP-II in UW228-2 and UW228-3 but not in Med-3 cells.	cysteinylglycine	43-45	cellular retinoic acid binding protein 2	Homo sapiens	78-86
22647260-6	2012	(1 muM for 24 hours) triggered an astrogliosis typified by an increased density of GFAP, which was mimicked by the A(2A)R agonist, CGS 26180 (30 nM), and prevented by the A(2A)R antagonist, SCH 58261 (100 nM).	cysteinylglycine	131-134	glial fibrillary acidic protein	Rattus norvegicus	83-87
21080412-3	2012	Here we report that activation of the excitatory A(2A) adenosine receptor by 2-[4-(2-p-carboxyethyl)phenylamino]-5"-N-ethylcarboxamidoadenosine (CGS 21680, 1-30 nM) facilitates AMPA-evoked currents in CA1 pyramidal neurons, by a mechanism dependent on PKA activation, but not on protein synthesis.	cysteinylglycine	145-148	carbonic anhydrase 1	Homo sapiens	201-204
22248199-14	2012	Tissue MMP-2 levels were significantly higher in the CG group compared other groups (P < 0.05).	cysteinylglycine	53-55	matrix metallopeptidase 2	Rattus norvegicus	7-12
22844323-7	2012	Moreover, a significant gene interaction of the carriers with the combined genotypes of miR-34b/c rs4938723CC and TP53 Arg72Pro CG/CC/GG had a decreased risk of IA, compared with those carrying miR-34b/c rs4938723CT/TT+TP53 Arg72Pro GG/CG/CC combined genotypes.	cysteinylglycine	128-130	microRNA 34b	Homo sapiens	88-95
22844323-7	2012	Moreover, a significant gene interaction of the carriers with the combined genotypes of miR-34b/c rs4938723CC and TP53 Arg72Pro CG/CC/GG had a decreased risk of IA, compared with those carrying miR-34b/c rs4938723CT/TT+TP53 Arg72Pro GG/CG/CC combined genotypes.	cysteinylglycine	128-130	tumor protein p53	Homo sapiens	114-118
22844323-7	2012	Moreover, a significant gene interaction of the carriers with the combined genotypes of miR-34b/c rs4938723CC and TP53 Arg72Pro CG/CC/GG had a decreased risk of IA, compared with those carrying miR-34b/c rs4938723CT/TT+TP53 Arg72Pro GG/CG/CC combined genotypes.	cysteinylglycine	128-130	microRNA 34b	Homo sapiens	194-201
22844323-7	2012	Moreover, a significant gene interaction of the carriers with the combined genotypes of miR-34b/c rs4938723CC and TP53 Arg72Pro CG/CC/GG had a decreased risk of IA, compared with those carrying miR-34b/c rs4938723CT/TT+TP53 Arg72Pro GG/CG/CC combined genotypes.	cysteinylglycine	128-130	tumor protein p53	Homo sapiens	219-223
22212269-9	2011	Although TNF-alpha and CRP, except for IL-6, showed a tendency to increase in CG, all three tended to decrease in EG after 8 weeks.	cysteinylglycine	78-80	tumor necrosis factor	Homo sapiens	9-18
22212269-9	2011	Although TNF-alpha and CRP, except for IL-6, showed a tendency to increase in CG, all three tended to decrease in EG after 8 weeks.	cysteinylglycine	78-80	C-reactive protein	Homo sapiens	23-26
22212269-9	2011	Although TNF-alpha and CRP, except for IL-6, showed a tendency to increase in CG, all three tended to decrease in EG after 8 weeks.	cysteinylglycine	78-80	interleukin 6	Homo sapiens	39-43
21428990-7	2011	In PG, a longer distance was found from inner canthus to oral commissure (dist1) on the impaired side in all investigated poses (PG non-affected-affected side: range of all poses 1 18 +- 4 45 to 1 80 +- 2 37 mm; CG right-left side: range -0 69 +- 1 55 to -0 43 +- 1 39 mm, Mann-Whitney tests: 0 0002 < P < 0 0423).	cysteinylglycine	212-214	rhomboid 5 homolog 1	Homo sapiens	74-79
21756897-0	2011	CGS 21680, an agonist of the adenosine (A2A) receptor, decreases acute lung inflammation.	cysteinylglycine	0-3	adenosine A2a receptor	Mus musculus	29-53
21756897-8	2011	Thus, based on these findings we propose that adenosine A(2A) receptor agonists such as CGS 21680 may be useful in the treatment of various inflammatory diseases.	cysteinylglycine	88-91	adenosine A2a receptor	Mus musculus	46-70
21937138-5	2011	RESULTS: Univariate and multivariate analyses of the experimental dataset showed that the CG/GG genotypes of HSPB1 rs2868371 were associated with significantly lower risk of grade >=3 RIET than the CC genotype (univariate hazard ratio [HR] 0.30; 95% confidence interval [CI], 0.10-0.91; P=0.033; multivariate HR 0.29; 95% CI, 0.09-0.97; P=0.045).	cysteinylglycine	90-92	heat shock protein family B (small) member 1	Homo sapiens	109-114
21457364-5	2011	Vegetative FWA expression is correlated with decreased methylation at non-CG sites in the region upstream of the transcription start site in species related to A. thaliana and we conclude that methylation of this region is critical for FWA silencing in these species.	cysteinylglycine	74-76	FLOWERING WAGENINGEN	Arabidopsis thaliana	11-14
21765105-0	2011	CGS 21680, an agonist of the adenosine (A2A) receptor, reduces progression of murine type II collagen-induced arthritis.	cysteinylglycine	0-3	adenosine A2a receptor	Mus musculus	29-53
21765105-10	2011	Plasma levels of proinflammatory cytokines such as tumor necrosis factor, interleukin 1ss (IL-1ss) and IL-6 were also reduced by CGS 21680.	cysteinylglycine	129-132	interleukin 6	Mus musculus	103-107
21793635-9	2011	RESULTS: The allelic frequencies of the AQP1 gene were the following: CC = 15%; CG = 49%; GG = 36%.	cysteinylglycine	80-82	aquaporin 1 (Colton blood group)	Homo sapiens	40-44
21867543-5	2011	Higher CR1 expression on erythrocytes in CC genotype versus CG+GG for both groups was detected, whereas no difference was observed for other cell populations.	cysteinylglycine	60-62	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	7-10
21457994-5	2011	There was a significant loss of PGP 9.5 and HuC/HuD expression in samples from horses with EGS that occurred to a greater extent in the CG/CMG than the CCG.	cysteinylglycine	136-138	ubiquitin C-terminal hydrolase L1	Equus caballus	32-39
21457994-9	2011	In contrast, TH fluorescence intensity was significantly reduced in the CG/CMG in EGS correlating with the greater loss of neurons.	cysteinylglycine	72-74	tyrosine 3-monooxygenase	Equus caballus	13-15
21745282-8	2011	Furthermore, there was a dose effect of the PNPLA3 I148M genotype, in that CG heterozygotes had a risk of NAFLD between CC and GG homozygotes [adjusted odds ratio (OR)=2.03, 95% confidence interval (CI)=1.23-3.375 for the GG genotype and adjusted OR=1.55, 95% CI=1.02-2.35 for the CG genotype].	cysteinylglycine	75-77	patatin like phospholipase domain containing 3	Homo sapiens	44-50
21397678-7	2011	RESULTS: Supplementation of CG extract to HFD fed mice significantly prevented HFD induced increment in bodyweight, lee index, plasma lipids and LEP, visceral adiposity and adipocyte hypertrophy.	cysteinylglycine	28-30	leptin	Mus musculus	145-148
21397678-8	2011	Also, CG extract supplementation resulted in down regulation of PPARgamma-2, SREBP1c, FAS and LEP expression along with up-regulation of CPT-1 in epididymal adipose tissue compared to HFD fed mice.	cysteinylglycine	6-8	peroxisome proliferator activated receptor gamma	Mus musculus	64-75
21397678-8	2011	Also, CG extract supplementation resulted in down regulation of PPARgamma-2, SREBP1c, FAS and LEP expression along with up-regulation of CPT-1 in epididymal adipose tissue compared to HFD fed mice.	cysteinylglycine	6-8	sterol regulatory element binding transcription factor 1	Mus musculus	77-84
21397678-8	2011	Also, CG extract supplementation resulted in down regulation of PPARgamma-2, SREBP1c, FAS and LEP expression along with up-regulation of CPT-1 in epididymal adipose tissue compared to HFD fed mice.	cysteinylglycine	6-8	leptin	Mus musculus	94-97
21397678-8	2011	Also, CG extract supplementation resulted in down regulation of PPARgamma-2, SREBP1c, FAS and LEP expression along with up-regulation of CPT-1 in epididymal adipose tissue compared to HFD fed mice.	cysteinylglycine	6-8	carnitine palmitoyltransferase 1b, muscle	Mus musculus	137-142
21397678-9	2011	In vitro study recorded significant anti-adipogenic effect of CG extract that resulted in decreased adipogenesis, TG accumulation, LEP release, G3PDH activity along with higher glycerol release without significantly altering viability of 3T3L1 pre-adipocytes.	cysteinylglycine	62-64	leptin	Mus musculus	131-134
21740815-8	2011	RESULTS: Both mRNA and protein levels of alpha-ENaC were markedly higher from 4 hours to 24 hours after exposure to 100 micromol/L CGS-21680.	cysteinylglycine	131-134	sodium channel epithelial 1 subunit alpha	Rattus norvegicus	41-51
21633598-5	2011	A similar association was also observed for the CG genotype of CD14 rs4914 (OR= 1.69, 95% CI 1.20-2.36, P = 0.002).	cysteinylglycine	48-50	CD14 molecule	Homo sapiens	63-67
21436623-5	2011	We identified 236 hypomethylated and 105 hypermethylated CG sites in lupus CD4 (+) T cells compared to normal controls, consistent with widespread DNA methylation changes in lupus T cells.	cysteinylglycine	57-59	CD4 molecule	Homo sapiens	75-78
21754086-2	2011	The configuration about each of the ethyl-ene bonds [1.342 (2) and 1.338 (2) A] is E. The three-dimensional crystal structure is stabilized by a combination of C-H O, C-H N, C-H pi inter-actions and pi-pi contacts between the independent mol-ecules [Cg(C(6) of quinoline) Cg(C(6) of quinoline) = 3.6719 (11) A].	cysteinylglycine	250-252	chimerin 1	Homo sapiens	160-177
21168155-7	2011	Variant PNPLA3 rs738409 genotypes were associated with increases in mean serum alanine aminotransferase level of 4.77 IU/L (P = .0435) in subjects with CG alleles and of 10.86 IU/L (P < .0001) in those with GG alleles compared with subjects with CC alleles.	cysteinylglycine	152-154	patatin like phospholipase domain containing 3	Homo sapiens	8-14
21209003-5	2011	In the presence of CGS-21680, inhibition of PLA2 had no further effect on the basolateral 50-pS K channels.	cysteinylglycine	19-22	phospholipase A2 group IB	Rattus norvegicus	44-48
21209003-6	2011	The possibility that CGS-21680-induced stimulation of the basolateral 50-pS K channels was partially achieved by inhibition of PLA2 in the TAL was also supported by the observation that CGS-21680 had no additional effect in the presence of AACOCF3.	cysteinylglycine	21-25	phospholipase A2 group IB	Rattus norvegicus	127-131
21209003-6	2011	The possibility that CGS-21680-induced stimulation of the basolateral 50-pS K channels was partially achieved by inhibition of PLA2 in the TAL was also supported by the observation that CGS-21680 had no additional effect in the presence of AACOCF3.	cysteinylglycine	21-24	phospholipase A2 group IB	Rattus norvegicus	127-131
21552333-9	2011	Interestingly, we observed two different CG methylation statuses in the hda6 mutant.	cysteinylglycine	41-43	histone deacetylase 6	Arabidopsis thaliana	72-76
21552333-10	2011	CG methylation was sustained in the hda6 mutant at some HDA6 target loci that were surrounded by flanking DNA-methylated regions.	cysteinylglycine	0-2	histone deacetylase 6	Arabidopsis thaliana	36-40
21552333-10	2011	CG methylation was sustained in the hda6 mutant at some HDA6 target loci that were surrounded by flanking DNA-methylated regions.	cysteinylglycine	0-2	histone deacetylase 6	Arabidopsis thaliana	56-60
21552333-11	2011	In contrast, complete loss of CG methylation occurred in the hda6 mutant at the HDA6 target loci that were isolated from flanking DNA methylation.	cysteinylglycine	30-32	histone deacetylase 6	Arabidopsis thaliana	61-65
21552333-11	2011	In contrast, complete loss of CG methylation occurred in the hda6 mutant at the HDA6 target loci that were isolated from flanking DNA methylation.	cysteinylglycine	30-32	histone deacetylase 6	Arabidopsis thaliana	80-84
20876230-6	2011	The A(2A) receptor-selective agonist 2-p-(2-carboxyethyl)phenethylamino-5-N-ethylcarboxamidoadenosine hydrochloride (CGS 21680) augmented ghrelin release concentration-dependently, whereas the A(1) receptor-selective agonist 2-chloro-N(6)-cyclopentyladenosine inhibited ghrelin release.	cysteinylglycine	117-120	ghrelin	Mus musculus	138-145
22091247-8	2011	RESULTS: Genotype frequencies for PPAR-gamma gene Pro12Ala (rs1801282) polymorphism were 0.86 for CC, 0.14 for CG, 0.00 for GG while allelic frequencies were 0.93 and 0.0.07 for C and G, respectively.	cysteinylglycine	111-113	peroxisome proliferator activated receptor gamma	Homo sapiens	34-44
21342520-6	2011	For example, one-base shift to the left brings arginine codons CGN, with CG at 1-2 positions, to the respective anticodons NCG, with CG at 2-3 positions.	cysteinylglycine	73-75	cingulin	Homo sapiens	63-66
21245167-5	2011	Crystal structures of the SUVH5 SRA domain bound to 5mC-containing DNA in either the fully or hemimethylated CG context or the methylated CHH context revealed a dual flip-out mechanism where both the 5mC and a base (5mC, C, or G, respectively) from the partner strand are simultaneously extruded from the DNA duplex and positioned within binding pockets of individual SRA domains.	cysteinylglycine	109-111	SU(VAR)3-9 homolog 5	Arabidopsis thaliana	26-31
21059181-6	2011	For the beta2 -adrenergic receptor SNP Rs1042714, patients with CFS had a lower frequency of the GG genotype and a higher frequency of the genotypes containing C (CG and CC) (p = 0.044).	cysteinylglycine	163-165	adrenoceptor beta 2	Homo sapiens	8-34
21177758-5	2011	Microarray analyses identified numerous C/EBPalpha/beta target genes in equine chorionic gonadotropin (eCG)-human (h)CG-treated mice.	cysteinylglycine	104-106	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	40-50
20876455-1	2011	We designed a whole tumor cell vaccine by "loading" lymphoma tumor cells with CG-enriched oligodeoxynucleotide (CpG), a ligand for the Toll-like receptor 9 (TLR9).	cysteinylglycine	78-80	toll-like receptor 9	Mus musculus	135-155
20876455-1	2011	We designed a whole tumor cell vaccine by "loading" lymphoma tumor cells with CG-enriched oligodeoxynucleotide (CpG), a ligand for the Toll-like receptor 9 (TLR9).	cysteinylglycine	78-80	toll-like receptor 9	Mus musculus	157-161
20876230-6	2011	The A(2A) receptor-selective agonist 2-p-(2-carboxyethyl)phenethylamino-5-N-ethylcarboxamidoadenosine hydrochloride (CGS 21680) augmented ghrelin release concentration-dependently, whereas the A(1) receptor-selective agonist 2-chloro-N(6)-cyclopentyladenosine inhibited ghrelin release.	cysteinylglycine	117-120	ghrelin	Mus musculus	270-277
20961717-9	2010	Mean plasma concentrations of glucose and insulin were significantly (P<0.05) higher in the TG than in the CG on almost all days during each treatment period.	cysteinylglycine	110-112	insulin	Capra hircus	42-49
20959287-7	2011	Analysis of hMLH1 MAPit data with MethylViewer showed that endogenous CG methylation and accessible GC sites were both mapped on single molecules at high resolution.	cysteinylglycine	70-72	mutL homolog 1	Homo sapiens	12-17
21647442-4	2011	We found a predictive role of RAD51 -135G>C SNP in RP development (adjusted hazard ratio [HR] = 0.52, 95% confidence interval [CI], 0.31-0.86, P = 0.010 for CG/CC vs. GG).	cysteinylglycine	160-162	RAD51 recombinase	Homo sapiens	30-35
21647442-5	2011	We also found that RAD51 -135G>C and XRCC2 R188H SNPs were independent prognostic factors for overall survival (adjusted HR = 1.70, 95% CI, 1.14-2.62, P = 0.009 for CG/CC vs. GG; and adjusted HR = 1.70; 95% CI, 1.02-2.85, P = 0.043 for AG vs. GG, respectively) and that the SNP-survival association was most pronounced in the presence of RP.	cysteinylglycine	168-170	RAD51 recombinase	Homo sapiens	19-24
21234122-9	2010	Finally, we observed that selective A(2A)AR activation with CGS-21680 blocked PMA-induced ERK1/2 phosphorylation and modulated the overexpression of functional nuclear orphan receptors 4A.	cysteinylglycine	60-63	mitogen-activated protein kinase 3	Homo sapiens	90-96
21120281-8	2010	In the animals of CG (10.95+-3.43) and AOM (8.92+-4.13) there was a significant difference of the FasL expression (p=0.026466821).	cysteinylglycine	18-20	Fas ligand	Rattus norvegicus	98-102
21120281-9	2010	A significantly decrease on the FasL expression was observed in the animals of CG (10.75+-3.33) and AOM (8.86+-4.19) in the top crypt (p=0.00003755*).	cysteinylglycine	79-81	Fas ligand	Rattus norvegicus	32-36
20121623-3	2010	Lactoperoxidase (LPO; EC 1.11.1.7) was purified from bovine milk with three purification steps: Amberlite CG-50 resin, CM-Sephadex C-50 ion-exchange, and Sephadex G-100 gel filtration chromatography, respectively.	cysteinylglycine	106-108	lactoperoxidase	Bos taurus	0-15
20433862-9	2010	In the follicular phase, Ach in CG increased 3beta-HSD and NE increased P450 aromatase.	cysteinylglycine	32-34	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Rattus norvegicus	45-54
20658482-8	2010	Meanwhile, the expressions of eNOS mRNA and eNOS protein and cGMP levels in the lung of CGS 26393-treated rats were increased by 62% (P < 0.05), 100% (P < 0.05), and 32% (P < 0.01), respectively, compared to the vehicle-treated rats.	cysteinylglycine	88-91	nitric oxide synthase 3	Rattus norvegicus	30-34
20658482-8	2010	Meanwhile, the expressions of eNOS mRNA and eNOS protein and cGMP levels in the lung of CGS 26393-treated rats were increased by 62% (P < 0.05), 100% (P < 0.05), and 32% (P < 0.01), respectively, compared to the vehicle-treated rats.	cysteinylglycine	88-91	nitric oxide synthase 3	Rattus norvegicus	44-48
20834229-5	2010	The ibm1-induced genic H3K9me depends on both histone methylase KYP/SUVH4 and DNA methylase CMT3, suggesting interdependence of two epigenetic marks--H3K9me and non-CG methylation.	cysteinylglycine	165-167	Transcription factor jumonji (jmjC) domain-containing protein	Arabidopsis thaliana	4-8
20737599-4	2010	In the CG and CranMG 91 +/- 8% and 93 +/- 12% of the neurons innervating the ICJ expressed TH- and DBH-IR, respectively.	cysteinylglycine	7-9	dopamine beta-hydroxylase	Equus caballus	99-102
20422415-5	2010	After stratifying for the JAK2 V617F mutational status and for the mutant allele burden, we demonstrated that GG/CG genotypes were significantly more frequent in V617F positive compared to V617F negative patients (p = 0.001), but not in V617F negative patients compared to controls (p = 0.29).	cysteinylglycine	113-115	Janus kinase 2	Homo sapiens	26-30
20143155-5	2010	The results showed NBS1 8360G > C polymorphism contributed to breast risk in overall populations (for CC vs. GG: OR = 0.75, 95% CI = 0.74-0.98, P = 0.13 for heterogeneity; for the recessive model CC vs. GG/CG: OR = 0.88, 95% CI = 0.77-1.00, P = 0.44 for heterogeneity).	cysteinylglycine	209-211	nibrin	Homo sapiens	19-23
20336794-4	2010	RESULTS: The ADH7 A92G GG and combined CG + GG genotypes were associated with a decreased risk of SCCHN (GG: adjusted OR, 0.32; 95% CI, 0.13-0.82; CG + GG: adjusted OR, 0.74; 95% CI, 0.59-0.94; FPRP, .098) compared with the CC genotype.	cysteinylglycine	147-149	alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide	Homo sapiens	13-17
20592333-10	2010	Multivariate regression analysis, including sex, age, body mass index, hypercholesterolaemia, smoking, hypertension diabetes, identified CG + CC genotype as the only independent predictor of preoperative CRP and IL-6 levels.	cysteinylglycine	137-139	C-reactive protein	Homo sapiens	204-207
20592333-10	2010	Multivariate regression analysis, including sex, age, body mass index, hypercholesterolaemia, smoking, hypertension diabetes, identified CG + CC genotype as the only independent predictor of preoperative CRP and IL-6 levels.	cysteinylglycine	137-139	interleukin 6	Homo sapiens	212-216
20564624-3	2010	RESULTS: The authors found that the ERCC2 Asp312Asn AA, MSH2 IVS1 + 9G > C CC, OGG1 Ser326Cys GG and CG + GG, and OGG1 748-15C > G GG and CG + GG genotypes were significantly associated with an increased risk of GB carcinogenesis (odds ratio [OR], 2.1, 1.8, 2.5, 1.8, 2.0, and 1.6, respectively).	cysteinylglycine	144-146	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	36-41
20564624-3	2010	RESULTS: The authors found that the ERCC2 Asp312Asn AA, MSH2 IVS1 + 9G > C CC, OGG1 Ser326Cys GG and CG + GG, and OGG1 748-15C > G GG and CG + GG genotypes were significantly associated with an increased risk of GB carcinogenesis (odds ratio [OR], 2.1, 1.8, 2.5, 1.8, 2.0, and 1.6, respectively).	cysteinylglycine	144-146	mutS homolog 2	Homo sapiens	56-60
20564624-3	2010	RESULTS: The authors found that the ERCC2 Asp312Asn AA, MSH2 IVS1 + 9G > C CC, OGG1 Ser326Cys GG and CG + GG, and OGG1 748-15C > G GG and CG + GG genotypes were significantly associated with an increased risk of GB carcinogenesis (odds ratio [OR], 2.1, 1.8, 2.5, 1.8, 2.0, and 1.6, respectively).	cysteinylglycine	144-146	8-oxoguanine DNA glycosylase	Homo sapiens	82-86
20162308-5	2010	A metabolic ratio (PG/CG) for CYP2C19 activity was determined on three separate occasions, 7 days apart.	cysteinylglycine	22-24	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	30-37
20453081-3	2010	The LH/CG bioactivity is elevated in the mice, with consequent highly stimulated ovarian progesterone (P(4)) production, in the face of normal estrogen secretion.	cysteinylglycine	7-9	exosome component 10	Mus musculus	103-107
20423609-1	2010	Natural phosphodiester bond CpG-DNA that contains immunomodulatory CpG motifs (PO-DNA) upregulates the expression of proinflammatory cytokines and induces an Ag-driven Th1 response in a CG sequence-dependent manner in mice.	cysteinylglycine	186-188	negative elongation factor complex member C/D, Th1l	Mus musculus	168-171
19924030-1	2010	In the present study, we tested the efficacy of treatment with the selective adenosine A2A receptor agonist 2-[p-(2-carboxyethyl)phenylethylamino]-50-ethylcarboxamidoadenosine (CGS 21680) on ischemia and reperfusion injury of the multivisceral organs.	cysteinylglycine	177-180	adenosine A2a receptor	Mus musculus	77-99
20423609-3	2010	In this study, we found that liposome-encapsulated PO-DNA upregulated the expression of human Beta-defensin-2 (hBD-2) and major histocompatibility class II molecules (HLA-DRA) in a CG sequence-dependent and liposome- dependent manner in human B cells.	cysteinylglycine	181-183	defensin beta 4A	Homo sapiens	94-109
20423609-3	2010	In this study, we found that liposome-encapsulated PO-DNA upregulated the expression of human Beta-defensin-2 (hBD-2) and major histocompatibility class II molecules (HLA-DRA) in a CG sequence-dependent and liposome- dependent manner in human B cells.	cysteinylglycine	181-183	defensin beta 4A	Homo sapiens	111-116
20423609-3	2010	In this study, we found that liposome-encapsulated PO-DNA upregulated the expression of human Beta-defensin-2 (hBD-2) and major histocompatibility class II molecules (HLA-DRA) in a CG sequence-dependent and liposome- dependent manner in human B cells.	cysteinylglycine	181-183	major histocompatibility complex, class II, DR alpha	Homo sapiens	167-174
19506792-7	2010	After adjusting for age, the IL6 -634G > C (rs1800796) allele showed association with osteoporosis (odds ratio (OR) for CC + CG = 2.51, p = 0.0047)), independent of statin use or smoking status.	cysteinylglycine	128-130	interleukin 6	Homo sapiens	29-32
19780043-7	2010	The 5-HT1A -1019 CC genotype group showed a larger Ne and stronger posterror slowing than the CG and GG genotype groups.	cysteinylglycine	94-96	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10
20056138-8	2010	In other experiments with the same rats, addition of the A2AR agonist CGS 21680 (5.15 mumol/kg) or the A1R agonist CCPA (2.71 mumol/kg) during the second week of caffeine treatment reversed the improvement of contralateral stepping by 59+/-4% and 30+/-3%, respectively.	cysteinylglycine	70-73	adenosine A2a receptor	Rattus norvegicus	57-61
20128036-11	2010	Increased risk of ESCC metastasis was found in heterozygote carriers of the MGMT Rs7068306 (CG vs CC, OR: 4.706, 95% CI: 1.872-11.833).	cysteinylglycine	92-94	O-6-methylguanine-DNA methyltransferase	Homo sapiens	76-80
19295488-0	2009	The selective adenosine A2A receptor agonist CGS 21680 reduces JNK MAPK activation in oligodendrocytes in injured spinal cord.	cysteinylglycine	45-48	adenosine A2a receptor	Mus musculus	14-36
19466942-9	2009	IL-6 secretion in UPEC-infected A498 cells was decreased by 38% when exposed to the A(2A) receptor agonist CGS 21680.	cysteinylglycine	107-110	interleukin 6	Homo sapiens	0-4
20664183-6	2010	RESULTS: p53 codon 72 GG genotype was associated with increased biochemical recurrence compared with CG+CC genotypes and poorer PSA-free survival.	cysteinylglycine	101-103	tumor protein p53	Homo sapiens	9-12
19295488-0	2009	The selective adenosine A2A receptor agonist CGS 21680 reduces JNK MAPK activation in oligodendrocytes in injured spinal cord.	cysteinylglycine	45-48	mitogen-activated protein kinase 8	Mus musculus	63-66
19922658-6	2009	RESULTS: In CG, a cytoplasmic immunoexpression for ERbeta was observed in spermatogonia, primary spermatocytes and spermatids.	cysteinylglycine	12-14	estrogen receptor 2	Rattus norvegicus	51-57
20095487-9	2009	ALP activity was higher in EG than in CG.	cysteinylglycine	38-40	PDZ and LIM domain 3	Rattus norvegicus	0-3
19732743-4	2009	The induction of hBD-2 was dependent on CG sequence and phosphorothioate backbone-modification.	cysteinylglycine	40-42	defensin beta 4A	Homo sapiens	17-22
19349390-7	2009	In patients with the IL-6 GG genotype, the mean PAP value was significantly higher and PH was more common than in CG or CC patients (adjusted odds ratio, 4.32; 95% confidence interval, 1.96 to 9.54).	cysteinylglycine	114-116	interleukin 6	Homo sapiens	21-25
19736056-5	2009	RESULTS: Evaluations of the CYP1B1 V432L variant (rs1056836) suggested increased risk of MM among persons with the CG and GG genotypes compared to the CC genotype [OR (95% CI)=1.4 (1.0-2.0)].	cysteinylglycine	115-117	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	28-34
20074465-12	2009	In contrast, the AST activity showed a significant increase in the CG.	cysteinylglycine	67-69	solute carrier family 17 member 5	Homo sapiens	17-20
21577691-2	2009	The crystal structure is stabilized by non-classical inter-molecular C-H O hydrogen bonding, and by inter-molecular C-Br pi inter-actions, with C-Br Cg = 3.629 A (Cg is the centroid of the benzene ring).	cysteinylglycine	149-151	carbonyl reductase 1	Homo sapiens	144-148
21577691-2	2009	The crystal structure is stabilized by non-classical inter-molecular C-H O hydrogen bonding, and by inter-molecular C-Br pi inter-actions, with C-Br Cg = 3.629 A (Cg is the centroid of the benzene ring).	cysteinylglycine	163-165	carbonyl reductase 1	Homo sapiens	116-120
21577691-2	2009	The crystal structure is stabilized by non-classical inter-molecular C-H O hydrogen bonding, and by inter-molecular C-Br pi inter-actions, with C-Br Cg = 3.629 A (Cg is the centroid of the benzene ring).	cysteinylglycine	163-165	carbonyl reductase 1	Homo sapiens	144-148
19226352-5	2009	Regarding serum parathyroid hormone (PTH) levels, the increase observed in the CG was higher than the changes observed in the other two groups but the differences were of marginal significance (P = 0.055).	cysteinylglycine	79-81	parathyroid hormone	Homo sapiens	16-35
19303821-3	2009	HRC was significantly lower in the CG compared to controls at 48 h during IHGT.	cysteinylglycine	35-37	histidine rich calcium binding protein	Homo sapiens	0-3
19441986-15	2009	CONCLUSIONS: Bioactive treatment with B2A effectively enhanced the fusion capacity of porous CGs.	cysteinylglycine	93-96	keratin-associated protein 1-1	Ovis aries	38-41
19346245-6	2009	We show here that Dug1p is a homodimer that can also function in a Dug2-Dug3-independent manner as a dipeptidase with high specificity for Cys-Gly and no activity toward tri- or tetrapeptides in vitro.	cysteinylglycine	139-146	metallodipeptidase	Saccharomyces cerevisiae S288C	18-23
19346245-6	2009	We show here that Dug1p is a homodimer that can also function in a Dug2-Dug3-independent manner as a dipeptidase with high specificity for Cys-Gly and no activity toward tri- or tetrapeptides in vitro.	cysteinylglycine	139-146	glutamine amidotransferase subunit DUG2	Saccharomyces cerevisiae S288C	67-71
19346245-6	2009	We show here that Dug1p is a homodimer that can also function in a Dug2-Dug3-independent manner as a dipeptidase with high specificity for Cys-Gly and no activity toward tri- or tetrapeptides in vitro.	cysteinylglycine	139-146	glutamine amidotransferase subunit DUG3	Saccharomyces cerevisiae S288C	72-76
19346245-8	2009	Yeast cells lacking Dug1p (dug1Delta) accumulate Cys-Gly.	cysteinylglycine	49-56	metallodipeptidase	Saccharomyces cerevisiae S288C	20-25
19346245-11	2009	The human orthologue CNDP2 also displays Cys-Gly peptidase activity, as seen by complementation of the dug1Delta mutant and by biochemical characterization, which revealed a high substrate specificity and affinity for Cys-Gly.	cysteinylglycine	41-48	carnosine dipeptidase 2	Homo sapiens	21-26
19208896-4	2009	The A(2A) receptor agonist CGS 21680 [2-p-(2-carboxyethyl)phenethylamino-5"-N-ethylcarboxamidoadenosine hydrochloride] augmented SLI release in a concentration-dependent manner, suggesting that A(2A) receptor activation is involved in the stimulatory effect of adenosine on SLI release.	cysteinylglycine	27-30	SHC (Src homology 2 domain containing) transforming protein 2	Mus musculus	129-132
19208896-4	2009	The A(2A) receptor agonist CGS 21680 [2-p-(2-carboxyethyl)phenethylamino-5"-N-ethylcarboxamidoadenosine hydrochloride] augmented SLI release in a concentration-dependent manner, suggesting that A(2A) receptor activation is involved in the stimulatory effect of adenosine on SLI release.	cysteinylglycine	27-30	SHC (Src homology 2 domain containing) transforming protein 2	Mus musculus	274-277
19288024-10	2009	Moreover, the severity of sleep-disordered breathing (measured by apnea hypopnea index) increased linearly in carriers of the C variant of IL-6 -572G/C polymorphism (14.3+/-5.1, 22.0+/-3.6 and 34.8+/-3.5 for GG, CG and CC, respectively; p=0.012).	cysteinylglycine	212-214	interleukin 6	Homo sapiens	139-143
19131508-6	2009	Given that the primary evolutionary change between LHbeta and CGbeta occurred at the carboxy terminus, these data suggested that the presence of the CGbeta carboxyl-terminal peptide region is responsible for the constitutive secretion of CG.	cysteinylglycine	62-64	chromogranin B	Rattus norvegicus	149-155
19141075-4	2009	GDNF (10 ng/mL) enhanced (by approximately 13%) glutamate release from rat striatal nerve endings, an effect potentiated (up to approximately 30%) by the A(2A) receptor agonist CGS 21680 (10 nM) and prevented by the A(2A) receptor antagonist, SCH 58261 (50 nM).	cysteinylglycine	177-180	glial cell derived neurotrophic factor	Rattus norvegicus	0-4
19131508-12	2009	These data show that the CGDeltaT analog resembles LH in its intracellular trafficking, further supporting the hypothesis that determinants at the carboxyl-terminal end of the CGbeta-subunit evolved from the LHbeta-subunit primarily to overcome the slow release and intracellular storage of LH resulting in rapid secretion of CG from the placenta.	cysteinylglycine	25-27	chromogranin B	Rattus norvegicus	176-182
19727335-16	2009	CGS-24592 pretreatment also caused a significant increase in MPO (29%, p = 0.026) as compared to mice with SB injury alone.	cysteinylglycine	0-3	myeloperoxidase	Mus musculus	61-64
20408500-3	2009	Induction of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4 by CGS (0.01, 0.3 and 3 mM) was evaluated in cryopreserved human hepatocytes, by determining CYP mRNA expression using quantitative RT-PCR.	cysteinylglycine	59-62	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	37-44
18987301-5	2009	The pressor responses to big endothelin-1 were significantly reduced by the neutral endopeptidase inhibitor thiorphan (dl-3-mercapto-2-benzylpropanoylglycine) (1 mg/kg) or the endothelin-converting enzyme inhibitor CGS 35066 [alpha-[(S)-(phosphonomethyl)amino]-3-dibenzofuranopropanoic acid] (0.1 mg/kg).	cysteinylglycine	215-218	endothelin 1	Mus musculus	29-41
19212064-3	2009	The disassembly is inhibited by cysteine, but not by cysteinylglycine, thus allowing us to monitor the progress of an enzymatic decomposition of cysteinylglycine into cysteine and glycine with APN.	cysteinylglycine	145-161	alanyl aminopeptidase, membrane	Homo sapiens	193-196
19452722-6	2009	CONCLUSION: The expressions of phosphorylated c-Jun are time-related and uniform in the time and position in CG after noise trauma.	cysteinylglycine	109-111	jun proto-oncogene	Mus musculus	46-51
18486136-11	2009	Analysis of plaque extracts also revealed the presence of enzyme product cysteinyl-glycine both as free and protein-bound form, confirming that GGT-dependent pro-oxidant reactions may occur within the plaque environment.	cysteinylglycine	73-90	gamma-glutamyltransferase light chain family member 3	Homo sapiens	144-147
20408500-3	2009	Induction of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4 by CGS (0.01, 0.3 and 3 mM) was evaluated in cryopreserved human hepatocytes, by determining CYP mRNA expression using quantitative RT-PCR.	cysteinylglycine	59-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
20408500-3	2009	Induction of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4 by CGS (0.01, 0.3 and 3 mM) was evaluated in cryopreserved human hepatocytes, by determining CYP mRNA expression using quantitative RT-PCR.	cysteinylglycine	59-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
20408500-1	2009	The induction and inhibition of human hepatic cytochrome P450 (CYP) isoforms by crystalline glucosamine sulfate (CGS) was investigated in vitro.	cysteinylglycine	113-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
20408500-1	2009	The induction and inhibition of human hepatic cytochrome P450 (CYP) isoforms by crystalline glucosamine sulfate (CGS) was investigated in vitro.	cysteinylglycine	113-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
19107369-6	2008	The IL-6 level in GG+CG group was significantly higher than that in CC group.	cysteinylglycine	21-23	interleukin 6	Homo sapiens	4-8
20408500-2	2009	Inhibition of CYP1A2, CYP2E1, CYP2C19, CYP2C9, CYP2D6, and CYP3A4 by CGS was assessed using recombinant human enzymes incubated with CGS (up to 3 mM expressed as free base).	cysteinylglycine	69-72	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	14-20
20408500-2	2009	Inhibition of CYP1A2, CYP2E1, CYP2C19, CYP2C9, CYP2D6, and CYP3A4 by CGS was assessed using recombinant human enzymes incubated with CGS (up to 3 mM expressed as free base).	cysteinylglycine	69-72	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	22-28
20408500-2	2009	Inhibition of CYP1A2, CYP2E1, CYP2C19, CYP2C9, CYP2D6, and CYP3A4 by CGS was assessed using recombinant human enzymes incubated with CGS (up to 3 mM expressed as free base).	cysteinylglycine	69-72	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	30-37
20408500-2	2009	Inhibition of CYP1A2, CYP2E1, CYP2C19, CYP2C9, CYP2D6, and CYP3A4 by CGS was assessed using recombinant human enzymes incubated with CGS (up to 3 mM expressed as free base).	cysteinylglycine	69-72	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	39-45
20408500-2	2009	Inhibition of CYP1A2, CYP2E1, CYP2C19, CYP2C9, CYP2D6, and CYP3A4 by CGS was assessed using recombinant human enzymes incubated with CGS (up to 3 mM expressed as free base).	cysteinylglycine	69-72	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	47-53
20408500-2	2009	Inhibition of CYP1A2, CYP2E1, CYP2C19, CYP2C9, CYP2D6, and CYP3A4 by CGS was assessed using recombinant human enzymes incubated with CGS (up to 3 mM expressed as free base).	cysteinylglycine	69-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65
20408500-2	2009	Inhibition of CYP1A2, CYP2E1, CYP2C19, CYP2C9, CYP2D6, and CYP3A4 by CGS was assessed using recombinant human enzymes incubated with CGS (up to 3 mM expressed as free base).	cysteinylglycine	133-136	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	14-20
20408500-3	2009	Induction of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4 by CGS (0.01, 0.3 and 3 mM) was evaluated in cryopreserved human hepatocytes, by determining CYP mRNA expression using quantitative RT-PCR.	cysteinylglycine	59-62	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	13-19
20408500-3	2009	Induction of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4 by CGS (0.01, 0.3 and 3 mM) was evaluated in cryopreserved human hepatocytes, by determining CYP mRNA expression using quantitative RT-PCR.	cysteinylglycine	59-62	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	21-27
20408500-3	2009	Induction of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4 by CGS (0.01, 0.3 and 3 mM) was evaluated in cryopreserved human hepatocytes, by determining CYP mRNA expression using quantitative RT-PCR.	cysteinylglycine	59-62	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	29-35
18849328-3	2008	Stimulation of A2AR with 2 microM (approximately EC50) CGS-21680 (CGS) produced a 17-28% increase in the Ca transient ratio (CTR) and maximum velocities (Vmax) of transient ratio increase (+MVT) and recovery (-MVT) but no change in the time-to-50% recovery (TTR).	cysteinylglycine	55-58	adenosine A2a receptor	Rattus norvegicus	15-19
19097273-7	2008	Finally, the A2AR agonist, 2-p-(2-carboxyethyl)-phenylethylamino-50-N-ethylcarboxamidoadenosine hydrochloride (CGS 21680), reduced ethanol consumption and preference in C57BL/6J mice.	cysteinylglycine	111-114	adenosine A2a receptor	Mus musculus	13-17
18665914-2	2008	MET1 maintains CG methylation, and DRM1/2 and CMT3 act redundantly to enforce non-CG methylation.	cysteinylglycine	15-17	methyltransferase 1	Arabidopsis thaliana	0-4
18665914-6	2008	Surprisingly, CG methylation was lost in a drm1/2/cmt3 mutant, and non-CG methylation was almost completely eliminated in a met1 mutant.	cysteinylglycine	14-16	domains rearranged methylase 1	Arabidopsis thaliana	43-49
18665914-6	2008	Surprisingly, CG methylation was lost in a drm1/2/cmt3 mutant, and non-CG methylation was almost completely eliminated in a met1 mutant.	cysteinylglycine	71-73	methyltransferase 1	Arabidopsis thaliana	124-128
18945701-4	2008	Hairpin bisulfite analysis shows correlated methylation of two CG sites in a distance of approximately 8-10 bp in the opposite DNA strands, which corresponds to the geometry of the two active sites in one Dnmt3a-C/3L-C tetramer.	cysteinylglycine	63-65	DNA methyltransferase 3 alpha	Homo sapiens	205-211
18203120-6	2008	The null distribution of Cg is well approximated by the chi2 distribution with (g-2) x (c-1) degrees of freedom.	cysteinylglycine	25-27	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	88-91
18927273-11	2008	Our results clarify and complement the current American Society of Clinical Oncology recommendations for G-CSF administration in neutropenia: High sustained G-CSF levels are needed to treat severe neutropenia and may be achieved by either CG or pegG.	cysteinylglycine	239-241	colony stimulating factor 3	Homo sapiens	105-110
18927273-11	2008	Our results clarify and complement the current American Society of Clinical Oncology recommendations for G-CSF administration in neutropenia: High sustained G-CSF levels are needed to treat severe neutropenia and may be achieved by either CG or pegG.	cysteinylglycine	239-241	colony stimulating factor 3	Homo sapiens	157-162
19043555-5	2008	Specifically, SUVH9 preferentially binds methylated asymmetric sites, while SUVH2 preferentially binds methylated CG sites.	cysteinylglycine	114-116	SU(VAR)3-9 homolog 2	Arabidopsis thaliana	76-81
19092295-5	2008	RAD52 GLN221GLU genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].	cysteinylglycine	26-28	RAD52 homolog, DNA repair protein	Homo sapiens	0-5
19092295-5	2008	RAD52 GLN221GLU genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].	cysteinylglycine	163-165	RAD52 homolog, DNA repair protein	Homo sapiens	0-5
18398905-2	2008	Histone deacetylase1 (HDAC1) binds suberanilohydroxamic acid (SAHA) and 7-phenyl-2, 4, 6-hepta-trienoyl hydroxamic acid (CG-1521) with moderately low affinity (DeltaG = -8.6 and -7.8 kcal mol(-1)).	cysteinylglycine	121-123	histone deacetylase 1	Homo sapiens	0-20
18398905-2	2008	Histone deacetylase1 (HDAC1) binds suberanilohydroxamic acid (SAHA) and 7-phenyl-2, 4, 6-hepta-trienoyl hydroxamic acid (CG-1521) with moderately low affinity (DeltaG = -8.6 and -7.8 kcal mol(-1)).	cysteinylglycine	121-123	histone deacetylase 1	Homo sapiens	22-27
18645003-1	2008	Previous studies comparing the effects of two histone deacetylase (HDAC) inhibitors, trichostatin A (TSA) and CG-1521, have shown that these compounds selectively inhibit HDAC and induce differentially acetylated p53 isoforms and assembly of mutually exclusive transcriptional complexes on the p21 promoter.	cysteinylglycine	110-112	tumor protein p53	Homo sapiens	213-216
18810583-10	2008	Among the KD patients, serum MMP-3 levels were higher in children with genotypes CG+GG compared to the CC group, but this difference was not significant.	cysteinylglycine	81-83	matrix metallopeptidase 3	Homo sapiens	29-34
18640664-8	2008	Alcohol exposure also resulted in an increase in maximal vessel response to CGS-21680, an adenosine A2A receptor agonist, but did not alter the concentration-dependent response curves to adenosine.	cysteinylglycine	76-79	adenosine receptor A2a	Ovis aries	90-112
18645003-1	2008	Previous studies comparing the effects of two histone deacetylase (HDAC) inhibitors, trichostatin A (TSA) and CG-1521, have shown that these compounds selectively inhibit HDAC and induce differentially acetylated p53 isoforms and assembly of mutually exclusive transcriptional complexes on the p21 promoter.	cysteinylglycine	110-112	H3 histone pseudogene 16	Homo sapiens	294-297
18645003-5	2008	These data show that the selective effects of CG-1521 and TSA on the assembly of transcription complexes are not unique to the p21 gene and suggest that selective inhibition of HDAC can lead to significant changes in gene expression through the acetylation of transcription factors including but not limited to p53.	cysteinylglycine	46-48	H3 histone pseudogene 16	Homo sapiens	127-130
18645003-5	2008	These data show that the selective effects of CG-1521 and TSA on the assembly of transcription complexes are not unique to the p21 gene and suggest that selective inhibition of HDAC can lead to significant changes in gene expression through the acetylation of transcription factors including but not limited to p53.	cysteinylglycine	46-48	tumor protein p53	Homo sapiens	311-314
18433292-2	2008	It is caused by mutations in the luteinizing hormone/chorionic gonadotropin receptor gene (LHCGR), which impair either LH/CG binding or signal transduction.	cysteinylglycine	93-95	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	33-84
18274826-6	2008	Haplotype analysis between -446C > T and -368T > G in the SLC22A5 promoter region showed that the CG allele appeared to be a risk haplotype for steroid resistance (CG: odds ratio, 4.13; 95 percent confidence interval, 1.41-12.1; P = 0.016).	cysteinylglycine	104-106	solute carrier family 22 member 5	Homo sapiens	64-71
17951456-8	2007	Interestingly, in rdr2 and drm2 mutant plants, we found that genes demethylated by ROS1 accumulate CG methylation, and we propose that this hypermethylation is due to the ROS1 down-regulation that occurs in these mutant backgrounds.	cysteinylglycine	99-101	RNA-dependent RNA polymerase 2	Arabidopsis thaliana	18-22
18393231-7	2008	Girls with CC genotype of IL-6 -634G/C gene had higher percentage of increase in BMD of total body (P= 0.027) and femoral trochanter (P= 0.028) than those with CG+ GG genotypes.	cysteinylglycine	160-162	interleukin 6	Homo sapiens	26-30
18094032-4	2008	cGS was induced by high-dose anti-thy1 antibody injection into uninephrectomized rats.	cysteinylglycine	0-3	Thy-1 cell surface antigen	Rattus norvegicus	34-38
17887955-7	2008	Their structural vicinity to galectin-1 prompts their classification as CG-1A (CG-16)/CG-1B (CG-14), whereas sequence similarity to mammalian galectin-2 gives reason to refer to the intestinal protein as CG-2.	cysteinylglycine	72-74	galectin 1	Homo sapiens	29-39
17887955-7	2008	Their structural vicinity to galectin-1 prompts their classification as CG-1A (CG-16)/CG-1B (CG-14), whereas sequence similarity to mammalian galectin-2 gives reason to refer to the intestinal protein as CG-2.	cysteinylglycine	72-74	galectin 1B	Gallus gallus	79-84
18758908-7	2008	Girls with CC genotype of IL-6 -634G/C gene had higher percentage accrual in BMD of total body (P = 0.032) and femoral trochanter (P = 0.048) than their CG + GG counterparts.	cysteinylglycine	153-155	interleukin 6	Homo sapiens	26-30
17683073-5	2007	However, we found a significant and consistent association with risk for a SNP in exon 1 (R68G) of the 5" neighboring gene WDR79 (rs2287499, OR (95% CI) = 1.08 (0.95-1.23) for CG vs. CC and 1.60 (1.04-2.47) for GG vs. CC, p-trend = 0.01).	cysteinylglycine	176-178	WD repeat containing antisense to TP53	Homo sapiens	123-128
17931351-3	2007	Here, we report the isolation of a transcriptionally suppressed epi-allele of the Arabidopsis thaliana phytochrome A gene (PHYA) termed phyA" that shows methylation only in symmetric CG sites resident in exonic regions.	cysteinylglycine	183-185	phytochrome A	Arabidopsis thaliana	103-116
17931351-3	2007	Here, we report the isolation of a transcriptionally suppressed epi-allele of the Arabidopsis thaliana phytochrome A gene (PHYA) termed phyA" that shows methylation only in symmetric CG sites resident in exonic regions.	cysteinylglycine	183-185	phytochrome A	Arabidopsis thaliana	123-127
17931351-3	2007	Here, we report the isolation of a transcriptionally suppressed epi-allele of the Arabidopsis thaliana phytochrome A gene (PHYA) termed phyA" that shows methylation only in symmetric CG sites resident in exonic regions.	cysteinylglycine	183-185	phytochrome A	Arabidopsis thaliana	136-140
17931351-5	2007	De-methylation of phyA" in the DNA methyl transferase I (met1) mutant background increased PHYA expression and restored the wild-type phenotype, confirming the pivotal role of exonic CG methylation in maintaining the altered epigenetic state.	cysteinylglycine	183-185	phytochrome A	Arabidopsis thaliana	18-22
18569589-5	2008	LC melting curve analyses of the hOGG1 exon 7 PCR product were characteristic of the probes hybridized to the non-mutated Ser-type (CC) at 65 degrees C, or to the Cys mutant (GG) at 59 degrees C. The distribution in the population of PAH-exposed workers (N=260) was 58% (CC), 38%(CG), and 4% (GG).	cysteinylglycine	280-282	8-oxoguanine DNA glycosylase	Homo sapiens	33-38
18569589-7	2008	The distribution of 8-oxodGuo adducts for the Ser326Cys variants of hOGG1 revealed geometric means (GM) of 5.83 (CC), 5.27 (CG), and 6.53 (GG) 8-oxodGuo adducts/10(6)dGuo.	cysteinylglycine	124-126	8-oxoguanine DNA glycosylase	Homo sapiens	68-73
17951456-8	2007	Interestingly, in rdr2 and drm2 mutant plants, we found that genes demethylated by ROS1 accumulate CG methylation, and we propose that this hypermethylation is due to the ROS1 down-regulation that occurs in these mutant backgrounds.	cysteinylglycine	99-101	domains rearranged methyltransferase 2	Arabidopsis thaliana	27-31
17951456-8	2007	Interestingly, in rdr2 and drm2 mutant plants, we found that genes demethylated by ROS1 accumulate CG methylation, and we propose that this hypermethylation is due to the ROS1 down-regulation that occurs in these mutant backgrounds.	cysteinylglycine	99-101	demeter-like 1	Arabidopsis thaliana	83-87
17951456-8	2007	Interestingly, in rdr2 and drm2 mutant plants, we found that genes demethylated by ROS1 accumulate CG methylation, and we propose that this hypermethylation is due to the ROS1 down-regulation that occurs in these mutant backgrounds.	cysteinylglycine	99-101	demeter-like 1	Arabidopsis thaliana	171-175
17904426-6	2007	ECE and its product ET-1(1-21) were detected in aorta and vena cava, and the ECE inhibitors phosphoramidon and CGS-26393 reduced big ET-1-induced contraction.	cysteinylglycine	111-114	endothelin converting enzyme 1	Rattus norvegicus	0-3
18089324-7	2007	The decreased p27kip1 expression in podocytes was related to cg and ah of the Banff 97 classification.	cysteinylglycine	61-63	cyclin dependent kinase inhibitor 1B	Homo sapiens	14-21
17904426-6	2007	ECE and its product ET-1(1-21) were detected in aorta and vena cava, and the ECE inhibitors phosphoramidon and CGS-26393 reduced big ET-1-induced contraction.	cysteinylglycine	111-114	endothelin converting enzyme 1	Rattus norvegicus	77-80
17643133-7	2007	CGS-26303 induced ECE-1 mRNA expression and ECE-1 promoter activity.	cysteinylglycine	0-3	endothelin converting enzyme 1	Homo sapiens	18-23
17643133-7	2007	CGS-26303 induced ECE-1 mRNA expression and ECE-1 promoter activity.	cysteinylglycine	0-3	endothelin converting enzyme 1	Homo sapiens	44-49
17643133-2	2007	We have studied the effect of CGS-26303 on ECE-1 expression in bovine aortic endothelial cells.	cysteinylglycine	30-33	endothelin converting enzyme 1	Bos taurus	43-48
17643133-8	2007	CGS-35066, a selective ECE-1 inhibitor, mimicked the effects of CGS-26303, suggesting that the effect was specific to ECE-1 inhibition.	cysteinylglycine	0-3	endothelin converting enzyme 1	Homo sapiens	23-28
17643133-4	2007	KEY RESULTS: ECE-1 activity was completely inhibited by CGS-26303 25 microM and phosphoramidon 100 microM.	cysteinylglycine	56-59	endothelin converting enzyme 1	Homo sapiens	13-18
17643133-8	2007	CGS-35066, a selective ECE-1 inhibitor, mimicked the effects of CGS-26303, suggesting that the effect was specific to ECE-1 inhibition.	cysteinylglycine	0-3	endothelin converting enzyme 1	Homo sapiens	118-123
17643133-5	2007	CGS-26303 and phosphoramidon, though not thiorphan, a neutral endopeptidase (NEP) inhibitor, stimulated ECE-1 expression in cells (maximal effect at 16 h, 25 microM).	cysteinylglycine	0-3	endothelin converting enzyme 1	Homo sapiens	104-109
17643133-8	2007	CGS-35066, a selective ECE-1 inhibitor, mimicked the effects of CGS-26303, suggesting that the effect was specific to ECE-1 inhibition.	cysteinylglycine	64-67	endothelin converting enzyme 1	Homo sapiens	23-28
17643133-8	2007	CGS-35066, a selective ECE-1 inhibitor, mimicked the effects of CGS-26303, suggesting that the effect was specific to ECE-1 inhibition.	cysteinylglycine	64-67	endothelin converting enzyme 1	Homo sapiens	118-123
17673620-5	2007	Furthermore UHRF1 contains a methyl DNA binding domain, the SRA (SET and RING associated) domain, that shows strong preferential binding to hemimethylated CG sites, the physiological substrate for DNMT1.	cysteinylglycine	155-157	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	12-17
17673620-5	2007	Furthermore UHRF1 contains a methyl DNA binding domain, the SRA (SET and RING associated) domain, that shows strong preferential binding to hemimethylated CG sites, the physiological substrate for DNMT1.	cysteinylglycine	155-157	macrophage scavenger receptor 1	Homo sapiens	60-63
17673620-5	2007	Furthermore UHRF1 contains a methyl DNA binding domain, the SRA (SET and RING associated) domain, that shows strong preferential binding to hemimethylated CG sites, the physiological substrate for DNMT1.	cysteinylglycine	155-157	DNA methyltransferase 1	Homo sapiens	197-202
17965600-1	2007	DNA methyltransferase 1 methylates hemi-methylated CG sites generated during DNA replication.	cysteinylglycine	51-53	DNA methyltransferase 1	Homo sapiens	0-23
17549378-6	2007	The Amc-HN-2 cell line (p16 exon-positive/mRNA-negative) had a single base deletion at codon 38 (CGG-Arg to CG), which resulted in a frameshift and a consequent stop signal at codon 44.	cysteinylglycine	97-99	cyclin dependent kinase inhibitor 2A	Homo sapiens	24-27
17459372-7	2007	Nicotine attenuated the restraint-induced expression of c-Fos in the PVN, LH, CeA, MeA, and Cg/RS, while leaving the BLA and PVT unaffected.	cysteinylglycine	92-94	FBJ osteosarcoma oncogene	Mus musculus	56-61
17659306-3	2007	The growth-stimulation of IMR90 cells in CG medium (free-serum) without FCS was induced in a dose-dependent manner up to 400 ng/ml of HMLA, HMLZ or chicken lysozyme (ChLZ), and also in a time-dependent manner until 48 h but was induced gradually until 1000 ng/ml of bovine alpha-lactalbumin (BVLA).	cysteinylglycine	41-43	lysozyme	Homo sapiens	156-164
17436274-8	2007	The homozygous cytosine-guanine (CG/CG) genotype of uridine phosphorylase glycosyltransferase 1A7 (UGT1A7) was associated with increased risk at younger ages but decreased risk at older ages.	cysteinylglycine	33-35	UDP glucuronosyltransferase family 1 member A7	Homo sapiens	52-97
17493708-2	2007	The selective adenosine A2A-receptor agonist 2-p-(2-carboxy ethyl) phenethylamino-5"-N-ethylcarboxamidoadenosine (CGS 21680; 100 nM) enhanced tritium overflow evoked by trains of 100 pulses at 5 Hz.	cysteinylglycine	114-117	adenosine A2a receptor	Rattus norvegicus	14-36
17498224-6	2007	Four different NOD2/CARD15 haplotypes were observed in our population [CG(-): 89.8%, CGC: 3.5%, CC(-): 1.6%, TG(-): 5.1%].	cysteinylglycine	71-73	nucleotide binding oligomerization domain containing 2	Homo sapiens	15-19
17498224-6	2007	Four different NOD2/CARD15 haplotypes were observed in our population [CG(-): 89.8%, CGC: 3.5%, CC(-): 1.6%, TG(-): 5.1%].	cysteinylglycine	71-73	nucleotide binding oligomerization domain containing 2	Homo sapiens	20-26
17436274-8	2007	The homozygous cytosine-guanine (CG/CG) genotype of uridine phosphorylase glycosyltransferase 1A7 (UGT1A7) was associated with increased risk at younger ages but decreased risk at older ages.	cysteinylglycine	33-35	UDP glucuronosyltransferase family 1 member A7	Homo sapiens	99-105
17436274-8	2007	The homozygous cytosine-guanine (CG/CG) genotype of uridine phosphorylase glycosyltransferase 1A7 (UGT1A7) was associated with increased risk at younger ages but decreased risk at older ages.	cysteinylglycine	36-38	UDP glucuronosyltransferase family 1 member A7	Homo sapiens	52-97
17436274-8	2007	The homozygous cytosine-guanine (CG/CG) genotype of uridine phosphorylase glycosyltransferase 1A7 (UGT1A7) was associated with increased risk at younger ages but decreased risk at older ages.	cysteinylglycine	36-38	UDP glucuronosyltransferase family 1 member A7	Homo sapiens	99-105
17429846-7	2007	Bisulfite DNA sequencing of the Tnfsf7 gene in MRL/lpr mice revealed that at 16 wk, CG pairs were hypomethylated compared to 5-wk-old mice, and that Tnfsf7 from MRL/lpr mice was hypomethylated at 16 wk relative to age-matched MRL(+/+) controls.	cysteinylglycine	84-86	CD70 antigen	Mus musculus	32-38
17588136-1	2007	OBJECTIVE: In this study we investigated the effect of CGS 21680 (2-p-(2-Carboxyethyl)phenethylamino-5-N-ethylcarboxamidoadenosine hydrochloride), an adenosine A2A receptor agonist, in a model of dextran sulphate sodium (DSS)-induced colitis.	cysteinylglycine	55-58	adenosine A2a receptor	Mus musculus	150-172
17437712-4	2007	Here, we present the 2.25 A crystal structure of the Zalpha domain of the RNA-editing enzyme ADAR1 (double-stranded RNA adenosine deaminase) complexed to a dUr(CG)(3) duplex RNA.	cysteinylglycine	160-162	adenosine deaminase RNA specific	Homo sapiens	93-98
17437712-4	2007	Here, we present the 2.25 A crystal structure of the Zalpha domain of the RNA-editing enzyme ADAR1 (double-stranded RNA adenosine deaminase) complexed to a dUr(CG)(3) duplex RNA.	cysteinylglycine	160-162	adenosine deaminase	Homo sapiens	120-139
17304104-6	2007	We found that Jurkat and CD4+ primary human T cells express most abundantly the A2A and A2B adenosine receptor subtypes, which mediate the suppressive effects of adenosine, as the A2 receptor agonist CGS 21680 suppressed IL-2 production, whereas the A2 receptor antagonist 3,7-dimethyl-1-(2-propynyl)xanthine augmented the enhancing effect of HS on T-cell function.	cysteinylglycine	200-203	interleukin 2	Homo sapiens	221-225
17367066-0	2007	Attenuation of experimental subarachnoid hemorrhage--induced cerebral vasospasm by the adenosine A2A receptor agonist CGS 21680.	cysteinylglycine	118-121	adenosine A2a receptor	Homo sapiens	87-109
17367066-3	2007	This study was designed to examine the effects of an adenosine A2A receptor agonist, (2(4-[2-carboxyethyl]phenyl)ethylamino)-5"-N-ethylcarboxamidoadenosine (CGS 21680), in the prevention of SAH-induced vasospasm.	cysteinylglycine	157-160	adenosine A2a receptor	Homo sapiens	53-75
17367066-11	2007	Induction of iNOS mRNA and protein in the BA by the SAH was significantly diminished by administration of CGS 21680.	cysteinylglycine	106-109	nitric oxide synthase 2	Homo sapiens	13-17
17367067-0	2007	Attenuation of experimental subarachnoid hemorrhage-induced increases in circulating intercellular adhesion molecule-1 and cerebral vasospasm by the endothelin-converting enzyme inhibitor CGS 26303.	cysteinylglycine	188-191	ICAM-1	Oryctolagus cuniculus	85-118
17179087-5	2007	Although dipeptides and tripeptides with a normal peptide bond such as cys-gly or glu-cys-gly required the presence of only a functional DUG1 gene that encoded a protein belonging to the M20A metallohydrolase family, the presence of an unusual peptide bond such as in the dipeptide, gamma-glu-cys, or in GSH, required the participation of the DUG2 and DUG3 gene products as well.	cysteinylglycine	71-78	metallodipeptidase	Saccharomyces cerevisiae S288C	137-141
17179087-5	2007	Although dipeptides and tripeptides with a normal peptide bond such as cys-gly or glu-cys-gly required the presence of only a functional DUG1 gene that encoded a protein belonging to the M20A metallohydrolase family, the presence of an unusual peptide bond such as in the dipeptide, gamma-glu-cys, or in GSH, required the participation of the DUG2 and DUG3 gene products as well.	cysteinylglycine	71-78	glutamine amidotransferase subunit DUG2	Saccharomyces cerevisiae S288C	343-347
17179087-5	2007	Although dipeptides and tripeptides with a normal peptide bond such as cys-gly or glu-cys-gly required the presence of only a functional DUG1 gene that encoded a protein belonging to the M20A metallohydrolase family, the presence of an unusual peptide bond such as in the dipeptide, gamma-glu-cys, or in GSH, required the participation of the DUG2 and DUG3 gene products as well.	cysteinylglycine	71-78	glutamine amidotransferase subunit DUG3	Saccharomyces cerevisiae S288C	352-356
17296780-8	2007	At 70 kg of BW, intramuscular fat (IMF) content of LM did not differ between CG and AL pigs (1.25 vs. 1.49%, respectively, P = 0.118), whereas CG pigs had less IMF in LM at 110 kg of BW (2.19 vs. 2.53% for CG and AL pigs, respectively, P = 0.034).	cysteinylglycine	143-145	IMF	Sus scrofa	160-163
17296780-8	2007	At 70 kg of BW, intramuscular fat (IMF) content of LM did not differ between CG and AL pigs (1.25 vs. 1.49%, respectively, P = 0.118), whereas CG pigs had less IMF in LM at 110 kg of BW (2.19 vs. 2.53% for CG and AL pigs, respectively, P = 0.034).	cysteinylglycine	143-145	IMF	Sus scrofa	160-163
17141888-1	2007	The present studies aimed to elucidate how the modulation of gamma-glutamyl transpeptidase (gammaGT) activity in human hepatoma (HepG2) cell line influences H(2)O(2) production, caspase 3 activity, protein S-thiolation by glutathione (GSH), cysteinyl-glycine (Cys-Gly) and cysteine (Cys), and the level of other redox forms of these thiols.	cysteinylglycine	241-258	inactive glutathione hydrolase 2	Homo sapiens	61-90
17239600-5	2007	Here we show that KYP-dependent H3K9me2 is found at non-CG methylation sites in addition to those rich in CG methylation.	cysteinylglycine	56-58	histone-lysine N-methyltransferase, H3 lysine-9 specific SUVH4-like protein	Arabidopsis thaliana	18-21
17121856-3	2007	This study investigates the action of two HDAC inhibitors, CG-1521 and trichostatin A, which stabilize Ac-Lys-373 p53 and Ac-Lys-382 p53, respectively, in LNCaP prostate cancer cells.	cysteinylglycine	59-61	tumor protein p53	Homo sapiens	114-117
17121856-3	2007	This study investigates the action of two HDAC inhibitors, CG-1521 and trichostatin A, which stabilize Ac-Lys-373 p53 and Ac-Lys-382 p53, respectively, in LNCaP prostate cancer cells.	cysteinylglycine	59-61	tumor protein p53	Homo sapiens	133-136
17121856-4	2007	Real-time PCR demonstrates that CG-1521 induces p21 transcription whereas trichostatin A does not alter the steady state level of p21 mRNA.	cysteinylglycine	32-34	H3 histone pseudogene 16	Homo sapiens	48-51
17077276-9	2007	Urinary loss of cys-gly together with lower concentrations of cysteine, glycine, and oxoproline in kidney tissue and altered expression of mRNA and proteins involved in glutathione (GSH) metabolism suggests that PEPT2 is predominantly a system for reabsorption of cys-gly originating from GSH break-down, thus contributing to resynthesis of GSH.	cysteinylglycine	16-23	solute carrier family 15 (H+/peptide transporter), member 2	Mus musculus	212-217
17077276-9	2007	Urinary loss of cys-gly together with lower concentrations of cysteine, glycine, and oxoproline in kidney tissue and altered expression of mRNA and proteins involved in glutathione (GSH) metabolism suggests that PEPT2 is predominantly a system for reabsorption of cys-gly originating from GSH break-down, thus contributing to resynthesis of GSH.	cysteinylglycine	264-271	solute carrier family 15 (H+/peptide transporter), member 2	Mus musculus	212-217
17141888-1	2007	The present studies aimed to elucidate how the modulation of gamma-glutamyl transpeptidase (gammaGT) activity in human hepatoma (HepG2) cell line influences H(2)O(2) production, caspase 3 activity, protein S-thiolation by glutathione (GSH), cysteinyl-glycine (Cys-Gly) and cysteine (Cys), and the level of other redox forms of these thiols.	cysteinylglycine	241-258	inactive glutathione hydrolase 2	Homo sapiens	92-99
17141888-1	2007	The present studies aimed to elucidate how the modulation of gamma-glutamyl transpeptidase (gammaGT) activity in human hepatoma (HepG2) cell line influences H(2)O(2) production, caspase 3 activity, protein S-thiolation by glutathione (GSH), cysteinyl-glycine (Cys-Gly) and cysteine (Cys), and the level of other redox forms of these thiols.	cysteinylglycine	260-267	inactive glutathione hydrolase 2	Homo sapiens	61-90
17141888-1	2007	The present studies aimed to elucidate how the modulation of gamma-glutamyl transpeptidase (gammaGT) activity in human hepatoma (HepG2) cell line influences H(2)O(2) production, caspase 3 activity, protein S-thiolation by glutathione (GSH), cysteinyl-glycine (Cys-Gly) and cysteine (Cys), and the level of other redox forms of these thiols.	cysteinylglycine	260-267	inactive glutathione hydrolase 2	Homo sapiens	92-99
17141888-4	2007	The inhibition of gammaGT activity by acivicin led to H(2)O(2) decrease after 1-h incubation which still persisted after 24 h. The inhibition of gammaGT activity in HepG2 cells was also connected with the lowering of S-thiolation with Cys and Cys-Gly and with increasing of caspase-3 activity.	cysteinylglycine	243-250	inactive glutathione hydrolase 2	Homo sapiens	18-25
17141888-4	2007	The inhibition of gammaGT activity by acivicin led to H(2)O(2) decrease after 1-h incubation which still persisted after 24 h. The inhibition of gammaGT activity in HepG2 cells was also connected with the lowering of S-thiolation with Cys and Cys-Gly and with increasing of caspase-3 activity.	cysteinylglycine	243-250	inactive glutathione hydrolase 2	Homo sapiens	145-152
17141888-6	2007	We suggest that the role of high gammaGT activity in HepG2 cells can be connected with production of reactive oxygen species and with S-thiolation with Cys and Cys-Gly that can influence activity of caspase 3.	cysteinylglycine	160-167	inactive glutathione hydrolase 2	Homo sapiens	33-40
17141888-6	2007	We suggest that the role of high gammaGT activity in HepG2 cells can be connected with production of reactive oxygen species and with S-thiolation with Cys and Cys-Gly that can influence activity of caspase 3.	cysteinylglycine	160-167	caspase 3	Homo sapiens	199-208
17965621-8	2006	Though the LEP CpG island is generally unmethylated in both human and mouse sperm, depletion of CG sites within the mouse promoter indicates occasional presence of methylated Lep epialleles in the germline.	cysteinylglycine	96-98	leptin	Mus musculus	175-178
17259328-0	2007	Functional neuroprotective effect of CGS 26303, a dual ECE inhibitor, on ischemic-reperfusion spinal cord injury in rats.	cysteinylglycine	37-40	endothelin converting enzyme 1	Rattus norvegicus	55-58
17259328-3	2007	Our previous studies demonstrated that the endothelin-converting enzyme (ECE) inhibitor, CGS 26303, possessed beneficial effects for the treatment of SAH and transient middle cerebral artery occlusion.	cysteinylglycine	89-92	endothelin converting enzyme 1	Rattus norvegicus	43-71
17259328-3	2007	Our previous studies demonstrated that the endothelin-converting enzyme (ECE) inhibitor, CGS 26303, possessed beneficial effects for the treatment of SAH and transient middle cerebral artery occlusion.	cysteinylglycine	89-92	endothelin converting enzyme 1	Rattus norvegicus	73-76
17264508-6	2007	Significantly higher VEGF serum levels were demonstrated in subjects with the CC genotype compared to those with the other (CG + GG) genotypes (60.4 +/- 32.1 vs. 44.1 +/- 23.5 ng/l; p < 0.01).	cysteinylglycine	124-126	vascular endothelial growth factor A	Homo sapiens	21-25
16990421-4	2006	RESULTS: Our data suggest that apoprotein B (apoB)-cysteinylglycine (CysGly), apoB-Hcy, and apoB-Cys concentrations are markedly higher in men than in women.	cysteinylglycine	51-67	apolipoprotein B	Homo sapiens	31-43
16990421-4	2006	RESULTS: Our data suggest that apoprotein B (apoB)-cysteinylglycine (CysGly), apoB-Hcy, and apoB-Cys concentrations are markedly higher in men than in women.	cysteinylglycine	51-67	apolipoprotein B	Homo sapiens	45-49
17273658-4	2007	HbA1 levels were significantly higher in PMC patients (12.5 +/- 0.6 vs 7.45 +/- 0.2% for GMC and 6.3 +/- 0.9% for CG; P < 0.05).	cysteinylglycine	114-116	hemoglobin subunit alpha 1	Homo sapiens	0-4
17060369-0	2007	Activity-structure correlations in divergent lectin evolution: fine specificity of chicken galectin CG-14 and computational analysis of flexible ligand docking for CG-14 and the closely related CG-16.	cysteinylglycine	164-166	galectin 1B	Gallus gallus	194-199
17023036-8	2006	RESULTS: The IL6 -174 genotype frequencies of CC (19%), CG (50%), and GG (31%) were in Hardy-Weinberg equilibrium and were similar to published frequencies in Caucasian controls.	cysteinylglycine	56-58	interleukin 6	Homo sapiens	13-16
16951055-4	2006	Here we describe a novel partial-function missense allele of the Arabidopsis SAH1 gene that causes loss of cytosine methylation specifically in non-CG contexts controlled by the CMT3 DNA MTase and transcriptional reactivation of a silenced reporter gene, without conferring developmental abnormalities.	cysteinylglycine	148-150	S-adenosyl-L-homocysteine hydrolase	Arabidopsis thaliana	77-81
16951055-4	2006	Here we describe a novel partial-function missense allele of the Arabidopsis SAH1 gene that causes loss of cytosine methylation specifically in non-CG contexts controlled by the CMT3 DNA MTase and transcriptional reactivation of a silenced reporter gene, without conferring developmental abnormalities.	cysteinylglycine	148-150	chromomethylase 3	Arabidopsis thaliana	178-182
17217681-8	2006	The improvement in BNP was also observed in CC [from (502.93 +/- 160.80) ng/L to (325.26 +/- 135.63) ng/L], CG [from (525.76 +/- 157.66) ng/L to (331.79 +/- 133.97) ng/L], but not GG [from (505.33 +/- 125.07) ng/L to (429.67 +/- 182.39) ng/L].	cysteinylglycine	108-110	natriuretic peptide B	Homo sapiens	19-22
16935271-7	2006	CGS 21680 also potentiated the effect of GDNF in striatal slices, providing that GABAergic transmission was inhibited; if not, the action of GDNF was attenuated by CGS 21680.	cysteinylglycine	0-3	glial cell derived neurotrophic factor	Rattus norvegicus	41-45
16867213-4	2006	ST 1535, at oral doses of 5 and 10 mg/kg, antagonizes catalepsy induced by intracerebroventricular administration of the A2A adenosine agonist CGS 21680 (10 microg/5 microl) in mice.	cysteinylglycine	143-146	immunoglobulin kappa variable 2D-29	Homo sapiens	121-124
16452987-4	2006	Co-administration of CPA and CGS 21680 also induced a significant increase in the striatal expression of preproenkephalin.	cysteinylglycine	29-32	proenkephalin	Homo sapiens	105-121
16501051-3	2006	In this study, we demonstrate that CGS-21680 (a selective agonist of the adenosine A2A receptor) and histamine also potently inhibit PAF biosynthesis in agonist [formyl Met-Leu-Phe (fMLP)]- and thapsigargin-activated human PMN.	cysteinylglycine	35-38	adenosine A2a receptor	Homo sapiens	73-95
16741051-2	2006	The goal of this study was to evaluate the effect of continuous intravenous infusion of a highly selective endothelin-converting enzyme-1 inhibitor, CGS 35066, on the prevention and reversal of cerebral vasospasm following SAH.	cysteinylglycine	149-152	endothelin-converting enzyme 1	Oryctolagus cuniculus	107-137
16581872-7	2006	Adenosine (1-100 nm) and the specific A2A receptor agonist CGS 21680 (1-50 nm) produced a concentration-dependant potentiation of the caffeine-induced Ca2+ release from saponin-skinned fibres.	cysteinylglycine	59-62	carbonic anhydrase 2	Mustela putorius furo	151-154
16581872-8	2006	The data plotted versus adenosine and CGS 21680 concentrations displayed sigmoid relationships (Hill relationship), with potentiation of Ca2+ release by 22.2 +/- 1.6 (n = 6) and 10.9 +/- 0.4% (n = 6), respectively.	cysteinylglycine	38-41	carbonic anhydrase 2	Mustela putorius furo	137-140
16501051-3	2006	In this study, we demonstrate that CGS-21680 (a selective agonist of the adenosine A2A receptor) and histamine also potently inhibit PAF biosynthesis in agonist [formyl Met-Leu-Phe (fMLP)]- and thapsigargin-activated human PMN.	cysteinylglycine	35-38	formyl peptide receptor 1	Homo sapiens	182-186
16428738-9	2006	The data indicate that bacterial DNA preparations from different species differ in their capacity to activate TLR-9, which is dependent on the individual [CG] content.	cysteinylglycine	155-157	toll like receptor 9	Homo sapiens	110-115
16426693-9	2006	The removal of CG/SMG decreased TH in the duodenum and stomach, but 180 days later TH-positive innervation was recovered.	cysteinylglycine	15-17	tyrosine hydroxylase	Mus musculus	32-34
16387843-6	2006	Suppression of thapsigargin-induced leukotriene synthesis by the selective A2AR agonist CGS-21680 was found to be more pronounced when PMN were cultured for 4 h with LPS or TNF-alpha.	cysteinylglycine	88-91	adenosine A2a receptor	Homo sapiens	75-79
16387843-6	2006	Suppression of thapsigargin-induced leukotriene synthesis by the selective A2AR agonist CGS-21680 was found to be more pronounced when PMN were cultured for 4 h with LPS or TNF-alpha.	cysteinylglycine	88-91	tumor necrosis factor	Homo sapiens	173-182
16385076-4	2006	Pretreatment of resting cells with the A2AR agonist 2-[p-(2-carboxyethyl)phenethylamino]-5"-N-ethylcarboxamidoadenosine (CGS 21680) or the pan-adenosine receptor agonist 5"-N-ethylcarboxamidoadenosine quickly desensitized cAMP responses to CGS 21680 restimulation, but TNF-alpha treatment prevented A2AR desensitization.	cysteinylglycine	121-124	adenosine A2a receptor	Homo sapiens	39-43
16432376-8	2006	Upon exposure of colonic tissues from normal or inflamed rats to dipyridamole plus adenosine deaminase, to abate endogenous adenosine levels, CGS 21680 evoked concentration-dependent reductions of contractile responses to TES, which were more intense in preparations from inflamed rats, and were antagonized by ZM 241385.	cysteinylglycine	142-145	adenosine deaminase	Rattus norvegicus	83-102
16395259-10	2006	There was a weak but significant impact of -180 C/G genotype on plasma levels of resistin (median 43.0+/-2.4 ng/ml in CC, 37.5+/-2.0 ng/ml in CG, and 41.1+/-4.9 ng/ml in GG; P<0.05).	cysteinylglycine	142-144	resistin	Mus musculus	81-89
16229487-11	2005	Replacement of dG at 5"-d(CG) with 2"-deoxyinosine (dI), which lacks the exocyclic C2 amino group present in dG, also prevented DNA ICL formation by 4, revealing an essential role for the dG C2 amino group in the interstrand cross-linking reaction between 4 and duplex DNA.	cysteinylglycine	26-28	Glutamate Carrier 2	Drosophila melanogaster	188-193
16143649-5	2006	Stimulation of A2AR with 2-P(2-carboxyethyl)phenethyl-amino-5"-N-ethylcarboxyamidoadenosine (CGS-21680) attenuated this antiadrenergic effect, resulting in a partial (constant flow preparation) or complete (constant pressure preparation) restoration of the ISO contractile response.	cysteinylglycine	93-96	adenosine A2a receptor	Mus musculus	15-19
16317519-7	2006	The results showed: (1) the body iron status in MG was kept at a high level compared to that of CG and SG, (2) Western blot showed DMT1 with iron responsive element (IRE) and FPN1 in duodenal epithelium which were higher in MG than that of CG and (3) the expression of hepatic hepcidin mRNA was down regulated in MG (p < 0.05).	cysteinylglycine	96-98	RoBo-1	Rattus norvegicus	131-135
16141383-3	2006	The specific adenosine A2A-receptor agonist CGS-21680 (CGS) or vehicle control was injected into the fourth ventricle of 14-day (n = 9), 21-day (n = 9), and adult (n = 5) urethane-anesthetized rats while diaphragm electromyogram was monitored as an index of respiratory neural output.	cysteinylglycine	44-47	adenosine A2a receptor	Rattus norvegicus	13-35
16284380-4	2005	After adjustment for age and smoking, the PCNA-6084C variant was significantly associated with an increased risk of bladder cancer [CC + CG versus GG, odds ratio (OR), 1.61; 95% confidence interval (95% CI), 1.00-2.61], as well as the XRCC1-26651G variant (GG+AG versus AA: OR, 1.73; 95% CI, 1.17-2.56).	cysteinylglycine	137-139	proliferating cell nuclear antigen	Homo sapiens	42-46
16271052-4	2005	Co-application of the A(2A)R agonist CGS 21680 with the mGlu5R agonist (RS)-2-chloro-s-hydroxyphenylglycine(CHPG) synergistically reduced field excitatory postsynaptic potentials in the CA1 area of rat hippocampal slices.	cysteinylglycine	37-40	glutamate receptor, metabotropic 5	Mus musculus	56-62
16271052-4	2005	Co-application of the A(2A)R agonist CGS 21680 with the mGlu5R agonist (RS)-2-chloro-s-hydroxyphenylglycine(CHPG) synergistically reduced field excitatory postsynaptic potentials in the CA1 area of rat hippocampal slices.	cysteinylglycine	37-40	carbonic anhydrase 1	Rattus norvegicus	186-189
16151631-8	2005	The reduction in postischemic apoptotic hepatic injury in the CGS-treated group was confirmed morphologically, by the significantly fewer apoptotic hepatocyte cells detected (p < 0.05); immunohistochemically, by the significantly weaker activation of caspase-3 compared to the ischemic group (p < 0.05); and by the TUNEL assay (p < 0.05).	cysteinylglycine	62-65	caspase 3	Rattus norvegicus	254-263
15769934-4	2005	cGS was induced by injection of anti-thy1 antibody into uninephrectomized Wistar rats.	cysteinylglycine	0-3	Thy-1 cell surface antigen	Rattus norvegicus	37-41
15880589-12	2005	In addition to resulting from selection pressure, this observation may be explained by the CG dinucleotide of codon 24 representing a mutational hot spot in the CDK4 gene.	cysteinylglycine	91-93	cyclin dependent kinase 4	Homo sapiens	161-165
15998246-0	2005	The S-thiolating activity of membrane gamma-glutamyltransferase: formation of cysteinyl-glycine mixed disulfides with cellular proteins and in the cell microenvironment.	cysteinylglycine	78-95	gamma-glutamyltransferase light chain family member 3	Homo sapiens	38-63
15918673-4	2005	Our analysis of MD and crystal structures shows that BII conformation is sequence specific and dinucleotides GC, CG, CA, TG, TA show high preference to take up BII conformation, while TT, TC, CT, CC dinucleotides rarely take up this conformation.	cysteinylglycine	113-115	calcium voltage-gated channel subunit alpha1 E	Homo sapiens	53-56
15918673-4	2005	Our analysis of MD and crystal structures shows that BII conformation is sequence specific and dinucleotides GC, CG, CA, TG, TA show high preference to take up BII conformation, while TT, TC, CT, CC dinucleotides rarely take up this conformation.	cysteinylglycine	113-115	calcium voltage-gated channel subunit alpha1 E	Homo sapiens	160-163
15918673-10	2005	In conformity with the sequence preference seen for dinucleotides in each strand, BII.BII combination of backbone conformation was observed only for GC, CG, CA, and TG containing dinucleotide steps.	cysteinylglycine	153-155	calcium voltage-gated channel subunit alpha1 E	Homo sapiens	82-85
15918673-10	2005	In conformity with the sequence preference seen for dinucleotides in each strand, BII.BII combination of backbone conformation was observed only for GC, CG, CA, and TG containing dinucleotide steps.	cysteinylglycine	153-155	calcium voltage-gated channel subunit alpha1 E	Homo sapiens	86-89
15998246-3	2005	Experiments show that the cysteinyl-glycine (CG) originating from cellular GGT-mediated glutathione (GSH) metabolism can efficiently thiolate cellular proteins, as well as proteins present in the extracellular environment.	cysteinylglycine	26-43	gamma-glutamyltransferase light chain family member 3	Homo sapiens	75-78
15998246-3	2005	Experiments show that the cysteinyl-glycine (CG) originating from cellular GGT-mediated glutathione (GSH) metabolism can efficiently thiolate cellular proteins, as well as proteins present in the extracellular environment.	cysteinylglycine	45-47	gamma-glutamyltransferase light chain family member 3	Homo sapiens	75-78
15998246-6	2005	The findings reported suggest that binding of CG ("protein S-cysteylglycylation") may represent an as yet unrecognized function of membrane GGT, likely playing a regulatory role(s) in the cell and its surroundings.	cysteinylglycine	46-48	gamma-glutamyltransferase light chain family member 3	Homo sapiens	140-143
15915030-10	2005	The adenosine A2A receptor agonist CGS-21680 mimicked the effect of ketamine in peritonitis, whereas the A2A receptor antagonists DMPX and ZM 241385 blocked its antiinflammatory effects.	cysteinylglycine	35-38	adenosine A2a receptor	Mus musculus	4-26
15963234-5	2005	RESULTS: In EMSA and DNAseI footprinting assays, a KLF15-GST fusion protein containing the C-terminal zinc-finger domains (123 amino acids) showed zinc-dependent and sequence-specific binding to a 9 bp consensus sequence containing a core CG/TCCCC.	cysteinylglycine	239-241	Kruppel like factor 15	Bos taurus	51-56
15849776-11	2005	In the group of patients who did not respond to AML-CG therapy, significantly higher proportions of UPA-R+ cells (31% vs. 14%, P = 0.0015, t-test) were found.	cysteinylglycine	52-54	plasminogen activator, urokinase	Homo sapiens	100-103
15743930-6	2005	In contrast, the NR2B H486F mutation increased the affinity of the typical antagonists CGS-19755 [(2R*,4S*)-4-phosphonomethyl-2-piperidine carboxylic acid] and 4-(3-phosphonopropyl) piperidine-2-carboxylic acid.	cysteinylglycine	87-90	glutamate ionotropic receptor NMDA type subunit 2B	Homo sapiens	17-21
15863236-5	2005	Reduction of L-[14C]cystine to L-[14C]cysteine in the presence of 1mM cysteinylglycine increases the uptake rate in HEK(GLT1), HEK(GLAST) and HEK(EAAC1) cells, but only a small proportion (<10%) of L-[14C]cysteine uptake in HEK(GLT1) and HEK(GLAST) cells occurs by the high affinity glutamate transporters.	cysteinylglycine	70-86	solute carrier family 1 member 2	Homo sapiens	120-124
15863236-5	2005	Reduction of L-[14C]cystine to L-[14C]cysteine in the presence of 1mM cysteinylglycine increases the uptake rate in HEK(GLT1), HEK(GLAST) and HEK(EAAC1) cells, but only a small proportion (<10%) of L-[14C]cysteine uptake in HEK(GLT1) and HEK(GLAST) cells occurs by the high affinity glutamate transporters.	cysteinylglycine	70-86	solute carrier family 1 member 3	Homo sapiens	131-136
15863236-5	2005	Reduction of L-[14C]cystine to L-[14C]cysteine in the presence of 1mM cysteinylglycine increases the uptake rate in HEK(GLT1), HEK(GLAST) and HEK(EAAC1) cells, but only a small proportion (<10%) of L-[14C]cysteine uptake in HEK(GLT1) and HEK(GLAST) cells occurs by the high affinity glutamate transporters.	cysteinylglycine	70-86	solute carrier family 1 member 1	Homo sapiens	146-151
15863236-5	2005	Reduction of L-[14C]cystine to L-[14C]cysteine in the presence of 1mM cysteinylglycine increases the uptake rate in HEK(GLT1), HEK(GLAST) and HEK(EAAC1) cells, but only a small proportion (<10%) of L-[14C]cysteine uptake in HEK(GLT1) and HEK(GLAST) cells occurs by the high affinity glutamate transporters.	cysteinylglycine	70-86	solute carrier family 1 member 2	Homo sapiens	231-235
15863236-5	2005	Reduction of L-[14C]cystine to L-[14C]cysteine in the presence of 1mM cysteinylglycine increases the uptake rate in HEK(GLT1), HEK(GLAST) and HEK(EAAC1) cells, but only a small proportion (<10%) of L-[14C]cysteine uptake in HEK(GLT1) and HEK(GLAST) cells occurs by the high affinity glutamate transporters.	cysteinylglycine	70-86	solute carrier family 1 member 3	Homo sapiens	245-250
15746940-2	2005	While p53 is constitutively acetylated at Lys320 in LNCaP cells, treatment with CG-1521, stabilizes the acetylation of p53 at Lys373, elevating p21 (and inducing cell cycle arrest).	cysteinylglycine	80-82	tumor protein p53	Homo sapiens	119-122
15746940-2	2005	While p53 is constitutively acetylated at Lys320 in LNCaP cells, treatment with CG-1521, stabilizes the acetylation of p53 at Lys373, elevating p21 (and inducing cell cycle arrest).	cysteinylglycine	80-82	H3 histone pseudogene 16	Homo sapiens	144-147
15539423-9	2005	Adenosine, NECA, and CGS-21680 produced an increase in maximal relaxation in A(1)AR((-/-)) compared with A(1)AR((+/+)) rings, whereas Cl-IBMECA did not produce contraction in either A(1)AR((+/+)) or A(1)AR((-/-)) rings.	cysteinylglycine	21-24	adenosine A1 receptor	Mus musculus	77-83
15677709-7	2005	This finding has to be considered in future models of the interaction of LH/CG with the LHR.	cysteinylglycine	76-78	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	88-91
15689617-6	2005	Moreover, the effect of CGS was blocked by an A2A-R-selective antagonist (CSC), two inhibitors of protein kinase A, and two dominant negative mutants of (CREB).	cysteinylglycine	24-27	adenosine A2a receptor	Rattus norvegicus	46-51
15689617-6	2005	Moreover, the effect of CGS was blocked by an A2A-R-selective antagonist (CSC), two inhibitors of protein kinase A, and two dominant negative mutants of (CREB).	cysteinylglycine	24-27	cAMP responsive element binding protein 1	Rattus norvegicus	154-158
15365991-1	2004	The alpha-globin chains are encoded by two duplicated genes (HBA2 and HBA1, 5"-3") showing overall sequence homology >96% and average CG content >60%.	cysteinylglycine	137-139	hemoglobin subunit alpha 1	Homo sapiens	70-74
16399403-4	2005	GGT also initiates the metabolism of glutathione S-conjugates to mercapturic acids by transferring the gamma-glutamyl moiety to an acceptor amino acid and releasing cysteinylglycine.	cysteinylglycine	165-181	inactive glutathione hydrolase 2	Homo sapiens	0-3
15829161-12	2005	ZM 241385 (adenosine A(2A) receptor antagonist) prevented the effect of CGS 21680 (0.1 mg/kg, i.p.).	cysteinylglycine	72-75	adenosine A2a receptor	Rattus norvegicus	11-35
15339928-8	2004	Interestingly, Dnmt1 is not able to methylate hemimethylated CG sites on different strands of the DNA in a processive manner, indicating that Dnmt1 keeps its orientation with respect to the DNA while methylating the CG sites on one strand of the DNA.	cysteinylglycine	216-218	DNA methyltransferase 1	Homo sapiens	15-20
15339928-8	2004	Interestingly, Dnmt1 is not able to methylate hemimethylated CG sites on different strands of the DNA in a processive manner, indicating that Dnmt1 keeps its orientation with respect to the DNA while methylating the CG sites on one strand of the DNA.	cysteinylglycine	216-218	DNA methyltransferase 1	Homo sapiens	142-147
15668172-3	2005	CG sites are maintained by a plant homolog of mammalian Dnmt1 acting on hemi-methylated DNA after replication.	cysteinylglycine	0-2	DNA methyltransferase 1	Homo sapiens	56-61
16614731-8	2005	Similar in vivo ACE, NEP, and ECE inhibitory activities were also observed with the orally active prodrug, CGS 37808 (L-tryptophan, N-[[1-[[(2S)-2-(acetylthio)-4-methyl-1-oxopentyl]amino]cyclopentyl]-carbonyl]-, methyl ester.	cysteinylglycine	107-110	endothelin converting enzyme 1	Rattus norvegicus	30-33
15838282-0	2004	CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.	cysteinylglycine	0-3	endothelin converting enzyme 1	Rattus norvegicus	74-104
15838282-0	2004	CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.	cysteinylglycine	0-3	membrane metallo-endopeptidase	Rattus norvegicus	106-133
15838282-0	2004	CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.	cysteinylglycine	0-3	angiotensin I converting enzyme	Rattus norvegicus	139-168
15838282-1	2004	CGS 35601 is a potent triple inhibitor of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.	cysteinylglycine	0-3	endothelin converting enzyme 1	Rattus norvegicus	42-72
15838282-1	2004	CGS 35601 is a potent triple inhibitor of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.	cysteinylglycine	0-3	membrane metallo-endopeptidase	Rattus norvegicus	74-101
15838282-1	2004	CGS 35601 is a potent triple inhibitor of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.	cysteinylglycine	0-3	angiotensin I converting enzyme	Rattus norvegicus	107-136
15464394-4	2004	A precyclic GnRH analog, [Cys-Gly]1[D-Ala]6[N(alpha)(eta-Cys-amino hexyl)]10GnRH (Gn-2), containing two hemi-chelator groups was synthesized.	cysteinylglycine	26-33	gonadotropin releasing hormone 1	Rattus norvegicus	12-16
15321739-5	2004	The adenosine receptor agonist 2-p-(carboxyethyl)phenethylamino-5"-N-ethylcarboxamidoadenosine hydrochloride (CGS 21680) decreased stability and half-life of PMA/phytohemagglutinin-induced TNF-alpha mRNA from 80 to 37 min.	cysteinylglycine	110-113	tumor necrosis factor	Homo sapiens	189-198
15312183-5	2004	Finally, the A2AR agonist CGS 21680 potentiated CHGP effects, an action that was reproduced and abolished, respectively, by forskolin (an activator of the cAMP/protein kinase A, PKA, pathway) and KT 5720 (a PKA inhibitor).	cysteinylglycine	26-29	adenosine A2a receptor	Rattus norvegicus	13-17
15302158-0	2004	CG sequence- and phosphorothioate backbone modification-dependent activation of the NF-kappaB-responsive gene expression by CpG-oligodeoxynucleotides in human RPMI 8226 B cells.	cysteinylglycine	0-2	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	84-93
12963055-6	2003	This inhibitor takes advantage of the three-nucleotide recognition motif characteristic of hDnmt1 and shows that the enzyme is inhibited in vitro by non-CG methylation which targets the enzyme to normally basepaired but unproductive nucleotides such as dG, dA, and dT.	cysteinylglycine	153-155	DNA methyltransferase 1	Homo sapiens	91-97
15105297-7	2004	CBS overexpression also significantly lowered serum cysteinylglycine (3.6 versus 2.8 micromol/L; P<0.003) levels and reduced the levels of many amino acids in the liver.	cysteinylglycine	52-68	cystathionine beta-synthase	Mus musculus	0-3
15604652-3	2004	Experiments designed to test the effect of a met1 mutation on both RNA-directed de novo and maintenance methylation of the target NOS promoter revealed in each case approximately wild type levels of non-CG methylation together with significant reductions of CG methylation.	cysteinylglycine	203-205	methyltransferase 1	Arabidopsis thaliana	45-49
15604652-3	2004	Experiments designed to test the effect of a met1 mutation on both RNA-directed de novo and maintenance methylation of the target NOS promoter revealed in each case approximately wild type levels of non-CG methylation together with significant reductions of CG methylation.	cysteinylglycine	258-260	methyltransferase 1	Arabidopsis thaliana	45-49
14583094-2	2004	The characterization of the purified enzyme (molecular mass of the native protein, molecular mass of the subunit and extensive primary structure analysis) allowed the unequivocal attribution of the cysteinyl-glycine hydrolysing activity, which is usually associated with alanyl aminopeptidase (EC 3.4.11.2) or membrane-bound dipeptidase (EC 3.4.13.19), to LAP (leucyl aminopeptidase; EC 3.4.11.1).	cysteinylglycine	198-215	leucine aminopeptidase 3	Bos taurus	356-359
14583094-2	2004	The characterization of the purified enzyme (molecular mass of the native protein, molecular mass of the subunit and extensive primary structure analysis) allowed the unequivocal attribution of the cysteinyl-glycine hydrolysing activity, which is usually associated with alanyl aminopeptidase (EC 3.4.11.2) or membrane-bound dipeptidase (EC 3.4.13.19), to LAP (leucyl aminopeptidase; EC 3.4.11.1).	cysteinylglycine	198-215	leucine aminopeptidase 3	Bos taurus	361-382
14583094-3	2004	Analysis of the pH dependence of Cys-Gly hydrolysis catalysed by LAP, supported by a molecular modelling approach to the enzyme-substrate conformation, gave insights into the ability of the enzyme to recognize Cys-Gly as a substrate.	cysteinylglycine	33-40	leucine aminopeptidase 3	Bos taurus	65-68
14583094-3	2004	Analysis of the pH dependence of Cys-Gly hydrolysis catalysed by LAP, supported by a molecular modelling approach to the enzyme-substrate conformation, gave insights into the ability of the enzyme to recognize Cys-Gly as a substrate.	cysteinylglycine	210-217	leucine aminopeptidase 3	Bos taurus	65-68
14583094-4	2004	Due to the effectiveness of LAP in hydrolysing Cys-Gly (K(m)=0.57 mM, kcat=6.0x10(3) min(-1) at pH 7.4 and 25 degrees C) with respect to other dipeptide substrates, a new role for this enzyme in glutathione turnover is proposed.	cysteinylglycine	47-54	leucine aminopeptidase 3	Bos taurus	28-31
14751870-5	2004	Adenosine (nonselective agonist), CPA (A(1)), CGS 21680 (A(2A)) or Cl-IB-MECA (A(3)), all increased ERK1/2 phosphorylation in a time- and dose-dependent manner.	cysteinylglycine	46-49	mitogen activated protein kinase 3	Rattus norvegicus	100-106
15175940-8	2004	RESULTS: When cases were divided according to the histologic type of the tumor, a significant difference in genotype frequencies for IL-1B-1473 was observed only between intestinal-type cases and controls (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.0-3.5 and OR 2.1 and 95% CI, 1.1-4.2 in the CG and GG genotypes, respectively).	cysteinylglycine	304-306	interleukin 1 beta	Homo sapiens	133-138
12794065-5	2003	Methylation was observed at CG sites in a loose ttnCGga(g/a) consensus sequence, suggesting that Dnmt2 has a more specialized role than other mammalian DNA methyltransferases.	cysteinylglycine	28-30	tRNA aspartic acid methyltransferase 1	Homo sapiens	97-102
12920200-6	2003	Down-regulation of currents by the A2aR agonist 2-[p-(2-carboxyeth yl)phenylethylamino]-5"-N-ethyolcarboxamidoadenosine (CGS-21680) was blocked by inhibiting protein tyrosine phosphatase (PTP; orthovanodate and dephostatin), but not by inhibiting cGK (KT-5823 and H-7).	cysteinylglycine	121-124	adenosine A2a receptor	Rattus norvegicus	35-39
12909194-5	2003	The selective adenosine A2A receptor agonist 4-[2-[[-6-amino-9-(N-ethyl-beta-D-ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl]benzene-propanoic acid (CGS 21680) stimulated a robust increase in [3H]cyclic AMP accumulation and p42/p44 MAPK phosphorylation.	cysteinylglycine	152-155	adenosine A2a receptor	Mus musculus	14-36
12920200-6	2003	Down-regulation of currents by the A2aR agonist 2-[p-(2-carboxyeth yl)phenylethylamino]-5"-N-ethyolcarboxamidoadenosine (CGS-21680) was blocked by inhibiting protein tyrosine phosphatase (PTP; orthovanodate and dephostatin), but not by inhibiting cGK (KT-5823 and H-7).	cysteinylglycine	121-124	protein tyrosine phosphatase, non-receptor type 1	Rattus norvegicus	158-186
12920200-6	2003	Down-regulation of currents by the A2aR agonist 2-[p-(2-carboxyeth yl)phenylethylamino]-5"-N-ethyolcarboxamidoadenosine (CGS-21680) was blocked by inhibiting protein tyrosine phosphatase (PTP; orthovanodate and dephostatin), but not by inhibiting cGK (KT-5823 and H-7).	cysteinylglycine	121-124	protein tyrosine phosphatase, non-receptor type 1	Rattus norvegicus	188-191
12906924-7	2003	Using partially purified GGT from HeLa-GGT cells, we show that cisplatin forms adducts with cysteinylglycine, depending only on GGT activity whereas carboplatin did not efficiently react with cysteinylglycine.	cysteinylglycine	92-108	gamma-glutamyltransferase light chain family member 3	Homo sapiens	25-28
12906924-8	2003	Thus, in this model system, GGT activity can affect platinum drugs cytotoxocity by two different ways: cisplatin can be detoxified extracellularly after reaction with the -SH group of cysteinylglycine; in the case of carboplatin, the supply of GSH precursors, initiated by GGT, increases the intracellular level of the tripeptide and provides enhanced defensive mechanisms to the cell.	cysteinylglycine	184-200	gamma-glutamyltransferase light chain family member 3	Homo sapiens	28-31
12909194-9	2003	Furthermore, treatment with Cl-IB-MECA (1 microM) or CGS 21680 (1 microM) alone produced a partial inhibition of lipopolysaccharide-induced TNF-alpha release (when compared to NECA), whereas a combination of both agonists resulted in the inhibition of TNF-alpha release comparable to that observed with NECA alone.	cysteinylglycine	53-56	tumor necrosis factor	Mus musculus	140-149
12700682-3	2003	CPT and MSX-3 produced motor activation at the same doses that selectively counteracted motor depression induced by CPA and CGS 21680, respectively.	cysteinylglycine	124-127	msh homeobox 3	Rattus norvegicus	8-13
12909194-9	2003	Furthermore, treatment with Cl-IB-MECA (1 microM) or CGS 21680 (1 microM) alone produced a partial inhibition of lipopolysaccharide-induced TNF-alpha release (when compared to NECA), whereas a combination of both agonists resulted in the inhibition of TNF-alpha release comparable to that observed with NECA alone.	cysteinylglycine	53-56	tumor necrosis factor	Mus musculus	252-261
12855303-3	2003	Without handles, the anticipatory activation of the Gastrocnemius Medialis displaced the COP forwards, enabling the backward shift of the CG required to rock back on heels.	cysteinylglycine	138-140	caspase recruitment domain family member 16	Homo sapiens	89-92
12929176-3	2003	We show that CE-LIF allows a baseline separation of total plasma cysteinylglycine, homocysteine, cysteine, and glutathione in less than 5 min when N-methyl-D-glucamine in run buffer was added.	cysteinylglycine	65-81	LIF interleukin 6 family cytokine	Homo sapiens	16-19
12887411-4	2003	Administration of a motor-depressant dose of the A2AR agonist CGS 21680 (0.5 mg/kg i.p.)	cysteinylglycine	62-65	adenosine A2a receptor	Rattus norvegicus	49-53
12887411-8	2003	Coadministration of CGS 21680 and CPA produced a synergistic induction of c-fos expression in the caudate-putamen, cingulate cortex, and especially the NAc.	cysteinylglycine	20-23	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	74-79
12620192-5	2003	Arabidopsis additionally methylates non-CG sites using CHROMOMETHYLASE3 (CMT3).	cysteinylglycine	40-42	chromomethylase 3	Arabidopsis thaliana	55-71
12775746-1	2003	PURPOSE: An increased incidence of thromboembolic events was observed during treatment with cisplatin-gemcitabine plus SU5416 (CG+SU5416), a tyrosine kinase inhibitor targeting the vascular endothelial growth factor (VEGF) receptor-1 and -2.	cysteinylglycine	127-129	fms related receptor tyrosine kinase 1	Homo sapiens	181-240
12775746-4	2003	MATERIALS AND METHODS: Markers for thrombin generation and endothelial cell activation were measured in three patients treated with CG+SU5416, two of whom developed a thromboembolic event.	cysteinylglycine	132-134	coagulation factor II, thrombin	Homo sapiens	35-43
12775746-9	2003	CONCLUSION: We hypothesize that endothelial cells deprived of VEGF after exposure to SU5416 became activated and more susceptible to damage during treatment with CG+SU5416, which was aggravated by a transient decrease in platelets, which are, among other things, carriers of VEGF.	cysteinylglycine	162-164	vascular endothelial growth factor A	Homo sapiens	62-66
12775746-9	2003	CONCLUSION: We hypothesize that endothelial cells deprived of VEGF after exposure to SU5416 became activated and more susceptible to damage during treatment with CG+SU5416, which was aggravated by a transient decrease in platelets, which are, among other things, carriers of VEGF.	cysteinylglycine	162-164	vascular endothelial growth factor A	Homo sapiens	275-279
12684736-4	2003	OBJECTIVE: The aim of this study was to determine whether CGS 21680, a selective adenosine A(2A) receptor agonist, can reverse the disruption of prepulse inhibition (PPI) of the acoustic startle response induced by the non-competitive antagonist of NMDA receptors phencyclidine (PCP) without producing motor side-effects in rats.	cysteinylglycine	58-61	adenosine A2a receptor	Rattus norvegicus	81-105
12951438-4	2003	Orally administered CG apparently showed anti-ulcer activity in rats via HSF activation and HSP70 induction.	cysteinylglycine	20-22	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	92-97
12706370-15	2003	A primary role in the protection of HK-2 cells appears to be played by cysteinyl-glycine, the proximal product of the GGT-mediated hydrolysis of GSH, which shows a high reactivity against CDDP resulting in the rapid inactivation of the drug.	cysteinylglycine	71-88	inactive glutathione hydrolase 2	Homo sapiens	118-121
12620192-5	2003	Arabidopsis additionally methylates non-CG sites using CHROMOMETHYLASE3 (CMT3).	cysteinylglycine	40-42	chromomethylase 3	Arabidopsis thaliana	73-77
12611453-1	2003	We have prepared conjugates of a membrane disrupting lytic peptide (hecate) and a 15-amino acid segment of the beta-chain of CG and hecate and the decapeptide, luteinizing hormone releasing hormone (LHRH).	cysteinylglycine	125-127	gonadotropin releasing hormone 1	Homo sapiens	160-197
12635523-5	2003	Neurons immunolabeled for HSP-72 appeared in the penumbral region adjacent to the infarct at 24 h and increased in number and distribution after pretreatment with NBQX or CGS-19755.	cysteinylglycine	171-174	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	26-32
12593839-5	2003	We have also shown for the first time that unlike a CpG DNA oligo that is highly proinflammatory, a CG-containing PNA is inert in triggering TNF-alpha response in cultured macrophages and in mice.	cysteinylglycine	100-102	tumor necrosis factor	Mus musculus	141-150
12372501-1	2002	Directed screening of metalloprotease inhibitors identified CGS 30084 (1) as a potent inhibitor of endothelin-converting enzyme-1 (ECE-1) in vitro (IC(50)=77 nM).	cysteinylglycine	60-63	endothelin converting enzyme 1	Rattus norvegicus	99-129
12584183-5	2003	We report that PKC delta is stimulated 2.0-2.5 fold by GSSG, (Cys-Gly)(2) and cystine, under conditions where PKC gamma and PKC epsilon are fully inactivated by cystine, and PKC alpha activity is affected marginally or not at all by the disulfides.	cysteinylglycine	62-69	protein kinase C, delta	Mus musculus	15-24
12507833-1	2003	The bactericidal potency of a synthetic peptide (CG 117-136) of human lysosomal cathepsin G (cat G) can be substantially increased by covalent attachment to its N- or C-termini, of saturated, linear fatty acids (FAs), namely those with C-8, C-10 and C-12 hydrocarbon chains.	cysteinylglycine	49-51	cathepsin G	Homo sapiens	80-91
12507833-1	2003	The bactericidal potency of a synthetic peptide (CG 117-136) of human lysosomal cathepsin G (cat G) can be substantially increased by covalent attachment to its N- or C-termini, of saturated, linear fatty acids (FAs), namely those with C-8, C-10 and C-12 hydrocarbon chains.	cysteinylglycine	49-51	homeobox C8	Homo sapiens	236-239
12507833-1	2003	The bactericidal potency of a synthetic peptide (CG 117-136) of human lysosomal cathepsin G (cat G) can be substantially increased by covalent attachment to its N- or C-termini, of saturated, linear fatty acids (FAs), namely those with C-8, C-10 and C-12 hydrocarbon chains.	cysteinylglycine	49-51	chromosome 12 open reading frame 57	Homo sapiens	241-245
12507833-4	2003	A marked increase in the propensity of FA-modified CG 117-136 to form an alpha-helix structure was observed for the C-8, C-10 and C-12 derivatives compared with unmodified/short-chain and long-chain (C-14, C-16, C-18) derivatives.	cysteinylglycine	51-53	homeobox C8	Homo sapiens	116-119
12507833-4	2003	A marked increase in the propensity of FA-modified CG 117-136 to form an alpha-helix structure was observed for the C-8, C-10 and C-12 derivatives compared with unmodified/short-chain and long-chain (C-14, C-16, C-18) derivatives.	cysteinylglycine	51-53	chromosome 12 open reading frame 57	Homo sapiens	121-125
12507833-4	2003	A marked increase in the propensity of FA-modified CG 117-136 to form an alpha-helix structure was observed for the C-8, C-10 and C-12 derivatives compared with unmodified/short-chain and long-chain (C-14, C-16, C-18) derivatives.	cysteinylglycine	51-53	Bardet-Biedl syndrome 9	Homo sapiens	212-216
12675513-0	2003	Identification of cytosolic leucyl aminopeptidase (EC 3.4.11.1) as the major cysteinylglycine-hydrolysing activity in rat liver.	cysteinylglycine	77-93	leucine aminopeptidase 3	Rattus norvegicus	28-49
12675513-3	2003	Here we demonstrate that cytosolic leucyl aminopeptidase (EC 3.4.11.1) is the major cysteinylglycine hydrolysing activity in rat liver.	cysteinylglycine	84-100	leucine aminopeptidase 3	Rattus norvegicus	35-56
12584183-5	2003	We report that PKC delta is stimulated 2.0-2.5 fold by GSSG, (Cys-Gly)(2) and cystine, under conditions where PKC gamma and PKC epsilon are fully inactivated by cystine, and PKC alpha activity is affected marginally or not at all by the disulfides.	cysteinylglycine	62-69	protein kinase C, epsilon	Mus musculus	124-135
12584183-5	2003	We report that PKC delta is stimulated 2.0-2.5 fold by GSSG, (Cys-Gly)(2) and cystine, under conditions where PKC gamma and PKC epsilon are fully inactivated by cystine, and PKC alpha activity is affected marginally or not at all by the disulfides.	cysteinylglycine	62-69	protein kinase C, alpha	Mus musculus	174-183
12540635-5	2003	Subjects with the C-174C genotype of the IL-6 gene had significantly lower energy expenditure than subjects with the G-174C or G-174G genotypes both in fasting (CC 13.68 +/- 1.98, CG 14.73 +/- 1.57, GG 14.81 +/- 2.01 kcal x kg(-1) x min(-1); P = 0.012) and during the euglycemic-hyperinsulinemic clamp (CC 15.24 +/- 2.05, CG 16.62 +/- 2.06, GG 16.66 +/- 2.50 kcal x kg(-1) x min(-1); P = 0.007).	cysteinylglycine	180-182	interleukin 6	Homo sapiens	41-45
12540635-5	2003	Subjects with the C-174C genotype of the IL-6 gene had significantly lower energy expenditure than subjects with the G-174C or G-174G genotypes both in fasting (CC 13.68 +/- 1.98, CG 14.73 +/- 1.57, GG 14.81 +/- 2.01 kcal x kg(-1) x min(-1); P = 0.012) and during the euglycemic-hyperinsulinemic clamp (CC 15.24 +/- 2.05, CG 16.62 +/- 2.06, GG 16.66 +/- 2.50 kcal x kg(-1) x min(-1); P = 0.007).	cysteinylglycine	322-324	interleukin 6	Homo sapiens	41-45
12573695-3	2003	All PBGS contain an active site metal binding sequence, determined herein to be either DXCXCX(Y/F)X(3)G(H/Q)CG or DXALDX(Y/F)X(3)G(H/Q)DG.	cysteinylglycine	108-110	aminolevulinate dehydratase	Homo sapiens	4-8
12459913-3	2003	In some PBGS, the cysteines of the metal switch sequence DXCXCX(Y/F)X(3)G(H/Q)CG have been demonstrated to bind a catalytic zinc, and in other PBGS, the aspartic acid residues of the metal switch sequence DXALDX(Y/F)X(3)G(H/Q)DG have been postulated to bind a catalytically essential magnesium and/or potassium.	cysteinylglycine	78-80	aminolevulinate dehydratase	Homo sapiens	8-12
12459913-3	2003	In some PBGS, the cysteines of the metal switch sequence DXCXCX(Y/F)X(3)G(H/Q)CG have been demonstrated to bind a catalytic zinc, and in other PBGS, the aspartic acid residues of the metal switch sequence DXALDX(Y/F)X(3)G(H/Q)DG have been postulated to bind a catalytically essential magnesium and/or potassium.	cysteinylglycine	78-80	aminolevulinate dehydratase	Homo sapiens	143-147
12478214-1	2002	The adenosine A2A receptor agonist CGS 21680 has shown effects similar to dopamine antagonists in behavioural assays in rats predictive for antipsychotic activity, without induction of extrapyramidal side-effects (EPS).	cysteinylglycine	35-38	adenosine A2a receptor	Rattus norvegicus	4-26
12372501-1	2002	Directed screening of metalloprotease inhibitors identified CGS 30084 (1) as a potent inhibitor of endothelin-converting enzyme-1 (ECE-1) in vitro (IC(50)=77 nM).	cysteinylglycine	60-63	endothelin converting enzyme 1	Rattus norvegicus	131-136
12075625-11	2002	The findings are compatible with the notions that (i) GGT-catalyzed transpeptidation was largely responsible for the growth advantage of M22 cells at limiting cysteine concentration, and for their high GSH content via the formation of GGC from a gamma-glutamyl donor (glutamine) and cyst(e)ine, and (ii) aminopeptidase/dipeptidase activity is rate-limiting in GSH repletion when GSH or CG serve as cysteine sources.	cysteinylglycine	386-388	gamma-glutamylcyclotransferase	Homo sapiens	235-238
12485918-5	2002	The exoenzyme gamma-glutamyltranspeptidase (GGT) removes the glutamate from extracellular GSH, producing cysteinyl-glycine from which a dipeptidase then generates cysteine, an amino acid often limiting for de novo GSH synthesis.	cysteinylglycine	105-122	inactive glutathione hydrolase 2	Homo sapiens	14-42
12480208-5	2002	The purpose of the present study was to investigate the effects of an ECE inhibitor, CGS 26303, on hemolysate-induced injury of cerebral vessel endothelial cells as well as the production of ET-1 from these cells.	cysteinylglycine	85-88	endothelin converting enzyme 1	Homo sapiens	70-73
12193064-0	2002	CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.	cysteinylglycine	0-3	endothelin converting enzyme 1	Rattus norvegicus	43-73
12193064-0	2002	CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.	cysteinylglycine	0-3	membrane metallo-endopeptidase	Rattus norvegicus	78-105
12193065-2	2002	The purpose of the present study was to characterize the inhibitory effects of CGS 34225, an orally active prodrug of CGS 34226, on ECE-1 and NEP in vivo.	cysteinylglycine	79-82	endothelin converting enzyme 1	Rattus norvegicus	132-137
12193065-2	2002	The purpose of the present study was to characterize the inhibitory effects of CGS 34225, an orally active prodrug of CGS 34226, on ECE-1 and NEP in vivo.	cysteinylglycine	79-82	membrane metallo-endopeptidase	Rattus norvegicus	142-145
12193065-2	2002	The purpose of the present study was to characterize the inhibitory effects of CGS 34225, an orally active prodrug of CGS 34226, on ECE-1 and NEP in vivo.	cysteinylglycine	118-121	endothelin converting enzyme 1	Rattus norvegicus	132-137
12110606-9	2002	A selective endothelin-converting enzyme (ECE) inhibitor, CGS 35066 (1 mg kg(-1)), significantly reduced the second phase pressor response and increase in PIP triggered by ET-1(1-31).	cysteinylglycine	58-61	prolactin-inducible protein homolog	Cavia porcellus	155-158
11988350-6	2002	This effect was strongly potentiated by co-perfusion with the A2AR agonist CGS 21680.	cysteinylglycine	75-78	adenosine A2a receptor	Rattus norvegicus	62-66
12429726-7	2002	A2AR agonism with 2-p-(2-carboxyethyl)phenethylamino-5"-N-ethylcarboxamido adenosine (CGS 21680) after LPS decreased TNF production in a dose- and time-dependent manner, whereas A2AR antagonism significantly increased TNF and blocked the inhibitory effect of CGS 21680.	cysteinylglycine	86-89	adenosine A2a receptor	Homo sapiens	0-4
12429726-7	2002	A2AR agonism with 2-p-(2-carboxyethyl)phenethylamino-5"-N-ethylcarboxamido adenosine (CGS 21680) after LPS decreased TNF production in a dose- and time-dependent manner, whereas A2AR antagonism significantly increased TNF and blocked the inhibitory effect of CGS 21680.	cysteinylglycine	86-89	tumor necrosis factor	Homo sapiens	117-120
12429726-7	2002	A2AR agonism with 2-p-(2-carboxyethyl)phenethylamino-5"-N-ethylcarboxamido adenosine (CGS 21680) after LPS decreased TNF production in a dose- and time-dependent manner, whereas A2AR antagonism significantly increased TNF and blocked the inhibitory effect of CGS 21680.	cysteinylglycine	86-89	adenosine A2a receptor	Homo sapiens	178-182
12429726-7	2002	A2AR agonism with 2-p-(2-carboxyethyl)phenethylamino-5"-N-ethylcarboxamido adenosine (CGS 21680) after LPS decreased TNF production in a dose- and time-dependent manner, whereas A2AR antagonism significantly increased TNF and blocked the inhibitory effect of CGS 21680.	cysteinylglycine	86-89	tumor necrosis factor	Homo sapiens	218-221
12429726-7	2002	A2AR agonism with 2-p-(2-carboxyethyl)phenethylamino-5"-N-ethylcarboxamido adenosine (CGS 21680) after LPS decreased TNF production in a dose- and time-dependent manner, whereas A2AR antagonism significantly increased TNF and blocked the inhibitory effect of CGS 21680.	cysteinylglycine	259-262	adenosine A2a receptor	Homo sapiens	0-4
12429726-7	2002	A2AR agonism with 2-p-(2-carboxyethyl)phenethylamino-5"-N-ethylcarboxamido adenosine (CGS 21680) after LPS decreased TNF production in a dose- and time-dependent manner, whereas A2AR antagonism significantly increased TNF and blocked the inhibitory effect of CGS 21680.	cysteinylglycine	259-262	tumor necrosis factor	Homo sapiens	117-120
12429726-9	2002	Phospho-CREB had been shown to inhibit nuclear factor-kappaB transcriptional activity, as was observed with CGS 21680 treatment.	cysteinylglycine	108-111	cAMP responsive element binding protein 1	Homo sapiens	8-12
12193123-1	2002	Continuous intra-arterial administration of a selective endothelin-converting enzyme (ECE) inhibitor CGS 35066 at a dose of 30 mg/kg decreased the mean arterial blood pressure (MABP) in conscious unrestrained normotensive rats and spontaneously hypertensive rats (SHRs).	cysteinylglycine	101-104	endothelin converting enzyme 1	Rattus norvegicus	86-89
12193135-4	2002	CGS 26393, a prodrug of CGS 26303, is an orally active, long-acting inhibitor of ECE-1.	cysteinylglycine	0-3	endothelin-converting enzyme 1	Oryctolagus cuniculus	81-86
12193135-4	2002	CGS 26393, a prodrug of CGS 26303, is an orally active, long-acting inhibitor of ECE-1.	cysteinylglycine	24-27	endothelin-converting enzyme 1	Oryctolagus cuniculus	81-86
12123741-6	2002	Cisplatin treatment also inhibited GGT-dependent production of reactive oxygen species, a process depending on the availability of cysteinylglycine produced during GSH catabolism.	cysteinylglycine	131-147	gamma-glutamyltransferase light chain family member 3	Homo sapiens	35-38
11853888-5	2002	Among the catechins present in GTPs, EGCG, ECG and CG are responsible for inhibiting P-gp.	cysteinylglycine	39-41	ATP binding cassette subfamily B member 1	Homo sapiens	85-89
11909610-8	2002	Both the anti-inflammatory and hypotensive responses to CGS 21680 were blocked by pretreatment with the selective adenosine A2A receptor antagonist, 4-(2-(7-amino-2-(2-furyl)(1,2,4)triazolo(2,3-a(1,3,5)triazin-5-yl amino)ethyl)phenol (ZM 241385), 3 mg x kg(-1) p.o., 1 h prior to the agonist.	cysteinylglycine	56-59	adenosine A2a receptor	Rattus norvegicus	114-136
11996368-0	2002	Study of Cd2+ complexation by the glutathione fragments Cys-Gly (CG) and gamma-Glu-Cys (gamma-EC) by differential pulse polarography.	cysteinylglycine	56-63	CD2 molecule	Homo sapiens	9-12
11996368-0	2002	Study of Cd2+ complexation by the glutathione fragments Cys-Gly (CG) and gamma-Glu-Cys (gamma-EC) by differential pulse polarography.	cysteinylglycine	65-67	CD2 molecule	Homo sapiens	9-12
11889173-6	2002	Furthermore, we assessed the consequences of PPAR gamma activation by the oxidized lipids, and we found that these lipids stimulate human CG production, a measure of trophoblast differentiation.	cysteinylglycine	138-140	peroxisome proliferator activated receptor gamma	Homo sapiens	45-55
11977539-12	2002	CGS 20267-related abnormalities in the laboratory tests for the 0.5 mg group were a decrease in WBC, and increases in GOT, GPT, LDH and gamma-GTP (5 patients, 14.3%) whereas those in the 1.0 mg group were increases in GPT, gamma-GTP, alkaline phosphatase, and total bilirubin (1 patient, 3.6%).	cysteinylglycine	0-3	glutamic--pyruvic transaminase	Homo sapiens	123-126
11977539-12	2002	CGS 20267-related abnormalities in the laboratory tests for the 0.5 mg group were a decrease in WBC, and increases in GOT, GPT, LDH and gamma-GTP (5 patients, 14.3%) whereas those in the 1.0 mg group were increases in GPT, gamma-GTP, alkaline phosphatase, and total bilirubin (1 patient, 3.6%).	cysteinylglycine	0-3	glutamic--pyruvic transaminase	Homo sapiens	218-221
11893909-3	2002	This study was designed to examine the effects of a highly selective ECE-1 inhibitor, CGS 35066, on SAH-induced cerbrovasospasm.	cysteinylglycine	86-89	endothelin-converting enzyme 1	Oryctolagus cuniculus	69-74
11796529-8	2002	This inhibitory effect was associated with significant decreases in human CG-stimulated expression levels of the mRNAs encoding steroid acute regulatory protein, and P450 cholesterol side-chain cleavage, 3beta-hydroxy steroid dehydrogenase, and 17beta-hydroxy steroid dehydrogenase type III enzymes.	cysteinylglycine	74-76	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	166-170
11751433-11	2001	The findings are compatible with the notions that (i) GGT-catalyzed transpeptidation was largely responsible for the growth advantage of M22 cells at limiting cysteine concentration, and for their high GSH content via the formation of GGC from a gamma-glutamyl donor (glutamine) and cyst(e)ine, and (ii) aminopeptidase/dipeptidase activity is rate-limiting in GSH repletion when GSH or CG serve as cysteine sources.	cysteinylglycine	386-388	gamma-glutamylcyclotransferase	Homo sapiens	235-238
11592966-10	2001	In contrast, ceruloplasmin was a highly efficient catalyst for the oxidation of cysteine and cysteinylglycine to cystine and bis(-S-cysteinylglycine), respectively.	cysteinylglycine	93-109	ceruloplasmin	Homo sapiens	13-26
12587783-7	2002	CRP levels were found to be significantly different between groups, higher in PG (6.2 +/- 0.86 mg/L) than those of CG (3.7 +/- 0.92 mg/L) and HG (0.854 +/- 0.2 mg/L) (p<0.05).	cysteinylglycine	115-117	C-reactive protein	Homo sapiens	0-3
11794533-9	2001	CGS 9343B inhibited the CaM-induced contraction, but did not inhibit the DAG-induced contraction.	cysteinylglycine	0-3	calmodulin 1	Homo sapiens	24-27
11794533-10	2001	CaM inhibited the DAG-induced contraction in the presence of CGS 9343B.	cysteinylglycine	61-64	calmodulin 1	Homo sapiens	0-3
11564822-5	2001	More importantly, the suppressive effect of adenosine and CGS-21680 on IL-12 production was significantly enhanced in cells pretreated with either IL-1 (10 U/ml) or TNF-alpha (100 U/ml) but markedly attenuated in cells pretreated with IFN-gamma (100 U/ml).	cysteinylglycine	58-61	interleukin 1 alpha	Homo sapiens	71-75
11592940-2	2001	CGS-21680, a selective adenosine A(2A) agonist, significantly increased levels of Epo in normoxic Hep3B cell cultures and in serum of normal mice under both normoxic and hypoxic conditions.	cysteinylglycine	0-3	erythropoietin	Homo sapiens	82-85
11564822-5	2001	More importantly, the suppressive effect of adenosine and CGS-21680 on IL-12 production was significantly enhanced in cells pretreated with either IL-1 (10 U/ml) or TNF-alpha (100 U/ml) but markedly attenuated in cells pretreated with IFN-gamma (100 U/ml).	cysteinylglycine	58-61	tumor necrosis factor	Homo sapiens	165-174
11564822-5	2001	More importantly, the suppressive effect of adenosine and CGS-21680 on IL-12 production was significantly enhanced in cells pretreated with either IL-1 (10 U/ml) or TNF-alpha (100 U/ml) but markedly attenuated in cells pretreated with IFN-gamma (100 U/ml).	cysteinylglycine	58-61	interferon gamma	Homo sapiens	235-244
11564822-6	2001	Similarly, IL-1 and TNF-alpha treatment potentiated the stimulatory effect of adenosine and CGS-21680 on IL-10 production, whereas IFN-gamma treatment almost completely abolished this effect.	cysteinylglycine	92-95	interleukin 1 alpha	Homo sapiens	11-15
11564822-6	2001	Similarly, IL-1 and TNF-alpha treatment potentiated the stimulatory effect of adenosine and CGS-21680 on IL-10 production, whereas IFN-gamma treatment almost completely abolished this effect.	cysteinylglycine	92-95	tumor necrosis factor	Homo sapiens	20-29
11564822-6	2001	Similarly, IL-1 and TNF-alpha treatment potentiated the stimulatory effect of adenosine and CGS-21680 on IL-10 production, whereas IFN-gamma treatment almost completely abolished this effect.	cysteinylglycine	92-95	interleukin 10	Homo sapiens	105-110
11502355-3	2001	Pretreatment with the selective A(2A)-receptor agonist, CGS 21680C (2 nM), potentiated the neurofacilitatory action of VIP (100 nM).	cysteinylglycine	56-59	vasoactive intestinal peptide	Rattus norvegicus	119-122
11529553-5	2001	Concentrations of estradiol-17beta and PSPB in jugular venous plasma and PGE in inferior vena cava plasma were decreased (P < or = 0.05) by treatment with CGS-16949A.	cysteinylglycine	158-161	surfactant protein B	Homo sapiens	39-43
11459824-5	2001	Thus, CMT3 is a key determinant for non-CG methylation.	cysteinylglycine	40-42	chromomethylase 3	Arabidopsis thaliana	6-10
11435907-6	2001	The A2AR agonist CGS 21680 was found to significantly increase IC50 values of competitive inhibition curves of the D2R/D3R antagonist [125I]iodosulpiride vs dopamine both in rat striatal and human striatal brain sections.	cysteinylglycine	17-20	adenosine A2a receptor	Rattus norvegicus	4-8
11409424-6	2001	CGS 21680 administration directly into the striatum immediately prior to the induction of intracerebral hemorrhage inhibited TNF-alpha mRNA and, 24 hours following induction, reduced parenchymal neutrophil infiltration (p < 0.001) and TUNEL-positive cells (p < 0.002) within and bordering the hematoma.	cysteinylglycine	0-3	tumor necrosis factor	Homo sapiens	125-134
11356700-2	2001	For this purpose, the direct effects of LIF were evaluated on basal and human (h)CG-stimulated testosterone synthesis by cultured, purified Leydig cells isolated from porcine testes.	cysteinylglycine	81-83	LIF interleukin 6 family cytokine	Homo sapiens	40-43
11212114-1	2001	Through directed screening of metalloprotease inhibitors, CGS 30084 (1) has been identified as a potent endothelin-converting enzyme-1 (ECE-1) inhibitor in vitro (IC50 = 77 nM).	cysteinylglycine	58-61	endothelin converting enzyme 1	Rattus norvegicus	104-134
11181522-8	2001	In vivo, CTGF and LO transcripts were significantly suppressed in GC 48 h after equine CG injection (10 IU, ip) compared with untreated controls and were further reduced 12 h after administration of additional 10 IU hCG to induce luteinization.	cysteinylglycine	87-89	cellular communication network factor 2	Equus caballus	9-13
11238719-7	2001	In contrast, intrastriatal perfusion with the 5-HT(1B) agonist CGS-12066 A (10 nM and 100 nM) did not induce any changes in L-DOPA-derived extracellular DA.	cysteinylglycine	63-66	5-hydroxytryptamine receptor 1B	Rattus norvegicus	46-53
11284446-4	2001	Administration of CGS 21680 (1.0 microg/kg per min) significantly increased CO (44+/-6%), HR (12+/-2%), Pmcf (24+/-4%) and dP/dt (24+/-5%) in TNF-alpha-treated rats.	cysteinylglycine	18-21	tumor necrosis factor	Rattus norvegicus	142-151
11212114-1	2001	Through directed screening of metalloprotease inhibitors, CGS 30084 (1) has been identified as a potent endothelin-converting enzyme-1 (ECE-1) inhibitor in vitro (IC50 = 77 nM).	cysteinylglycine	58-61	endothelin converting enzyme 1	Rattus norvegicus	136-141
11078330-3	2000	The aim of this study was to optimize CGS 26303 for greater potency and selectivity towards ECE-1 inhibition.	cysteinylglycine	38-41	endothelin converting enzyme 1	Homo sapiens	92-97
11105798-4	2000	RESULTS: A highly significant correlation r = 0.70, 0.74, 0.77 (p < 0.0001) was found between 1/SCyst, 1/SCreat, C(CG), respectively, and Cin.	cysteinylglycine	118-120	pyridoxal phosphatase	Homo sapiens	141-144
11063908-2	2000	The present study demonstrates for the first time that an established cell line expressing GGT-rel, a human GGT-related enzyme, metabolizes extracellular GSH to cysteinylglycine (CysGly) in a time-dependent manner when cells were incubated in a medium containing 2.5 mM GSH and 25 mM glycylglycine.	cysteinylglycine	161-177	inactive glutathione hydrolase 2	Homo sapiens	91-94
11063908-2	2000	The present study demonstrates for the first time that an established cell line expressing GGT-rel, a human GGT-related enzyme, metabolizes extracellular GSH to cysteinylglycine (CysGly) in a time-dependent manner when cells were incubated in a medium containing 2.5 mM GSH and 25 mM glycylglycine.	cysteinylglycine	161-177	inactive glutathione hydrolase 2	Homo sapiens	108-111
11063908-2	2000	The present study demonstrates for the first time that an established cell line expressing GGT-rel, a human GGT-related enzyme, metabolizes extracellular GSH to cysteinylglycine (CysGly) in a time-dependent manner when cells were incubated in a medium containing 2.5 mM GSH and 25 mM glycylglycine.	cysteinylglycine	179-185	inactive glutathione hydrolase 2	Homo sapiens	91-94
11063908-2	2000	The present study demonstrates for the first time that an established cell line expressing GGT-rel, a human GGT-related enzyme, metabolizes extracellular GSH to cysteinylglycine (CysGly) in a time-dependent manner when cells were incubated in a medium containing 2.5 mM GSH and 25 mM glycylglycine.	cysteinylglycine	179-185	inactive glutathione hydrolase 2	Homo sapiens	108-111
11078330-8	2000	CGS 35066 also exhibited a potent and sustained ECE-1 inhibitory activity in vivo, blocking the pressor response to big ET-1 by 84%.	cysteinylglycine	0-3	endothelin converting enzyme 1	Homo sapiens	48-53
11078415-2	2000	The purpose of this study was to investigate the effect of CGS 26303, an endothelin-converting enzyme (ECE) inhibitor, on puromycin aminonucleoside (PA)-induced nephrosis in rats.	cysteinylglycine	59-62	endothelin converting enzyme 1	Rattus norvegicus	73-101
11078366-5	2000	More drastically, pretreatment with 100 microM CGS 26303 for 30 min decreased the production of ET-1 and big ET-1 by 94% and 87%, respectively, when compared with the untreated control.	cysteinylglycine	47-50	endothelin 1	Bos taurus	96-100
11078415-2	2000	The purpose of this study was to investigate the effect of CGS 26303, an endothelin-converting enzyme (ECE) inhibitor, on puromycin aminonucleoside (PA)-induced nephrosis in rats.	cysteinylglycine	59-62	endothelin converting enzyme 1	Rattus norvegicus	103-106
11078330-8	2000	CGS 35066 also exhibited a potent and sustained ECE-1 inhibitory activity in vivo, blocking the pressor response to big ET-1 by 84%.	cysteinylglycine	0-3	endothelin 1	Homo sapiens	120-124
11078366-5	2000	More drastically, pretreatment with 100 microM CGS 26303 for 30 min decreased the production of ET-1 and big ET-1 by 94% and 87%, respectively, when compared with the untreated control.	cysteinylglycine	47-50	endothelin 1	Bos taurus	109-113
11027590-2	2000	Besides, the extracellular cleavage of GSH by GGT leads to reactive oxygen species (ROS) production, depending on the generation and enhanced reactivity of cysteinylglycine (CysGly).	cysteinylglycine	156-172	inactive glutathione hydrolase 2	Homo sapiens	46-49
11027590-2	2000	Besides, the extracellular cleavage of GSH by GGT leads to reactive oxygen species (ROS) production, depending on the generation and enhanced reactivity of cysteinylglycine (CysGly).	cysteinylglycine	174-180	inactive glutathione hydrolase 2	Homo sapiens	46-49
10917953-12	2000	CONCLUSIONS: We conclude that the recombinant human C5a receptor antagonist CGS 32359 inhibits surgical ischemia-reperfusion injury after coronary occlusion.	cysteinylglycine	76-79	complement C5a receptor 1	Homo sapiens	52-64
11018307-1	2000	Effects of nerve growth factor (NGF), adenosine and an adenosine A(2A) receptor agonist (CGS 21680) on the phosphorylation of extracellular-regulated kinases 1/2 (ERK1/2) were examined in PC12 cells.	cysteinylglycine	89-92	mitogen activated protein kinase 3	Rattus norvegicus	163-169
11018307-2	2000	Adenosine and CGS 21680stimulated ERK1/2, but inhibited the phosphorylation of ERK1/2 induced by a 10 min incubation with NGF.	cysteinylglycine	14-17	mitogen activated protein kinase 3	Rattus norvegicus	34-40
11018307-2	2000	Adenosine and CGS 21680stimulated ERK1/2, but inhibited the phosphorylation of ERK1/2 induced by a 10 min incubation with NGF.	cysteinylglycine	14-17	mitogen activated protein kinase 3	Rattus norvegicus	79-85
11018307-3	2000	Longer treatment with CGS 21680 and NGF (1-2h) resulted in an additive effect on the activation of ERK1/2.	cysteinylglycine	22-25	mitogen activated protein kinase 3	Rattus norvegicus	99-105
10999947-6	2000	The A(2A) receptor agonist CGS 21680 [2-[p-(2-carbonylethyl)phenylethylamino-5"-N-ethylcarboxa midoadenosin e] dose dependently activated G(olf) subunits in striatal membranes as shown by photolabeling with [alpha-(32)P]m-acetylanilido-GTP followed by immunoprecipitation with a specific antibody against G(olf).	cysteinylglycine	27-30	G protein subunit alpha L	Rattus norvegicus	138-144
10999947-6	2000	The A(2A) receptor agonist CGS 21680 [2-[p-(2-carbonylethyl)phenylethylamino-5"-N-ethylcarboxa midoadenosin e] dose dependently activated G(olf) subunits in striatal membranes as shown by photolabeling with [alpha-(32)P]m-acetylanilido-GTP followed by immunoprecipitation with a specific antibody against G(olf).	cysteinylglycine	27-30	G protein subunit alpha L	Rattus norvegicus	305-311
10999947-7	2000	Transfection of G(olf) cDNA into Chinese hamster ovary cells, which stably express human adenosine A(2A) receptors, led to an increased efficacy of CGS 21680, as evidenced by a stronger cAMP response, indicating that activation of G(olf) by A(2A) receptors leads to a biological signal.	cysteinylglycine	148-151	G protein subunit alpha L	Rattus norvegicus	16-22
10999947-7	2000	Transfection of G(olf) cDNA into Chinese hamster ovary cells, which stably express human adenosine A(2A) receptors, led to an increased efficacy of CGS 21680, as evidenced by a stronger cAMP response, indicating that activation of G(olf) by A(2A) receptors leads to a biological signal.	cysteinylglycine	148-151	G protein subunit alpha L	Rattus norvegicus	231-237
10960067-4	2000	Comparison of A(2A)R-expressing (+/+) and A(2A)R-deficient (-/-) cells in cyclic AMP accumulation assays confirmed that the A(2A)R agonist CGS 21680 is indeed selective for A(2A) receptors in T-lymphocytes.	cysteinylglycine	139-142	adenosine A2a receptor	Mus musculus	14-20
10960067-4	2000	Comparison of A(2A)R-expressing (+/+) and A(2A)R-deficient (-/-) cells in cyclic AMP accumulation assays confirmed that the A(2A)R agonist CGS 21680 is indeed selective for A(2A) receptors in T-lymphocytes.	cysteinylglycine	139-142	adenosine A2a receptor	Mus musculus	42-48
10960067-4	2000	Comparison of A(2A)R-expressing (+/+) and A(2A)R-deficient (-/-) cells in cyclic AMP accumulation assays confirmed that the A(2A)R agonist CGS 21680 is indeed selective for A(2A) receptors in T-lymphocytes.	cysteinylglycine	139-142	adenosine A2a receptor	Mus musculus	42-48
10960067-5	2000	Incubation of A(2A)R-expressing thymocytes with extracellular adenosine or CGS 21680 in vitro results in the death of about 7-15% of thymocytes.	cysteinylglycine	75-78	adenosine A2a receptor	Mus musculus	14-20
10960067-7	2000	The A(2A) receptor-specific lymphotoxicity of CGS 21680 is also demonstrated in a long-term (6-day) in vitro model of thymocyte positive selection where addition of A(2A)R antagonist ZM 241,385 did block the effects of CGS 21680, allowing the survival of T cells.	cysteinylglycine	46-49	adenosine A2a receptor	Mus musculus	165-171
10999833-5	2000	The production of angiogenin by cultured GCs was stimulated with the addition of human CG or cAMP or under the hypoxic milieu.	cysteinylglycine	87-89	angiogenin	Homo sapiens	18-28
10986126-11	2000	The binding motif of WAY-151693 in the MMP-13 complex is consistent with our previously reported MMP-1:CGS-27023A NMR structure and is similar to the MMP-13: RS-130830 X-ray structure.	cysteinylglycine	103-106	matrix metallopeptidase 13	Homo sapiens	39-45
10986126-11	2000	The binding motif of WAY-151693 in the MMP-13 complex is consistent with our previously reported MMP-1:CGS-27023A NMR structure and is similar to the MMP-13: RS-130830 X-ray structure.	cysteinylglycine	103-106	matrix metallopeptidase 1	Homo sapiens	39-44
10987444-1	2000	Through directed screening of compounds prepared as metalloprotease inhibitors a compound, CGS 30084, that had potent endothelin converting enzyme-1 (ECE-1) in vitro inhibitory activity (IC50 = 77 nM) was identified.	cysteinylglycine	91-94	endothelin converting enzyme 1	Rattus norvegicus	118-148
10987444-1	2000	Through directed screening of compounds prepared as metalloprotease inhibitors a compound, CGS 30084, that had potent endothelin converting enzyme-1 (ECE-1) in vitro inhibitory activity (IC50 = 77 nM) was identified.	cysteinylglycine	91-94	endothelin converting enzyme 1	Rattus norvegicus	150-155
10926524-1	2000	The full three-dimensional structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent, sulfonamide hydroxamic acid inhibitor (CGS 27023) has been determined by NMR spectroscopy.	cysteinylglycine	155-158	matrix metallopeptidase 13	Homo sapiens	70-83
10926524-1	2000	The full three-dimensional structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent, sulfonamide hydroxamic acid inhibitor (CGS 27023) has been determined by NMR spectroscopy.	cysteinylglycine	155-158	matrix metallopeptidase 13	Homo sapiens	85-91
10669576-2	2000	Because of its unique structural characteristics and long duration of action in vivo, the dual ECE-1 and neutral endopeptidase 24.11 (NEP) inhibitor, CGS 26303, was selected as an attractive lead for further optimization of potency and selectivity.	cysteinylglycine	150-153	endothelin converting enzyme 1	Homo sapiens	95-100
10844093-0	2000	Inhibition of mechanotransducer currents in crayfish sensory neuron by CGS 9343B, a calmodulin antagonist.	cysteinylglycine	71-74	calmodulin 1	Homo sapiens	84-94
10844093-6	2000	These results suggest that CGS 9343B, as a calmodulin antagonist, can also block mechanosensitive channels, possibly by being incorporated into the lipid membrane and/or interacting with the channel protein.	cysteinylglycine	27-30	calmodulin 1	Homo sapiens	43-53
10861469-8	2000	This activation of MMP-2 may be caused by MT1-MMP of the cancer cells, since it was inhibited by a series of MMP inhibitors, including ethylenediaminetetraacetic acid (EDTA), the tissue inhibitor of metalloproteinase-2 (TIMP-2), and the MMP inhibitor CGS 27023A, but not by TIMP-1.	cysteinylglycine	251-254	matrix metallopeptidase 2	Homo sapiens	19-24
10861469-8	2000	This activation of MMP-2 may be caused by MT1-MMP of the cancer cells, since it was inhibited by a series of MMP inhibitors, including ethylenediaminetetraacetic acid (EDTA), the tissue inhibitor of metalloproteinase-2 (TIMP-2), and the MMP inhibitor CGS 27023A, but not by TIMP-1.	cysteinylglycine	251-254	matrix metallopeptidase 14	Homo sapiens	42-49
10861469-8	2000	This activation of MMP-2 may be caused by MT1-MMP of the cancer cells, since it was inhibited by a series of MMP inhibitors, including ethylenediaminetetraacetic acid (EDTA), the tissue inhibitor of metalloproteinase-2 (TIMP-2), and the MMP inhibitor CGS 27023A, but not by TIMP-1.	cysteinylglycine	251-254	TIMP metallopeptidase inhibitor 2	Homo sapiens	179-218
10807662-8	2000	The calmodulin antagonist W-7 and cytochalasin B which enhances actin depolymerization also prevented the effect of CGS 21680; the calmodulin kinase II inhibitors CaM kinase II(281 - 309) and KN-93 but not the inactive structural analogue KN-92 were also effective.	cysteinylglycine	116-119	calmodulin 1	Rattus norvegicus	4-14
10807662-8	2000	The calmodulin antagonist W-7 and cytochalasin B which enhances actin depolymerization also prevented the effect of CGS 21680; the calmodulin kinase II inhibitors CaM kinase II(281 - 309) and KN-93 but not the inactive structural analogue KN-92 were also effective.	cysteinylglycine	116-119	calmodulin 1	Rattus norvegicus	131-141
10815633-12	2000	ACE inhibitors captopril, CL 24817, enalapril and CGS 13945 prevented the markers of endothelial dysfunction.	cysteinylglycine	50-53	angiotensin I converting enzyme	Rattus norvegicus	0-3
10669576-2	2000	Because of its unique structural characteristics and long duration of action in vivo, the dual ECE-1 and neutral endopeptidase 24.11 (NEP) inhibitor, CGS 26303, was selected as an attractive lead for further optimization of potency and selectivity.	cysteinylglycine	150-153	membrane metalloendopeptidase	Homo sapiens	105-132
10669576-2	2000	Because of its unique structural characteristics and long duration of action in vivo, the dual ECE-1 and neutral endopeptidase 24.11 (NEP) inhibitor, CGS 26303, was selected as an attractive lead for further optimization of potency and selectivity.	cysteinylglycine	150-153	membrane metalloendopeptidase	Homo sapiens	134-137
10694245-6	2000	However, CGRP (10 - 30 nM) significantly increased the field EPSP slope when applied to hippocampal slices in the presence of the A(1) receptor antagonist, 1,3-dipropyl-8-cyclopenthyl xanthine (DPCPX, 10 nM), or in the presence of the A(2A) adenosine receptor agonist CGS 21680 (10 nM).	cysteinylglycine	268-271	calcitonin-related polypeptide alpha	Rattus norvegicus	9-13
10652212-15	2000	Cell proliferation stimulated by IL-1beta was reduced by the addition of the Arom inhibitor fadrozole-HCL (CGS-16949A).	cysteinylglycine	107-110	interleukin 1 beta	Homo sapiens	33-41
10652212-15	2000	Cell proliferation stimulated by IL-1beta was reduced by the addition of the Arom inhibitor fadrozole-HCL (CGS-16949A).	cysteinylglycine	107-110	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	77-81
10642375-5	2000	Lower resting [H(+)] values in the PG vs. CG resulted from lower values for arterialized PCO(2) (Pa(CO(2))) and total weak acid ([A](tot)), which were partly offset by a lower strong-ion difference ([SID]).	cysteinylglycine	42-44	complement C2	Homo sapiens	97-106
10954036-0	2000	CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.	cysteinylglycine	0-3	endothelin converting enzyme 1	Rattus norvegicus	68-98
11211158-3	2000	The synthetic peptide Cys-Gly-(Arg-Gly-Asp)-Ser-Pro-Lys, containing the cell-adhesive region of fibronectin (RGD), has been grafted to the polymer substrate via the cysteine residue using a procedure recently developed in the authors laboratory.	cysteinylglycine	22-29	fibronectin 1	Rattus norvegicus	96-107
10714888-4	2000	The same effect was induced by the adenosine A1 receptor agonist, N6-Cyclopentyladenosine (CPA) whereas the selective adenosine A2A receptor agonist CGS 21680 increased the naloxone-precipitated withdrawal phenomenon.	cysteinylglycine	149-152	adenosine receptor A2a	Cavia porcellus	118-140
10570011-2	1999	Equine CG- and hCG-treated TNFRI null mice ovulated more ova than did controls at two distinct times during the prepubertal period (Day 21: 13.4 +/- 1.7 vs. 7.3 +/- 1.4, P < 0.05; Day 25: 20.7 +/- 2.7 vs. 13.0 +/- 1.3, P < 0.05).	cysteinylglycine	7-9	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	27-32
10954036-0	2000	CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.	cysteinylglycine	0-3	membrane metallo-endopeptidase	Rattus norvegicus	103-130
10954036-5	2000	CGS 34043 is one such compound, which inhibited the activities of ECE-1a and NEP with IC50 values of 5.8 and 110 nM, respectively.	cysteinylglycine	0-3	endothelin converting enzyme 1	Rattus norvegicus	66-69
10954036-5	2000	CGS 34043 is one such compound, which inhibited the activities of ECE-1a and NEP with IC50 values of 5.8 and 110 nM, respectively.	cysteinylglycine	0-3	membrane metallo-endopeptidase	Rattus norvegicus	77-80
10445339-5	1999	The CG dinucleotide at the exon 3-intron 3 junction of the growth hormone-1 gene appears to be a hot spot for point mutations.	cysteinylglycine	4-6	growth hormone 1	Homo sapiens	59-75
10551869-11	1999	The preference of DNMT1 for hemimethylated DNA may be the result of positive cooperativity of AdoMet binding mediated by allosteric activation by the methylated CG steps.	cysteinylglycine	161-163	DNA methyltransferase 1	Homo sapiens	18-23
10456184-5	1999	This might result from an intrinsic abnormality in CG, involving the IGFs and/or the Inhibin/Activin/Follistatin systems.	cysteinylglycine	51-53	inhibin subunit beta E	Homo sapiens	93-100
10456184-5	1999	This might result from an intrinsic abnormality in CG, involving the IGFs and/or the Inhibin/Activin/Follistatin systems.	cysteinylglycine	51-53	follistatin	Homo sapiens	101-112
9831898-0	1998	Haemodynamic effects of a selective adenosine A2A receptor agonist, CGS 21680, in chronic heart failure in anaesthetized rats.	cysteinylglycine	68-71	adenosine A2a receptor	Rattus norvegicus	36-58
10353819-1	1999	The solution structure of the catalytic fragment of human fibroblast collagenase (MMP-1) complexed with a sulfonamide derivative of a hydroxamic acid compound (CGS-27023A) has been determined using two-dimensional and three-dimensional heteronuclear NMR spectroscopy.	cysteinylglycine	160-163	matrix metallopeptidase 1	Homo sapiens	82-87
10353819-2	1999	The solution structure of the complex was calculated by means of hybrid distance geometry-simulated annealing using a combination of experimental NMR restraints obtained from the previous refinement of the inhibitor-free MMP-1 (1) and recent restraints for the MMP-1:CGS-27023A complex.	cysteinylglycine	267-270	matrix metallopeptidase 1	Homo sapiens	261-266
10353819-8	1999	A minimal set of NMR experiments in combination with the free MMP-1 assignments were used to assign the MMP-1 (1)H, 13C, and 15N resonances in the MMP-1:CGS-27023A complex.	cysteinylglycine	153-156	matrix metallopeptidase 1	Homo sapiens	62-67
10353819-8	1999	A minimal set of NMR experiments in combination with the free MMP-1 assignments were used to assign the MMP-1 (1)H, 13C, and 15N resonances in the MMP-1:CGS-27023A complex.	cysteinylglycine	153-156	matrix metallopeptidase 1	Homo sapiens	104-109
10353819-8	1999	A minimal set of NMR experiments in combination with the free MMP-1 assignments were used to assign the MMP-1 (1)H, 13C, and 15N resonances in the MMP-1:CGS-27023A complex.	cysteinylglycine	153-156	matrix metallopeptidase 1	Homo sapiens	104-109
9927311-3	1999	In the present study, gonadotropin regulation of PACAP gene expression was examined in PMSG/human (h)CG-treated immature rat ovaries and cultured preovulatory follicles.	cysteinylglycine	101-103	adenylate cyclase activating polypeptide 1	Homo sapiens	49-54
10092996-5	1999	The plasma levels of cysteinylglycine and vitamin B12 correlated positively with circulating E-selectin and VCAM-1, respectively, whereas folate in serum and blood correlated negatively with P-selectin.	cysteinylglycine	21-37	selectin E	Homo sapiens	93-103
10092996-5	1999	The plasma levels of cysteinylglycine and vitamin B12 correlated positively with circulating E-selectin and VCAM-1, respectively, whereas folate in serum and blood correlated negatively with P-selectin.	cysteinylglycine	21-37	vascular cell adhesion molecule 1	Homo sapiens	108-114
9890627-4	1999	The selective adenosine A2a-receptor agonist CGS 21680 induced enhanced mRNA expression of both Kv1.3 and ROMK1, as well as an elevation of Kv1.3 protein.	cysteinylglycine	45-48	adenosine A2a receptor	Rattus norvegicus	14-36
9890627-4	1999	The selective adenosine A2a-receptor agonist CGS 21680 induced enhanced mRNA expression of both Kv1.3 and ROMK1, as well as an elevation of Kv1.3 protein.	cysteinylglycine	45-48	potassium inwardly-rectifying channel, subfamily J, member 1	Rattus norvegicus	106-111
10336115-6	1999	We show that, in striatal slices, the D2 receptor agonist, quinpirole, strongly inhibits the phosphorylation of DARPP-32 induced by either the D1 receptor agonist, SKF 81297, or the A2A receptor agonist, CGS 21680.	cysteinylglycine	204-207	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	112-120
10336131-7	1999	The adenosine A2a receptor agonist CGS 21680 produced a long-lasting depression of ongoing activity.	cysteinylglycine	35-38	adenosine A2a receptor	Rattus norvegicus	4-26
9870871-4	1998	RESULTS: IL-1alpha stimulation of cartilage resulted in a fragmentation of COMP, which was inhibited by MMP inhibitors CGS 27023A and BB-94.	cysteinylglycine	119-122	interleukin 1 alpha	Bos taurus	9-18
9823544-9	1998	We further confirmed the hypothesis that cysteinylglycine (CysGly), a product of GGT/GSH reaction, identified by high-performance liquid chromatography, but not GSH, was responsible for ROS formation initiated by the reductive release of iron from transferrin.	cysteinylglycine	41-57	gamma-glutamyltransferase light chain family member 3	Homo sapiens	81-84
9823544-9	1998	We further confirmed the hypothesis that cysteinylglycine (CysGly), a product of GGT/GSH reaction, identified by high-performance liquid chromatography, but not GSH, was responsible for ROS formation initiated by the reductive release of iron from transferrin.	cysteinylglycine	41-57	transferrin	Homo sapiens	248-259
9823544-9	1998	We further confirmed the hypothesis that cysteinylglycine (CysGly), a product of GGT/GSH reaction, identified by high-performance liquid chromatography, but not GSH, was responsible for ROS formation initiated by the reductive release of iron from transferrin.	cysteinylglycine	59-65	gamma-glutamyltransferase light chain family member 3	Homo sapiens	81-84
9823544-9	1998	We further confirmed the hypothesis that cysteinylglycine (CysGly), a product of GGT/GSH reaction, identified by high-performance liquid chromatography, but not GSH, was responsible for ROS formation initiated by the reductive release of iron from transferrin.	cysteinylglycine	59-65	transferrin	Homo sapiens	248-259
9814473-8	1998	The activity of ECE-1 was significantly enhanced by the treatment of human CG (10 U/mL) and interleukin (IL)-1 (10 ng/mL) during 4-day culture, whereas no significant alteration was observed by IL-4 (10 ng/mL) and IL-10 (10 ng/mL) treatment.	cysteinylglycine	75-77	endothelin converting enzyme 1	Homo sapiens	16-21
9814473-8	1998	The activity of ECE-1 was significantly enhanced by the treatment of human CG (10 U/mL) and interleukin (IL)-1 (10 ng/mL) during 4-day culture, whereas no significant alteration was observed by IL-4 (10 ng/mL) and IL-10 (10 ng/mL) treatment.	cysteinylglycine	75-77	interleukin 10	Homo sapiens	214-219
10330225-5	1999	When A2aR were stimulated in myocytes that had the antiadrenergic actions of adenosine (Ado) abolished by either treatment with pertussis toxin (PTx) or the presence of 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), an adenosine A1-receptor antagonist, the maximum increases in Ca2+ transients were similarly nominal (with PTx: 10(-4) M CGS-21680, 14 +/- 6% and 10(-4) M Ado, 15 +/- 4%; without PTx: 10(-5) M Ado + 2 x 10(-7) M DPCPX, 19 +/- 1%).	cysteinylglycine	334-337	adenosine A2a receptor	Rattus norvegicus	5-9
10208531-1	1999	The effect of the adenosine A2A receptor agonist CGS 21680 on glutamate and aspartate release was investigated in the striatum of young and old rats by microdialysis experiments.	cysteinylglycine	49-52	adenosine A2a receptor	Rattus norvegicus	18-40
10025506-8	1999	Three CG-containing restriction sites within this island were analyzed and found all or variably methylated in four T-plastin-negative leukemia cell lines.	cysteinylglycine	6-8	plastin 3	Homo sapiens	116-125
9794464-3	1998	Results showed that human CG (hCG) stimulated the binding of [32P]AAGTP to a 45-kDa protein(s) in follicular membranes that comigrated with immunoreactive G alphas, G alphaq/11, and G alpha13.	cysteinylglycine	26-28	G protein subunit alpha 13	Homo sapiens	165-191
9845970-4	1998	A model of the human A3 receptor, docked with the triazoloquinazoline reference ligand CGS 15953 (9-chloro-2-(2-furyl)[1,2,4]triazolo[1,5-c]quinazolin-5-amine), was built and analyzed to help interpret these results.	cysteinylglycine	87-90	T cell immune regulator 1, ATPase H+ transporting V0 subunit a3	Homo sapiens	21-23
9834965-1	1998	Methylation of dinucleotide CG residues located in the 5" end of the CYP2E1 gene has been demonstrated to play a role in the control of gene expression in the human developing liver.	cysteinylglycine	28-30	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	69-75
9653922-6	1998	This adduct acted as a substrate for the enzyme gamma-glutamyltranspeptidase and the product of this reaction, the 4-chloro-7-sulphobenzofurazanyl derivative of cysteinylglycine, acted as a substrate for either dipeptidase or aminopeptidase M.	cysteinylglycine	161-177	alanyl aminopeptidase, membrane	Homo sapiens	226-242
9645680-2	1998	injection of interleukin-1beta(IL-1beta, 80 ng) significantly blunted the testosterone response to 1 U/kg human CG (hCG), an effect that we attributed to the stimulation of inhibitory pathways connecting the hypothalamus to the testes.	cysteinylglycine	112-114	interleukin 1 beta	Homo sapiens	13-30
9645680-2	1998	injection of interleukin-1beta(IL-1beta, 80 ng) significantly blunted the testosterone response to 1 U/kg human CG (hCG), an effect that we attributed to the stimulation of inhibitory pathways connecting the hypothalamus to the testes.	cysteinylglycine	112-114	interleukin 1 beta	Homo sapiens	31-39
9645680-2	1998	injection of interleukin-1beta(IL-1beta, 80 ng) significantly blunted the testosterone response to 1 U/kg human CG (hCG), an effect that we attributed to the stimulation of inhibitory pathways connecting the hypothalamus to the testes.	cysteinylglycine	112-114	chorionic gonadotropin subunit beta 5	Homo sapiens	116-119
9661624-5	1998	Human embryonic 293 cells expressing hLHR mutant (L457R) or hLHR wild-type bound CG with high affinity.	cysteinylglycine	81-83	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	37-41
9661624-5	1998	Human embryonic 293 cells expressing hLHR mutant (L457R) or hLHR wild-type bound CG with high affinity.	cysteinylglycine	81-83	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	60-64
9543146-10	1998	Because the increased expression of glycodelin in the baboon endometrium coincided with peak levels of CG, a simulated pregnant baboon model was used to confirm hormonal regulation.	cysteinylglycine	103-105	progestagen associated endometrial protein	Homo sapiens	36-46
9650577-3	1998	Treatment of the cells with the A2A receptor agonist CGS 21680 inhibited both NO production and iNOS expression induced by stimulation with either LPS/IFN-gamma or TNF-alpha/IL-1beta, whereas the A1 and A3 receptor agonists, CPA and Cl-IB-MECA, respectively, did not have significant inhibitory effects.	cysteinylglycine	53-56	inositol-3-phosphate synthase 1	Homo sapiens	96-100
9650577-3	1998	Treatment of the cells with the A2A receptor agonist CGS 21680 inhibited both NO production and iNOS expression induced by stimulation with either LPS/IFN-gamma or TNF-alpha/IL-1beta, whereas the A1 and A3 receptor agonists, CPA and Cl-IB-MECA, respectively, did not have significant inhibitory effects.	cysteinylglycine	53-56	interferon regulatory factor 6	Homo sapiens	147-150
9650577-3	1998	Treatment of the cells with the A2A receptor agonist CGS 21680 inhibited both NO production and iNOS expression induced by stimulation with either LPS/IFN-gamma or TNF-alpha/IL-1beta, whereas the A1 and A3 receptor agonists, CPA and Cl-IB-MECA, respectively, did not have significant inhibitory effects.	cysteinylglycine	53-56	interferon gamma	Homo sapiens	151-160
9650577-3	1998	Treatment of the cells with the A2A receptor agonist CGS 21680 inhibited both NO production and iNOS expression induced by stimulation with either LPS/IFN-gamma or TNF-alpha/IL-1beta, whereas the A1 and A3 receptor agonists, CPA and Cl-IB-MECA, respectively, did not have significant inhibitory effects.	cysteinylglycine	53-56	tumor necrosis factor	Homo sapiens	164-173
9650577-3	1998	Treatment of the cells with the A2A receptor agonist CGS 21680 inhibited both NO production and iNOS expression induced by stimulation with either LPS/IFN-gamma or TNF-alpha/IL-1beta, whereas the A1 and A3 receptor agonists, CPA and Cl-IB-MECA, respectively, did not have significant inhibitory effects.	cysteinylglycine	53-56	interleukin 1 beta	Homo sapiens	174-182
9674968-11	1998	One example is the low amount of extracellular glutathione in hepatoma cell lines, which probably was due to its rapid degradation to cysteinylglycine by gamma-glutamyl-transpeptidase.	cysteinylglycine	134-150	inactive glutathione hydrolase 2	Homo sapiens	154-183
9543146-15	1998	These studies indicate that a posttranslationally modified glycodelin homolog is synthesized by the baboon uterus during early pregnancy and appears to be regulated directly by CG.	cysteinylglycine	177-179	progestagen associated endometrial protein	Homo sapiens	59-69
9458912-1	1998	CGS-21680 (CGS), a highly selective adenosine A2a receptor agonist, may excite the fetal carotid bodies.	cysteinylglycine	0-3	adenosine receptor A2a	Ovis aries	36-58
9522162-11	1998	CGS 8515 (a specific 5-lipoxygenase inhibitor, 10(-6) M) did not change BK (10(-5) M)-induced relaxation on the muscle alone, and caused an increase of BK-induced relaxation on the muscle within epithelium-intact trachea compared with that obtained without CGS 8515.	cysteinylglycine	0-3	arachidonate 5-lipoxygenase	Rattus norvegicus	21-35
9595403-1	1998	Optimization of an aminophosphonic acid series of compounds for inhibition of endothelin-converting enzyme (ECE) has led to the discovery of CGS 31447.	cysteinylglycine	141-144	endothelin converting enzyme 1	Homo sapiens	108-111
9871438-2	1998	In a subset of striatal neurons (70-80%), NMDA-induced inward currents were inhibited by the adenosine A2A receptor selective agonist CGS 21680.	cysteinylglycine	134-137	adenosine A2a receptor	Rattus norvegicus	93-115
9871438-5	1998	Extracellular dibutyryl cAMP, a membrane permeable analogue of cAMP, and intracellular Sp-cAMPS, an activator of cAMP-dependent protein kinases (PKA), both abolished the CGS 21680-induced inhibition.	cysteinylglycine	170-173	calmodulin 2, pseudogene 1	Rattus norvegicus	90-95
9595404-2	1998	The ortho-substituted benzofused macrocyclic lactams, such as CGS 26670, are generally potent NEP inhibitors but poor ACE inhibitors.	cysteinylglycine	62-65	membrane metallo-endopeptidase	Rattus norvegicus	94-97
9595386-5	1998	Here, the stimulated (lipopolysaccharide or interleukin-1 beta) production of ET-1 from guinea pig tracheal epithelial cells was abolished by CGS 26303 or CGS 26393, two ECE/neutral endopeptidase (NEP) inhibitors, but was unaffected by CGS 24592, a specific NEP inhibitor.	cysteinylglycine	142-145	interleukin-1 beta	Cavia porcellus	44-62
9595386-5	1998	Here, the stimulated (lipopolysaccharide or interleukin-1 beta) production of ET-1 from guinea pig tracheal epithelial cells was abolished by CGS 26303 or CGS 26393, two ECE/neutral endopeptidase (NEP) inhibitors, but was unaffected by CGS 24592, a specific NEP inhibitor.	cysteinylglycine	155-158	interleukin-1 beta	Cavia porcellus	44-62
9595386-5	1998	Here, the stimulated (lipopolysaccharide or interleukin-1 beta) production of ET-1 from guinea pig tracheal epithelial cells was abolished by CGS 26303 or CGS 26393, two ECE/neutral endopeptidase (NEP) inhibitors, but was unaffected by CGS 24592, a specific NEP inhibitor.	cysteinylglycine	155-158	interleukin-1 beta	Cavia porcellus	44-62
9595404-2	1998	The ortho-substituted benzofused macrocyclic lactams, such as CGS 26670, are generally potent NEP inhibitors but poor ACE inhibitors.	cysteinylglycine	62-65	angiotensin I converting enzyme	Rattus norvegicus	118-121
9375692-4	1997	When the adenosine A1 receptor was blocked by CPT, the hippocampal extracellular 5-HT level was increased by adenosine, CGS-21680, and PD-125944, and decreased by caffeine, DMPX, and APNEA.	cysteinylglycine	120-123	adenosine A1 receptor	Rattus norvegicus	9-30
9435569-7	1997	Cysteinylglycine, released from glutathione at the cell surface by gamma-glutamyl transpeptidase, also stimulated uptake after reduction of cystine.	cysteinylglycine	0-16	gamma-glutamyltransferase 1	Rattus norvegicus	67-96
9388046-11	1997	Thus CGS 30440, an orally active prodrug, has been shown to be a novel antihypertensive agent with dual ACE/NEP inhibitory activity in SHRs.	cysteinylglycine	5-8	angiotensin I converting enzyme	Rattus norvegicus	104-107
9464658-5	1997	The A2A agonist, CGS 21680 (3-30 nM) facilitated 45Ca2+ influx in CA3 synaptosomes, with a maximum increase of 22.9 +/- 3.9% at 10 nM, and was virtually devoid of effect in CA1 synaptosomes.	cysteinylglycine	17-20	carbonic anhydrase 3	Rattus norvegicus	66-69
9464658-5	1997	The A2A agonist, CGS 21680 (3-30 nM) facilitated 45Ca2+ influx in CA3 synaptosomes, with a maximum increase of 22.9 +/- 3.9% at 10 nM, and was virtually devoid of effect in CA1 synaptosomes.	cysteinylglycine	17-20	carbonic anhydrase 1	Rattus norvegicus	173-176
9464658-6	1997	This facilitatory effect of CGS 21680 (10 nM) in CA3 synaptosomes was prevented by the A2A antagonist 8-(3-chlorostyryl)caffeine (CSC; 200 nM), but not by the A1 antagonist, DPCPX (20 or 100 nM).	cysteinylglycine	28-31	carbonic anhydrase 3	Rattus norvegicus	49-52
9388046-11	1997	Thus CGS 30440, an orally active prodrug, has been shown to be a novel antihypertensive agent with dual ACE/NEP inhibitory activity in SHRs.	cysteinylglycine	5-8	membrane metallo-endopeptidase	Rattus norvegicus	108-111
9074711-7	1997	However, acute vasodilation with nifedipine (a Ca2+ influx blocker) or CGS-21680 (A2-purinergic receptor agonist) increased the peak heparin-releasable LPL activity in hearts isolated from SHR rats.	cysteinylglycine	71-74	lipoprotein lipase	Rattus norvegicus	152-155
9342779-6	1997	The most selective 5-HT1B agonist tested, CGS 12066B (3-17 mg/kg; IP), completely substituted for the 1.0 g/kg ethanol, but not for 1.5 or 2.0 g/kg ethanol.	cysteinylglycine	42-45	5-hydroxytryptamine receptor 1B	Rattus norvegicus	19-25
9254094-13	1997	The ECE inhibitor CGS 26303 thus represents a promising therapeutic agent for the treatment of cerebral vasospasm following aneurysmal SAH.	cysteinylglycine	18-21	endothelin converting enzyme 1	Homo sapiens	4-7
9196090-6	1997	We found that among ETs, only ET-1 was steadily released under basal conditions over 24 h. The basal production was attenuated by both phosphoramidon and CGS 26 303, dual NEP and ECE inhibitors.	cysteinylglycine	154-157	endothelin 1	Homo sapiens	30-34
9109363-0	1997	Inhibition of LTB4 biosynthesis in situ by CGS 23885, a potent 5-lipoxygenase inhibitor, correlates with its pleural fluid concentrations in an experimentally induced rat pleurisy model.	cysteinylglycine	43-46	arachidonate 5-lipoxygenase	Rattus norvegicus	63-77
9309219-12	1997	Side-by-side Im and Py rings differentiate GC from CG base pairs because of tight steric contacts and sp2 hybridization at the amine nitrogen atom, with the favored conformations being G/Im,Py/C and C/Py,Im/G.	cysteinylglycine	51-53	Sp2 transcription factor	Homo sapiens	102-105
9291146-4	1997	Whereas the A1-specific agonist cyclopentyladenosine (CPA) only minimally affected NGF release, the A2a-specific agonist CGS-21680 triggered the greatest increase in microglial NGF synthesis.	cysteinylglycine	121-124	nerve growth factor	Rattus norvegicus	177-180
9231749-6	1997	The glutathione resynthesis in the presence of CysGly plus glutamate was totally inhibited in the presence of buthionine sulfoximine, an inhibitor of gamma-glutamylcysteine synthetase.	cysteinylglycine	47-53	glutamate-cysteine ligase, catalytic subunit	Rattus norvegicus	150-183
9234198-15	1997	In contrast, the adenosine A2A receptor agonist 2-p-(2-carboxyethyl)-phenethylamino-5"-N-ethylcarboxamidoadenosine (CGS 21680; 0.5-1.0 microM) did not significantly affect the EPSPm.	cysteinylglycine	116-119	adenosine A2a receptor	Rattus norvegicus	17-39
9219861-2	1997	Stimulation of adenosine A2A receptors by CGS 21680 (5 mg/kg) induced an increase in Fos-like immunoreactivity in the rat nucleus accumbens shell, while in the rostral pole and core CGS 21680 induced Fos-like immunoreactivity only after a high dose.	cysteinylglycine	42-45	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	85-88
9219861-2	1997	Stimulation of adenosine A2A receptors by CGS 21680 (5 mg/kg) induced an increase in Fos-like immunoreactivity in the rat nucleus accumbens shell, while in the rostral pole and core CGS 21680 induced Fos-like immunoreactivity only after a high dose.	cysteinylglycine	42-45	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	200-203
9219861-3	1997	CGS 21680 (5 mg/kg) stimulated c-fos expression also in the lateral septal nucleus and dorso-medial striatum, but not in the dorso-lateral striatum.	cysteinylglycine	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	31-36
9219861-5	1997	Administration of the selective A2A antagonist SCH 58261 counteracted CGS 21680-induced Fos-like immunoreactivity.	cysteinylglycine	70-73	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	88-91
9219861-6	1997	Lesions of the dopaminergic mesostriatal projection by 6-hydroxydopamine and stimulation of dopamine D2/D3 receptors by quinpirole, prevented CGS 21680-induced Fos-like immunoreactivity in the nucleus accumbens shell.	cysteinylglycine	142-145	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	160-163
9205829-4	1997	RESULTS: The intrinsic partial clearance of PG to CG ranged from 0.41-10.11 h-1, and was related to the number of functional CYP2C19 alleles present.	cysteinylglycine	50-52	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	125-132
9163341-2	1997	In this study we have examined the possibility that GSNO is a substrate for gamma-glutamyl transpeptidase (gamma-GT), an enzyme that hydrolyses the gamma-glutamyl moiety of glutathione to give glutamate and cysteinylglycine.	cysteinylglycine	207-223	gamma-glutamyltransferase 1	Rattus norvegicus	76-105
9163341-2	1997	In this study we have examined the possibility that GSNO is a substrate for gamma-glutamyl transpeptidase (gamma-GT), an enzyme that hydrolyses the gamma-glutamyl moiety of glutathione to give glutamate and cysteinylglycine.	cysteinylglycine	207-223	gamma-glutamyltransferase 1	Rattus norvegicus	107-115
9163341-5	1997	In the presence of contaminating transition metal ions, gamma-GT accelerated the release of ;NO from GSNO, as CG-SNO is more susceptible to transition metal ion-dependent decomposition than GSNO.	cysteinylglycine	110-112	gamma-glutamyltransferase 1	Rattus norvegicus	56-64
9139850-7	1997	The gamma-glutamyl acceptor glycylglycine, a co-substrate for gamma-GT, potentiated the growth-inhibitory effect of GSH, which in contrast was decreased by the gamma-GT inhibitors, serine-borate complex and acivicin, suggesting that the production of reactive forms of oxygen (probably H(2)O(2)) was mediated by cysteinyl-glycine after GSH hydrolysis.	cysteinylglycine	312-329	inactive glutathione hydrolase 2	Homo sapiens	62-70
8768735-6	1996	Receptors resulting from injection of hNMDAR1A, hNMDAR2A and hNMDAR2B transcripts in a 1:1:1 ratio were indistinguishable from hNMDAR1A/2B receptors in terms of their sensitivity to NMDA, glycine, D-serine, CGS 19755 and CGP 40116.	cysteinylglycine	207-210	glutamate ionotropic receptor NMDA type subunit 2B	Homo sapiens	61-69
9021753-3	1997	Phorbol ester (TPA, 2.5 ng/ml) treatment resulted in an atypical pattern of CG release in which there was a greater net loss of CGs in the equatorial region of the egg than in the region opposite the spindle.	cysteinylglycine	128-131	promotion susceptibility QTL 1	Mus musculus	15-18
8906843-3	1996	pretreatment of mice with CGS-21680 HCl (CGS), a selective agonist of A2 adenosine receptors, at 0.2 to 2 mg/kg caused an augmentation of plasma IL-10 levels induced by i.p.	cysteinylglycine	26-29	interleukin 10	Mus musculus	145-150
8906843-3	1996	pretreatment of mice with CGS-21680 HCl (CGS), a selective agonist of A2 adenosine receptors, at 0.2 to 2 mg/kg caused an augmentation of plasma IL-10 levels induced by i.p.	cysteinylglycine	41-44	interleukin 10	Mus musculus	145-150
9038241-0	1997	Activation of CGS 12094 (prinomide metabolite) to 1,4-benzoquinone by myeloperoxidase: implications for human idiosyncratic agranulocytosis.	cysteinylglycine	14-17	myeloperoxidase	Homo sapiens	70-85
9038241-5	1997	During the MPO-catalyzed metabolism of CGS 12094, reactive intermediates that irreversibly bound to protein and cysteine were generated.	cysteinylglycine	39-42	myeloperoxidase	Homo sapiens	11-14
9051198-2	1997	The present study evaluates CGS 25159, a synthetic isoflavan, as a putative inhibitor of CETP activity of human and hamster plasma.	cysteinylglycine	28-31	cholesteryl ester transfer protein	Homo sapiens	89-93
8987845-5	1996	The 5HT1B receptor agonists TFMPP and CGS 12066A, administered systemically, inhibited light-induced phase shifts of the circadian activity rhythm in a dose-dependent manner at phase delay and phase advance time points.	cysteinylglycine	38-41	5-hydroxytryptamine receptor 1B	Homo sapiens	4-9
8906843-8	1996	In the RAW 264.7 macrophage cell line, pretreatment of the cells with both CGS and CCPA inhibited LPS-induced IL-10, TNF-alpha, and NO production, each in a concentration-dependent manner.	cysteinylglycine	75-78	interleukin 10	Mus musculus	110-115
8906843-8	1996	In the RAW 264.7 macrophage cell line, pretreatment of the cells with both CGS and CCPA inhibited LPS-induced IL-10, TNF-alpha, and NO production, each in a concentration-dependent manner.	cysteinylglycine	75-78	tumor necrosis factor	Mus musculus	117-126
8902227-2	1996	In noncapacitated spermatozoa, quantitative analysis revealed that the fractured plasma membrane overlying the equatorial segment carried the highest PLA2-CG labeling density.	cysteinylglycine	155-157	phospholipase A2, group V	Mus musculus	150-154
8902227-9	1996	However, surface replicas revealed an increased PLA2-CG labeling on the external surface of the plasma membrane covering the postacrosomal region, the middle piece, and the principal piece.	cysteinylglycine	53-55	phospholipase A2, group V	Mus musculus	48-52
8897460-0	1996	The selective adenosine A2A receptor antagonist SCH 58261 discriminates between two different binding sites for [3H]-CGS 21680 in the rat brain.	cysteinylglycine	117-120	adenosine A2a receptor	Rattus norvegicus	14-36
8888409-1	1996	The aromatase inhibitor, fadrozole hydrochloride (CGS 16949A), was developed for the treatment of breast cancer, and has not been available for pediatric use because of the lack of information about potential reproductive toxicology.	cysteinylglycine	50-53	cytochrome P450, family 19, subfamily a, polypeptide 1	Rattus norvegicus	4-13
8675990-5	1996	Replicas of both protoplasmic and exoplasmic fracture faces of the plasma membrane of boar sperm head showed a relatively low density of PLA2-CG labeling.	cysteinylglycine	142-144	phospholipase A2 group IIA	Homo sapiens	137-141
8732271-5	1996	The FMLP-induced synthesis of LTB4 in whole blood pretreated with LPS and TNF-alpha was dose-dependently inhibited by adenosine analogues in the following order of potency; 5"(N-ethyl)carboxamidoadenosine (NECA) approximately equal to CGS 21680 > 2-Cl-adenosine > N6-cyclopentyladenosine (CPA), indicating the involvement of the adenosine A2 receptor subtype.	cysteinylglycine	235-238	formyl peptide receptor 1	Homo sapiens	4-8
8735638-13	1996	In contrast, the selective adenosine A2a receptor agonist, CGS-21680 (1.0 microM), exerted no metabolic or mechanical effects.	cysteinylglycine	59-62	adenosine A2a receptor	Rattus norvegicus	27-49
8663190-1	1996	Membrane-bound dipeptidase (MBD) participates in the degradation of glutathione by cleaving the cysteinyl-glycine bond of cystinyl bisglycine (oxidized cysteinyl-glycine) following removal of a gamma-glutamyl group by gamma-glutamyl transpeptidase (GGT).	cysteinylglycine	96-113	gamma-glutamyltransferase 1	Mus musculus	218-247
8663190-1	1996	Membrane-bound dipeptidase (MBD) participates in the degradation of glutathione by cleaving the cysteinyl-glycine bond of cystinyl bisglycine (oxidized cysteinyl-glycine) following removal of a gamma-glutamyl group by gamma-glutamyl transpeptidase (GGT).	cysteinylglycine	96-113	gamma-glutamyltransferase 1	Mus musculus	249-252
8752587-3	1996	Intense potentiation of D1-dependent turning behaviour and c-Fos expression was also observed after administration of the A2a/A1 antagonist CGS 15943.	cysteinylglycine	140-143	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	59-64
8732271-5	1996	The FMLP-induced synthesis of LTB4 in whole blood pretreated with LPS and TNF-alpha was dose-dependently inhibited by adenosine analogues in the following order of potency; 5"(N-ethyl)carboxamidoadenosine (NECA) approximately equal to CGS 21680 > 2-Cl-adenosine > N6-cyclopentyladenosine (CPA), indicating the involvement of the adenosine A2 receptor subtype.	cysteinylglycine	235-238	tumor necrosis factor	Homo sapiens	74-83
8869738-4	1996	Substrates for MRP include thioether-linked conjugates of lipophilic compounds with glutathione, cysteinyl glycine, cysteine, and N-acetyl cysteine, but also glutathione disulfide, and glucuronate conjugates such as etoposide glucuronide.	cysteinylglycine	97-114	ATP binding cassette subfamily C member 1	Homo sapiens	15-18
8692280-1	1996	The binding of the adenosine A2A receptor selective agonist 2-[4-(2-p-carboxyethyl)phenylamino] -5"-N-ethylcarboxamidoadenosine (CGS 21680) to the rat hippocampal and cerebral cortical membranes was studied and compared with that to striatal membranes.	cysteinylglycine	129-132	adenosine A2a receptor	Rattus norvegicus	19-41
8584257-3	1995	Conversely, slice perfusion with the selective A1 adenosine receptor antagonists DPCPX (0.2 microM) or with the selective A2 adenosine receptor agonist CGS 21680 significantly (P < 0.05) increased the number of slices showing a transient CA1 epileptiform bursting during the hypoxic period but did not affect the duration of the hypoxia-induced epileptiform bursting.	cysteinylglycine	152-155	carbonic anhydrase 1	Rattus norvegicus	241-244
8541231-2	1995	Aromatase activity could be inhibited by administering CGS 16949A (50 micrograms/day/rat) via a mini osmotic Alzet pump (model 2002) for 3 days during pseudopregnancy.	cysteinylglycine	55-58	cytochrome P450, family 19, subfamily a, polypeptide 1	Rattus norvegicus	0-9
8788434-6	1995	However, the adenosine A2A receptor agonist 2-p-(carboxyethyl)-phenylamino-5"-N-ethylcarboxamidoadenosine (CGS 21680) had a greater effect on blood pressure in morphine-dependent rats compared to opiate naive rats.	cysteinylglycine	107-110	adenosine A2a receptor	Rattus norvegicus	13-35
7472521-5	1995	We found that NMDA receptor blockade using dizocilpine (MK-801), DL-2-amino-5-phosphonovaleric acid (APV), or CGS 19755, was highly effective in reducing CA1 injury in organotypic hippocampal cultures, caused by complete oxygen and glucose deprivation.	cysteinylglycine	110-113	carbonic anhydrase 1	Homo sapiens	154-157
7595490-5	1995	Haloperidol increased the density of striatal A2a receptors by 33% (control, 522.4 +/- 20.7 fmol/mg of protein; haloperidol, 694.6 +/- 23.6 fmol/mg of protein; p < 0.001) without changing their affinity for [3H]CGS-21680 (control, 19.2 +/- 2.2 nM; haloperidol, 21.4 +/- 2.3 nM).	cysteinylglycine	214-217	spectrin, alpha, non-erythrocytic 1	Rattus norvegicus	46-49
7595490-7	1995	Binding characteristics and the pharmacological displacement profile of the increased [3H]CGS-21680 binding sites confirmed them as A2a receptors.	cysteinylglycine	90-93	spectrin, alpha, non-erythrocytic 1	Rattus norvegicus	132-135
8559275-5	1995	The TRH analogue CG 3703 (100 and 500 micrograms/animal i.v.	cysteinylglycine	17-19	thyrotropin releasing hormone	Rattus norvegicus	4-7
7544275-2	1995	IL-1 blocks human CG-induced cAMP and testosterone formation, as well as cytochrome P450 side-chain cleavage messenger RNA (mRNA) expression.	cysteinylglycine	18-20	interleukin 1 alpha	Homo sapiens	0-4
7562557-4	1995	During a steady-state infusion of CSC, the animals received 1000 micrograms/kg of the adenosine A2a receptor agonist CGS 21680C [the sodium salt of 2-p-(2-carboxyethyl) phenylethylamino-5"-N-ethylcarboxamidoadenosine] i.v.	cysteinylglycine	117-120	adenosine A2a receptor	Rattus norvegicus	86-108
7561855-5	1995	Superfusion of single tissue slices with 0.1-100 nM CGS-21680, a selective adenosine A2a receptor agonist, for 5 min before the S2 stimulus produced a significant concentration-dependent increase in the S2/S1 fractional release ratio that was maximal (31.3% increase) at 1.0 nM.	cysteinylglycine	52-55	adenosine A2a receptor	Rattus norvegicus	75-97
7501252-2	1995	The A2A agonist, CGS 21680, increased the veratridine-evoked release of [3H]acetylcholine from hippocampal synaptosomes.	cysteinylglycine	17-20	spectrin, alpha, non-erythrocytic 1	Rattus norvegicus	4-7
7665979-2	1995	Intravenous injections of CGS-21680 (100 to 500 nmol/kg mouse/day) and DPMA (50 to 500 nmol/kg mouse/day) for 4 days produced significant increases in serum levels of EPO in exhypoxic polycythemic mice.	cysteinylglycine	26-29	erythropoietin	Mus musculus	167-170
7665979-3	1995	CGS-21680 (10(-7) to 10(-6) mol/L) and DPMA (10(-8) to 10(-5) mol/L) also produced significant increases in medium levels of EPO in a cloned EPO-producing Hep3B hepatocellular carcinoma cell line after 18 hours of incubation in 1% O2.	cysteinylglycine	0-3	erythropoietin	Homo sapiens	125-128
7665979-3	1995	CGS-21680 (10(-7) to 10(-6) mol/L) and DPMA (10(-8) to 10(-5) mol/L) also produced significant increases in medium levels of EPO in a cloned EPO-producing Hep3B hepatocellular carcinoma cell line after 18 hours of incubation in 1% O2.	cysteinylglycine	0-3	erythropoietin	Homo sapiens	141-144
7501284-3	1995	The adenosine A2a receptor localization to striatopallidal neurons suggests that a selective activation of the striatopallidal efferent pathway is involved in the expression of catalepsy induced by intrastriatal infusion of CGS 21680C.	cysteinylglycine	224-227	adenosine A2a receptor	Rattus norvegicus	4-26
7672038-5	1995	[3H]CGS-19755 binding to the nonischemic hemisphere was characterized by KD estimates ranging from 59 to 97 nM and BMAX values ranging from 143 (108-192) pmol/g tissue in cortex to 569 (515-641) pmol/g tissue in CA1.	cysteinylglycine	4-7	carbonic anhydrase 1	Rattus norvegicus	212-215
7491819-4	1995	P18-specific Ab responses were found with liposomes containing CG-P18 but not P18.	cysteinylglycine	63-65	H3 histone pseudogene 12	Homo sapiens	0-3
7491819-4	1995	P18-specific Ab responses were found with liposomes containing CG-P18 but not P18.	cysteinylglycine	63-65	H3 histone pseudogene 12	Homo sapiens	66-69
7491819-4	1995	P18-specific Ab responses were found with liposomes containing CG-P18 but not P18.	cysteinylglycine	63-65	H3 histone pseudogene 12	Homo sapiens	66-69
7791101-12	1995	Inhibition of gamma-glutamyl transpeptidase activity with acivicin largely prevented the degradation to the cysteinylglycine and dicysteinylglycine conjugates of BSP.	cysteinylglycine	108-124	gamma-glutamyltransferase 1	Rattus norvegicus	14-43
7477908-1	1995	The induction of the early-gene c-fos after administration of the adenosine A2a receptor agonist CGS 21680, was studied in the striatum of normal rats or in rats with a unilateral 6-hydroxydopamine lesion of the dopaminergic nigrostriatal neurons.	cysteinylglycine	97-100	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	32-37
7477908-1	1995	The induction of the early-gene c-fos after administration of the adenosine A2a receptor agonist CGS 21680, was studied in the striatum of normal rats or in rats with a unilateral 6-hydroxydopamine lesion of the dopaminergic nigrostriatal neurons.	cysteinylglycine	97-100	adenosine A2a receptor	Rattus norvegicus	66-88
7477908-3	1995	Blockade of muscarine receptors by scopolamine (5 mg/kg) partially prevents, and stimulation of dopamine D2 receptors by quinpirole (0.5 mg/kg) completely reverses, CGS 21680-induced c-fos expression in the 6-hydroxydopamine-lesioned striatum.	cysteinylglycine	165-168	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	183-188
7773536-2	1995	The aim of the present investigation was to determine the relationship between the blood concentration and haemodynamic effects of the adenosine A2a receptor agonist, CGS 21680C (the sodium salt of 2-p-(2-carboxyethyl)phenylethylamino-5"-N-ethylcarboxamidoadeno sin e) in conscious normotensive rats.	cysteinylglycine	167-170	adenosine A2a receptor	Rattus norvegicus	135-157
7774839-2	1995	As a result of this interaction there is an increased synthesis of CG and hPL, probably as a result of the increased CG and hPL synthesis by the cytotrophoblasts.	cysteinylglycine	67-69	galectin 1	Homo sapiens	124-127
7774839-2	1995	As a result of this interaction there is an increased synthesis of CG and hPL, probably as a result of the increased CG and hPL synthesis by the cytotrophoblasts.	cysteinylglycine	117-119	galectin 1	Homo sapiens	74-77
7714123-5	1995	Recombinant LIF-induced CG production was significantly blocked by anti-gp130 antibody but not by anti-IL-6 receptor antibody, whereas rIL-6-induced CG was completely blocked by both antibodies.	cysteinylglycine	24-26	LIF interleukin 6 family cytokine	Homo sapiens	12-15
7714123-5	1995	Recombinant LIF-induced CG production was significantly blocked by anti-gp130 antibody but not by anti-IL-6 receptor antibody, whereas rIL-6-induced CG was completely blocked by both antibodies.	cysteinylglycine	24-26	interleukin 6 cytokine family signal transducer	Homo sapiens	72-77
7714123-5	1995	Recombinant LIF-induced CG production was significantly blocked by anti-gp130 antibody but not by anti-IL-6 receptor antibody, whereas rIL-6-induced CG was completely blocked by both antibodies.	cysteinylglycine	149-151	interleukin 6	Rattus norvegicus	135-140
7714123-6	1995	Recombinant LIF- and rIL-6-induced CG productions were both significantly blocked by genistein, a tyrosine kinase inhibitor, suggesting an involvement of tyrosine kinase in gp130-mediated CG production.	cysteinylglycine	35-37	LIF interleukin 6 family cytokine	Homo sapiens	12-15
7714123-6	1995	Recombinant LIF- and rIL-6-induced CG productions were both significantly blocked by genistein, a tyrosine kinase inhibitor, suggesting an involvement of tyrosine kinase in gp130-mediated CG production.	cysteinylglycine	35-37	interleukin 6	Rattus norvegicus	21-26
7714123-6	1995	Recombinant LIF- and rIL-6-induced CG productions were both significantly blocked by genistein, a tyrosine kinase inhibitor, suggesting an involvement of tyrosine kinase in gp130-mediated CG production.	cysteinylglycine	35-37	interleukin 6 cytokine family signal transducer	Homo sapiens	173-178
21153182-4	1995	This stimulatory effect of insulin could be prevented by treatment with calmodulin antagonists trifluoperazine, thioridazine or CGS 9343 B (a potent and selective inhibitor of calmodulin activity), which strongly suggests that calmodulin is involved in this action of insulin.	cysteinylglycine	128-131	insulin	Homo sapiens	27-34
21153182-4	1995	This stimulatory effect of insulin could be prevented by treatment with calmodulin antagonists trifluoperazine, thioridazine or CGS 9343 B (a potent and selective inhibitor of calmodulin activity), which strongly suggests that calmodulin is involved in this action of insulin.	cysteinylglycine	128-131	calmodulin 1	Homo sapiens	72-82
21153182-4	1995	This stimulatory effect of insulin could be prevented by treatment with calmodulin antagonists trifluoperazine, thioridazine or CGS 9343 B (a potent and selective inhibitor of calmodulin activity), which strongly suggests that calmodulin is involved in this action of insulin.	cysteinylglycine	128-131	calmodulin 1	Homo sapiens	176-186
21153182-4	1995	This stimulatory effect of insulin could be prevented by treatment with calmodulin antagonists trifluoperazine, thioridazine or CGS 9343 B (a potent and selective inhibitor of calmodulin activity), which strongly suggests that calmodulin is involved in this action of insulin.	cysteinylglycine	128-131	calmodulin 1	Homo sapiens	176-186
21153182-4	1995	This stimulatory effect of insulin could be prevented by treatment with calmodulin antagonists trifluoperazine, thioridazine or CGS 9343 B (a potent and selective inhibitor of calmodulin activity), which strongly suggests that calmodulin is involved in this action of insulin.	cysteinylglycine	128-131	insulin	Homo sapiens	268-275
7881753-2	1995	The putative high affinity binding site for the adenosine A2A receptor agonist 2-p-(2-carboxyethyl)phenethyl-amino-5"-N- ethylcarboxamidoadenosine (CGS 21680) in the rat cerebral cortex was characterized by use of a number of selective A1 and A2 adenosine receptor ligands, and compared to the characteristics of the more abundant striatal A2A receptor.	cysteinylglycine	148-151	adenosine A2a receptor	Rattus norvegicus	48-70
8034720-7	1994	In addition, this mutation reduces the binding affinity of an aromatase inhibitor, 4-hydroxyandrostenedione, and increases the binding affinity of two aromatase inhibitors, aminoglutethimide and CGS 16949.	cysteinylglycine	195-198	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	62-71
7705435-3	1994	The adenosine A2A receptor agonist, 2-[p-(2-carboxyethyl)phenethylamino]-5"-N-ethylcarboxamideadeno sine (CGS 21680C, 3 nM), but not the adenosine A1 receptor agonist, R-N6-phenylisopropyl adenosine (R-PIA, 300 nM), partially blocked the DMPP (1 microM) facilitation.	cysteinylglycine	106-109	adenosine A2a receptor	Rattus norvegicus	4-26
7855732-4	1994	Exogenous 5-HT and the 5-HT1B agonist, CGS-12066B, both decreased the K(+)-stimulated release of [3H]5-HT.	cysteinylglycine	39-42	5-hydroxytryptamine receptor 1B	Rattus norvegicus	23-29
7965760-7	1994	Treatment with the selective 5-HT1B agonist CGS 12066B (7-trifluoromethyl-4-(4-methyl-1-piperazinyl)-pyrolo[1,2-a] quinoxaline 1:2 maleate salt) (1.25-160 micrograms/kg i.v.)	cysteinylglycine	44-47	5-hydroxytryptamine receptor 1B	Rattus norvegicus	29-35
7840272-7	1995	On the contrary, arterial rings incubated with the A2-receptor agonist 2-p-(2-carboxyethyl)phenethyl-amino-5"-N-ethylcarboxamidoadenosine (CGS-21680) did not show significant alteration of the ET-1 contractility when incubated with CGS-21680 alone or in combination with PDBu.	cysteinylglycine	139-142	endothelin 1	Homo sapiens	193-197
8587471-5	1995	As predicted by its pharmacokinetics, the inhibitory activity of CGS 26393 persisted for up to 8 h. These findings demonstrate that CGS 26393 in an orally active, long-acting ECE inhibitor in vivo.	cysteinylglycine	65-68	endothelin converting enzyme 1	Rattus norvegicus	175-178
8034720-7	1994	In addition, this mutation reduces the binding affinity of an aromatase inhibitor, 4-hydroxyandrostenedione, and increases the binding affinity of two aromatase inhibitors, aminoglutethimide and CGS 16949.	cysteinylglycine	195-198	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	151-160
7924416-5	1994	Treatment of the HRPE cells with a selective calmodulin antagonist CGS 9343 B (CGS) led to a marked decrease in taurine transport activity.	cysteinylglycine	67-70	calmodulin 1	Homo sapiens	45-55
8207430-4	1994	The A2A agonist CGS-21680 (30 nM) produced a greater increase of the evoked release of [3H]ACh in the CA3 than in the dentate gyrus areas, whereas no consistent effect was found in the CA1 area or in the whole hippocampal slice.	cysteinylglycine	16-19	carbonic anhydrase 3	Rattus norvegicus	102-105
7987069-0	1994	Functional and morphological characterization of neuropathy induced with 5-lipoxygenase inhibitor CGS 21595.	cysteinylglycine	98-101	arachidonate 5-lipoxygenase	Rattus norvegicus	73-87
7987069-1	1994	Peripheral toxic neuropathy induced in rats with a 5-lipoxygenase inhibitor CGS 21,595 was characterized using special functional tests and pathological procedures.	cysteinylglycine	76-79	arachidonate 5-lipoxygenase	Rattus norvegicus	51-65
7953635-3	1994	Receptor autoradiographic studies with [3H]CGS 21680 (30 nM), a selective adenosine A2a receptor agonist, showed specific binding sites in the hippocampus.	cysteinylglycine	43-46	adenosine A2a receptor	Rattus norvegicus	74-96
7953635-6	1994	Electrophysiological studies in the Schaffer fibers/CA1 pyramids showed that upon activation of the A2a receptors with CGS 21680 (10 nM) the ability of the adenosine A1 receptor agonist, CPA, to inhibit neuronal activity was significantly attenuated.	cysteinylglycine	119-122	carbonic anhydrase 1	Rattus norvegicus	52-55
7953635-6	1994	Electrophysiological studies in the Schaffer fibers/CA1 pyramids showed that upon activation of the A2a receptors with CGS 21680 (10 nM) the ability of the adenosine A1 receptor agonist, CPA, to inhibit neuronal activity was significantly attenuated.	cysteinylglycine	119-122	spectrin, alpha, non-erythrocytic 1	Rattus norvegicus	100-103
7953635-6	1994	Electrophysiological studies in the Schaffer fibers/CA1 pyramids showed that upon activation of the A2a receptors with CGS 21680 (10 nM) the ability of the adenosine A1 receptor agonist, CPA, to inhibit neuronal activity was significantly attenuated.	cysteinylglycine	119-122	adenosine A1 receptor	Rattus norvegicus	156-177
8183440-3	1994	The efficacy of the 5-HT1B selective agonist 7-trifluoromethyl-4-(4-1-piperazinyl)-pyrrolo[1,2-a]quinoxaline (CGS 12066B) in reducing K(+)-evoked [3H]acetylcholine release from hippocampal synaptosomes was determined 24 hr after the last administration.	cysteinylglycine	110-113	5-hydroxytryptamine receptor 1B	Rattus norvegicus	20-26
8018698-2	1994	Treatment of cells with the calmodulin antagonist CGS 9343B results in a marked stimulation of the system L activity.	cysteinylglycine	50-53	calmodulin 1	Homo sapiens	28-38
8018698-5	1994	The stimulatory effect of CGS 9343B is reproducible with other calmodulin antagonists.	cysteinylglycine	26-29	calmodulin 1	Homo sapiens	63-73
8018698-12	1994	The apparent competitive nature between the effects of H+ and CGS 9343B is also observed with other calmodulin antagonists.	cysteinylglycine	62-65	calmodulin 1	Homo sapiens	100-110
7515977-0	1994	Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11.	cysteinylglycine	25-28	membrane metallo-endopeptidase	Rattus norvegicus	71-98
8004402-9	1994	Both the nicotinic acetylcholine receptor agonist, 1,1-dimethyl-4-phenylpiperazinium, and the A2a adenosine receptor agonist, CGS 21680C, increased evoked [3H]-ACh release, but only CGS 21680C potentiated the facilitatory effect of CGRP.	cysteinylglycine	126-129	calcitonin-related polypeptide alpha	Rattus norvegicus	232-236
8299556-7	1994	Treatment of the cells with the calmodulin antagonist CGS 9343 B stimulated the uptake of leucine and tryptophan, but inhibited the uptake of T3.	cysteinylglycine	54-57	calmodulin 1	Homo sapiens	32-42
7511246-6	1993	The TX synthetase inhibitor CGS 12970 (4.0 microM and 40.0 microM) effectively blocked the generation of TXB2, but increased prostacyclin (PGI2) generation and potentiated the release of IL-6.	cysteinylglycine	28-31	interleukin 6	Rattus norvegicus	187-191
8369737-1	1993	The subcellular distribution of the adenosine A2a receptor in rat striatum has been investigated using specific binding of the A2a-selective ligand [3H]-CGS 21680.	cysteinylglycine	153-156	adenosine A2a receptor	Rattus norvegicus	36-58
8253091-6	1993	The results show that mutants from groups 2, 3, 5 and XP-A can complement all other CGs tested.	cysteinylglycine	84-87	XPA, DNA damage recognition and repair factor	Homo sapiens	54-58
8395000-1	1993	Using an in vitro binding-site selection assay, we have demonstrated that c-Myc-Max complexes bind not only to canonical CACGTG or CATGTG motifs that are flanked by variable sequences but also to noncanonical sites that consist of an internal CG or TG dinucleotide in the context of particular variations in the CA--TG consensus.	cysteinylglycine	123-125	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	74-79
8231731-7	1993	Also one single episode of spreading depression gave rise to a significant increase of cortical BDNF mRNA levels (to 207% of control), which was attenuated (by 61%) after administration of the competitive NMDA receptor antagonist CGS 19755.	cysteinylglycine	230-233	brain-derived neurotrophic factor	Rattus norvegicus	96-100
8224738-3	1993	Electron microscopic studies have revealed that calmodulin (CaM) antagonists, trifluoperazine, thioridazine, pimozide and CGS 9343B, were most effective in preserving muscle structure.	cysteinylglycine	122-125	calmodulin 1	Rattus norvegicus	48-58
8224738-3	1993	Electron microscopic studies have revealed that calmodulin (CaM) antagonists, trifluoperazine, thioridazine, pimozide and CGS 9343B, were most effective in preserving muscle structure.	cysteinylglycine	122-125	calmodulin 1	Rattus norvegicus	60-63
8478613-2	1993	Moreover, the pattern of CG methylation within the TNF gene is readily distinguishable in DNA derived from cells of these two types.	cysteinylglycine	25-27	tumor necrosis factor	Mus musculus	51-54
8492136-3	1993	The selective adenosine A2a receptor agonist CGS-21680 (3.0-10 nM) significantly increased electrically stimulated release (overflow) of GABA, with 10 nM CGS-21680 resulting in a 44% increase compared with the control.	cysteinylglycine	45-48	adenosine A2a receptor	Rattus norvegicus	14-36
1381016-4	1992	The calmodulin inhibitors trifluoperazine, W-7, calmidazolium, W-13, and CGS 9343B improved postischemic contractile function and/or reduced LDH release.	cysteinylglycine	73-76	calmodulin 1	Rattus norvegicus	4-14
1446751-0	1992	Specific cleavage of DNA at CG sites by Co(III) and Ni(II) desferal complexes.	cysteinylglycine	28-30	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	40-47
1356152-5	1992	On analyzing species differences in biliary excretion of GSH-related thiols and disulfides, it was concluded that biliary excretion of GS-Cys-Gly was related to the excretion of both GSSG and Cys-Gly, which is formed from GSH by gamma-glutamyltransferase (gamma-GT)-catalyzed hydrolysis.	cysteinylglycine	138-145	gamma-glutamyltransferase 1	Rattus norvegicus	229-254
1356152-5	1992	On analyzing species differences in biliary excretion of GSH-related thiols and disulfides, it was concluded that biliary excretion of GS-Cys-Gly was related to the excretion of both GSSG and Cys-Gly, which is formed from GSH by gamma-glutamyltransferase (gamma-GT)-catalyzed hydrolysis.	cysteinylglycine	138-145	gamma-glutamyltransferase 1	Rattus norvegicus	256-264
1356152-6	1992	Species with low hepatic gamma-GT (i.e., hamsters and mice) excreted little Cys-Gly in bile.	cysteinylglycine	76-83	gamma-glutamyltransferase 1	Rattus norvegicus	25-33
1356152-8	1992	Rats and guinea pigs, which have high hepatic gamma-GT activities, excreted large amounts of both Cys-Gly and GS-Cys-Gly.	cysteinylglycine	98-105	gamma-glutamyltransferase 1	Rattus norvegicus	46-54
1356152-9	1992	Treatment of rats with acivicin, an inhibitor of gamma-GT, decreased the biliary excretion of both Cys-Gly and GS-Cys-Gly.	cysteinylglycine	99-106	gamma-glutamyltransferase 1	Rattus norvegicus	49-57
8434049-0	1993	Effect of the TRH analogue, CG 3703, on prolactin secretion in the pseudopregnant rat.	cysteinylglycine	28-30	prolactin	Rattus norvegicus	40-49
8434049-1	1993	The effect of the TRH analogue, CG 3703 (AG), on secretion of prolactin (Prl) was studied in pseudopregnant rats.	cysteinylglycine	32-34	prolactin	Rattus norvegicus	62-71
8434049-1	1993	The effect of the TRH analogue, CG 3703 (AG), on secretion of prolactin (Prl) was studied in pseudopregnant rats.	cysteinylglycine	32-34	prolactin	Rattus norvegicus	73-76
1407664-1	1992	The A2 adenosine receptor agonist, CGS 21680 in nanomolar concentrations, reversibly increased in a concentration-dependent manner the amplitude of orthodromically-evoked population spikes recorded from the CA1 pyramidal cell layer of rat hippocampal slices.	cysteinylglycine	35-38	carbonic anhydrase 1	Rattus norvegicus	207-210
1382372-0	1992	Influence of CGS 9343B, an inhibitor of calmodulin activity, on histamine release from isolated rat mast cells.	cysteinylglycine	13-16	calmodulin 1	Rattus norvegicus	40-50
1522756-6	1992	The incidence of reappearance of the CA1 PS during reoxygenation after long- (45 min) lasting hypoxia was significantly increased (P less than 0.05) by slice perfusion with MK 801 (50 microM), while it was not significantly affected by slice perfusion with caffeine (50 microM) or DPCPX (0.2 microM) or L-PIA (0.2 microM) or CPA (0.05 microM) or CGS 21680 (5 microM).	cysteinylglycine	346-349	carbonic anhydrase 1	Rattus norvegicus	37-40
1374260-2	1992	The voltammetric DOPAC signal in the Locus coeruleus, used as a measure of NE neuronal activity, was increased after systemic application of the 5-HT1B agonist CGS-12066B, the 5-HT2 antagonist ritanserin, and, to a lesser extent, by ipsapirone, a 5-HT1A agonist.	cysteinylglycine	160-163	5-hydroxytryptamine receptor 1B	Rattus norvegicus	145-151
1374260-2	1992	The voltammetric DOPAC signal in the Locus coeruleus, used as a measure of NE neuronal activity, was increased after systemic application of the 5-HT1B agonist CGS-12066B, the 5-HT2 antagonist ritanserin, and, to a lesser extent, by ipsapirone, a 5-HT1A agonist.	cysteinylglycine	160-163	5-hydroxytryptamine receptor 1A	Rattus norvegicus	247-253
1632058-0	1992	Toxic peripheral neuropathy with demyelination in Sprague-Dawley rats given CGS 21595--a 5-lipoxygenase inhibitor.	cysteinylglycine	76-79	arachidonate 5-lipoxygenase	Rattus norvegicus	89-103
1738111-7	1992	Similar to the pharmacological characteristics of the 5HT1B site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT.	cysteinylglycine	213-216	5-hydroxytryptamine receptor 1B	Rattus norvegicus	54-59
1954882-6	1991	Testes collected at 21 days from fetuses treated at day 19 in utero with human CG or testosterone, also showed less staining for holo-MIS, but, surprisingly, increased staining for the N- and C-terminal fragments.	cysteinylglycine	79-81	anti-Mullerian hormone	Homo sapiens	134-137
1954882-7	1991	These changes in MIS protein were accompanied by no or minimal changes in MIS messenger RNA levels, indicating that human CG and testosterone do not affect transcription, but may regulate the cleavage and/or dissociation of MIS.	cysteinylglycine	122-124	anti-Mullerian hormone	Homo sapiens	17-20
2037062-3	1991	The alpha hCG secreted into the medium represented approximately 20-30% of the total hCG synthesized by vAc alpha CG infected insect cells.	cysteinylglycine	11-13	chorionic gonadotropin subunit beta 5	Homo sapiens	85-88
1805230-0	1991	Isolation increases a behavioral response to the selective 5-HT 1B agonist CGS 120 66B.	cysteinylglycine	75-78	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	59-66
1665286-1	1991	CGS 22745, and aralkyl hydroxamic acid, inhibited 5-hydroxyeicosatetraenoic acid (5-HETE) and leukotriene B4 (LTB4) synthesis in guinea pig leukocytes (IC50 = 0.6 microM).	cysteinylglycine	0-3	prostaglandin reductase 1	Cavia porcellus	110-114
1651314-6	1991	The results indicate that 11 amino acids of the TSH receptor (Lys-201 to Lys-211) and the corresponding region of the LH/CG receptor (Thr-202 to Ile-212) are important for specific TSH and human CG binding, respectively.	cysteinylglycine	121-123	thyroid stimulating hormone receptor	Homo sapiens	48-60
2046018-8	1991	In contrast plasma renin activity increased significantly in response to the intrarenal infusion of 0.075 micrograms/kg/min of CGS 21680A, a dose which leaked from the kidney and lowered BP.	cysteinylglycine	127-130	renin	Homo sapiens	19-24
1833660-1	1991	In mice, isolation-induced social behavioural deficits are attenuated by stimulants of 5-HT1B receptors, such as TFMPP or CGS 120 66B.	cysteinylglycine	122-125	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	87-93
1783470-4	1991	When the protective potency of the specific 5-lipoxygenase inhibitors (MK 886, CGS 81585) was tested in endotoxin-induced leukopenia and shock, they were found to be ineffective.	cysteinylglycine	79-82	arachidonate 5-lipoxygenase	Mus musculus	44-58
1992482-6	1991	With respect to hormone binding, substitution of the entire extracellular domain of the LH/CG receptor for the corresponding region of the TSH receptor resulted in high-affinity human CG binding with complete loss of TSH binding.	cysteinylglycine	91-93	thyroid stimulating hormone receptor	Homo sapiens	139-151
1848792-3	1991	Preliminary results obtained with the novel calmodulin inhibitor CGS 9343B, which blocked the elevation of cAMP, and with the cyclogenase inhibitor indomethacin, which partially blocked the actions of the agonists but not those of high K+, suggest that calmodulin and arachidonate metabolites may be two components of the signaling pathway.	cysteinylglycine	65-68	calmodulin 1	Rattus norvegicus	44-54
2050288-0	1991	Effect of the calmodulin antagonist CGS 9343B on skin burns.	cysteinylglycine	36-39	calmodulin 1	Homo sapiens	14-24
2050288-2	1991	CGS 9343B is a novel, potent and selective inhibitor of calmodulin activity, which unlike other known calmodulin antagonists, does not inhibit protein kinase C activity and does not possess potential antidopaminergic activity.	cysteinylglycine	0-3	calmodulin 1	Homo sapiens	56-66
2050288-2	1991	CGS 9343B is a novel, potent and selective inhibitor of calmodulin activity, which unlike other known calmodulin antagonists, does not inhibit protein kinase C activity and does not possess potential antidopaminergic activity.	cysteinylglycine	0-3	calmodulin 1	Homo sapiens	102-112
2150180-7	1990	The mixed 5-HT1A/1B-agonist CGS 12066B at 10 mg kg-1 potentiated hypothermia and had no effect on hypoactivity.	cysteinylglycine	28-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	10-16
2273083-1	1990	Benazepril hydrochloride (CGS 14824A) is an orally active, nonsulfhydryl compound that is transformed in vivo to a long-acting inhibitor of angiotensin-converting enzyme (ACE).	cysteinylglycine	26-29	angiotensin I converting enzyme	Homo sapiens	140-169
2273083-1	1990	Benazepril hydrochloride (CGS 14824A) is an orally active, nonsulfhydryl compound that is transformed in vivo to a long-acting inhibitor of angiotensin-converting enzyme (ACE).	cysteinylglycine	26-29	angiotensin I converting enzyme	Homo sapiens	171-174
2127956-7	1990	These studies demonstrate that hormonal regulation of LH/CG receptor mRNA in rat ovarian cells parallels changes in LH/CG receptor levels and involves diverse molecular mechanisms, including 1) low concentrations of cAMP (elicited by FSH) in developing follicles, 2) inhibition by high concentrations of cAMP (elicited by LH/CG) in PO follicles, and 3) induction and maintenance by PRL in corpora lutea of gestation.	cysteinylglycine	57-59	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	116-130
1671413-4	1991	Of the compounds tested, 4,5-methano-AP5 analogue 26 was the most potent selective NMDA antagonist; however, potency was lower than that for [[(+/-)-2-carboxypiperidin-4-yl]methyl]phosphonic acid (CGS 19755, 5).	cysteinylglycine	197-200	adaptor related protein complex 5 subunit beta 1	Homo sapiens	37-40
2211722-1	1990	Two monoclonal anti-Z-DNA antibodies, Z22 and Z44, were shown to bind to the oligonucleotides, d(CG)2 and d(CG)3, and to interact with different parts of the helix.	cysteinylglycine	97-99	small nucleolar RNA, C/D box 79	Homo sapiens	38-41
2213023-2	1990	The binding of [3H]CGS 21680, as determined by standard radioligand binding technique in the presence of exogenously added adenosine deaminase, reached equilibrium after 40 min at 25 degrees C. In saturation studies, a single class of high-affinity binding sites with values for KD of 22 +/- 0.5 nM and Bmax of 444 +/- 63 fmol/mg of protein were observed.	cysteinylglycine	19-22	adenosine deaminase	Rattus norvegicus	123-142
2226298-2	1990	In vitro stimulation with human CG (hCG) (0.2 IU/ml) caused a 75-fold increase in testosterone production.	cysteinylglycine	32-34	hypertrichosis 2 (generalised, congenital)	Homo sapiens	36-39
26629098-8	2015	In addition, the significant relationship between MIF -173G/C gene polymorphism and gastrointestinal tumors (CC+CG vs. GG, OR: 1.25, 95% CI=1.05-1.50), hematological malignancy (CC+CG vs. GG, OR: 1.27, 95% CI=1.03-1.56), gynecolgical tumors (CC vs. CG+ GG, OR: 1.51, 95% CI=1.04-2.19) risk was found.	cysteinylglycine	112-114	macrophage migration inhibitory factor	Homo sapiens	50-53
2156991-7	1990	These results agree with previous receptor binding studies suggesting that CGS 21680 is a relatively selective agonist at the high affinity adenosine A2a receptor in striatum, with little intrinsic activity at the low affinity A2b site in hippocampus.	cysteinylglycine	75-78	adenosine A2a receptor	Rattus norvegicus	140-162
1975081-8	1990	The decreased entries and time spent on the open arm of the maze following TFMPP or mCPP administration was possibly mediated by an antagonistic action at 5-HT1B receptors, since this effect was reversed by the selective 5-HT1B agonist CGS 12066B.	cysteinylglycine	236-239	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	155-161
1975081-8	1990	The decreased entries and time spent on the open arm of the maze following TFMPP or mCPP administration was possibly mediated by an antagonistic action at 5-HT1B receptors, since this effect was reversed by the selective 5-HT1B agonist CGS 12066B.	cysteinylglycine	236-239	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	221-227
2281039-1	1990	The o-naphthoquinone derivative, CGS 8515 (I), is a potent inhibitor (IC50, 0.1 microM) of 5-lipoxygenase, but its therapeutic potential is compromised by a short plasma half-life (22 min) and extremely poor oral bioavailability (less than 2%).	cysteinylglycine	33-36	arachidonate 5-lipoxygenase	Homo sapiens	91-105
2080946-2	1990	Benazepril (CGS 14824A HCl) is a new prodrug type angiotensin converting enzyme (ACE) inhibitor.	cysteinylglycine	12-15	angiotensin-converting enzyme	Oryctolagus cuniculus	50-79
2080946-2	1990	Benazepril (CGS 14824A HCl) is a new prodrug type angiotensin converting enzyme (ACE) inhibitor.	cysteinylglycine	12-15	angiotensin-converting enzyme	Oryctolagus cuniculus	81-84
2120352-5	1990	Therefore, unmethylation of these CG sites can contribute in preventing mCG----TG/CA changes in this region, which would lead to extensive alterations of the secondary structure of the 5" portion of the HLA-DR alpha MRNA.	cysteinylglycine	34-36	major histocompatibility complex, class II, DR alpha	Homo sapiens	203-215
2120352-6	1990	On the other hand, the selective pressure to maintain unaltered the methylated CG dinucleotides in the coding regions of the HLA-DR alpha gene could be due to codon restrictions, since the majority of the methylation-related CG----TG or CG----CA variations would generate aminoacid changes.	cysteinylglycine	79-81	major histocompatibility complex, class II, DR alpha	Homo sapiens	125-137
26629098-8	2015	In addition, the significant relationship between MIF -173G/C gene polymorphism and gastrointestinal tumors (CC+CG vs. GG, OR: 1.25, 95% CI=1.05-1.50), hematological malignancy (CC+CG vs. GG, OR: 1.27, 95% CI=1.03-1.56), gynecolgical tumors (CC vs. CG+ GG, OR: 1.51, 95% CI=1.04-2.19) risk was found.	cysteinylglycine	181-183	macrophage migration inhibitory factor	Homo sapiens	50-53
26629098-8	2015	In addition, the significant relationship between MIF -173G/C gene polymorphism and gastrointestinal tumors (CC+CG vs. GG, OR: 1.25, 95% CI=1.05-1.50), hematological malignancy (CC+CG vs. GG, OR: 1.27, 95% CI=1.03-1.56), gynecolgical tumors (CC vs. CG+ GG, OR: 1.51, 95% CI=1.04-2.19) risk was found.	cysteinylglycine	181-183	macrophage migration inhibitory factor	Homo sapiens	50-53
15351206-7	2004	Tat-induced TNF-alpha production was inhibited 90 +/- 6% by CGS 21680 and concurrent treatment with okadaic acid blocked the inhibitory actions of CGS 21680.	cysteinylglycine	60-63	tumor necrosis factor	Homo sapiens	12-21
15351206-7	2004	Tat-induced TNF-alpha production was inhibited 90 +/- 6% by CGS 21680 and concurrent treatment with okadaic acid blocked the inhibitory actions of CGS 21680.	cysteinylglycine	147-150	tumor necrosis factor	Homo sapiens	12-21
34198460-6	2021	Functional enrichment analysis showed that CGs were mainly enriched in the "Calcineurin-NFAT (nuclear factor of activated T-cells)" signaling pathway, particularly regulator of calcineurin 1 (RCAN1), and protein phosphatase 3 regulatory subunit B, alpha (PPP3R1).	cysteinylglycine	43-46	regulator of calcineurin 1	Homo sapiens	164-190
34324979-4	2021	The elevation in the CNDP2 protein levels was confirmed by immunoblot analyses and this elevation was accompanied by an increase in hydrolytic activity towards cysteinylglycine, the intermediate degradation product of glutathione after the removal of the gamma-glutamyl group, in xCT KO macrophages.	cysteinylglycine	160-176	CNDP dipeptidase 2 (metallopeptidase M20 family)	Mus musculus	21-26
34324979-4	2021	The elevation in the CNDP2 protein levels was confirmed by immunoblot analyses and this elevation was accompanied by an increase in hydrolytic activity towards cysteinylglycine, the intermediate degradation product of glutathione after the removal of the gamma-glutamyl group, in xCT KO macrophages.	cysteinylglycine	160-176	solute carrier family 7 (cationic amino acid transporter, y+ system), member 11	Mus musculus	280-283
34453970-3	2022	Treatment of CGS-exposed dams with the NAD+-stabilizing agent P7C3-A20 during pregnancy and postpartum, however, preserved normal maternal care behavior.	cysteinylglycine	13-16	TNF alpha induced protein 3	Homo sapiens	67-70
34453970-4	2022	CGS also caused abnormally low weight gain during gestation and postpartum, which was partially ameliorated by maternal treatment with P7C3-A20.	cysteinylglycine	0-3	TNF alpha induced protein 3	Homo sapiens	140-143
34198460-6	2021	Functional enrichment analysis showed that CGs were mainly enriched in the "Calcineurin-NFAT (nuclear factor of activated T-cells)" signaling pathway, particularly regulator of calcineurin 1 (RCAN1), and protein phosphatase 3 regulatory subunit B, alpha (PPP3R1).	cysteinylglycine	43-46	regulator of calcineurin 1	Homo sapiens	192-197
34198460-6	2021	Functional enrichment analysis showed that CGs were mainly enriched in the "Calcineurin-NFAT (nuclear factor of activated T-cells)" signaling pathway, particularly regulator of calcineurin 1 (RCAN1), and protein phosphatase 3 regulatory subunit B, alpha (PPP3R1).	cysteinylglycine	43-46	protein phosphatase 3 regulatory subunit B, alpha	Homo sapiens	255-261
2790019-4	1989	The difference in hydration free energies between the Z and the B conformations (delta delta GH(Z-B] was determined from these surfaces to be -0.494 kcal/mol for C-5 methylated d(CG), 0.228 kcal/mol for unmethylated d(CG), 0.756 kcal/mol for d(CA)-d(TG), and 0.896 kcal/mol for d(TA) dinucleotides.	cysteinylglycine	179-181	complement C5	Homo sapiens	162-165
35148992-7	2022	In glioblastoma cells expressing GGT1, pharmacological inhibition or deletion of GGT1 suppressed the cell density-induced increase in intracellular glutathione levels and cell viability under cystine deprivation, which were restored by the addition of cysteinylglycine, the GGT product of glutathione cleavage.	cysteinylglycine	252-268	gamma-glutamyltransferase 1	Homo sapiens	81-85
2795459-0	1989	Novel calmodulin antagonist CGS 9343B inhibits secretory diarrhea.	cysteinylglycine	28-31	calmodulin 2	Mus musculus	6-16
2795459-3	1989	We tested a selective inhibitor of calmodulin, CGS 9343B, for antidiarrheal activity in two different models of secretory diarrhea.	cysteinylglycine	47-50	calmodulin 2	Mus musculus	35-45
2769391-8	1989	Interferon-gamma treatment in vitro increased the percentage of CG 12-positive cells by 12% and the amount of cell-surface CG 12 antigens by 38% as compared to untreated cells.	cysteinylglycine	64-66	interferon gamma	Homo sapiens	0-16
2769391-8	1989	Interferon-gamma treatment in vitro increased the percentage of CG 12-positive cells by 12% and the amount of cell-surface CG 12 antigens by 38% as compared to untreated cells.	cysteinylglycine	123-125	interferon gamma	Homo sapiens	0-16
2790019-4	1989	The difference in hydration free energies between the Z and the B conformations (delta delta GH(Z-B] was determined from these surfaces to be -0.494 kcal/mol for C-5 methylated d(CG), 0.228 kcal/mol for unmethylated d(CG), 0.756 kcal/mol for d(CA)-d(TG), and 0.896 kcal/mol for d(TA) dinucleotides.	cysteinylglycine	218-220	complement C5	Homo sapiens	162-165
2790019-5	1989	These delta delta GH(Z-B) values were compared to the experimental B- to Z-DNA transition energies of -0.56 kcal/mol that we measured for C-5 methylated d(CG), 0.69-1.30 kcal/mol reported for unmethylated d(CG), 1.32-1.48 kcal/mol reported for d(CA)-d(TG), and 2.3-2.4 kcal/mol for d(TA) dinucleotides.	cysteinylglycine	155-157	complement C5	Homo sapiens	138-141
2790019-5	1989	These delta delta GH(Z-B) values were compared to the experimental B- to Z-DNA transition energies of -0.56 kcal/mol that we measured for C-5 methylated d(CG), 0.69-1.30 kcal/mol reported for unmethylated d(CG), 1.32-1.48 kcal/mol reported for d(CA)-d(TG), and 2.3-2.4 kcal/mol for d(TA) dinucleotides.	cysteinylglycine	207-209	complement C5	Homo sapiens	138-141
2917008-0	1989	Improvement of ischemia-reperfusion-induced myocardial dysfunction by modulating calcium-overload using a novel, specific calmodulin antagonist, CGS 9343B.	cysteinylglycine	145-148	calmodulin-3	Sus scrofa	122-132
2917008-2	1989	A novel specific inhibitor of calmodulin, CGS 9343B, was used to pretreat an ischemic heart in an effort to enhance myocardial preservation.	cysteinylglycine	42-45	calmodulin-3	Sus scrofa	30-40
2517031-5	1989	All of the xanthine derivatives tested and CG-4203 blocked the leukopenia induced by recombinant tumor necrosis factor, which is a major endogenous mediator for endotoxin toxicity.	cysteinylglycine	43-45	tumor necrosis factor	Mus musculus	97-118
2768222-6	1989	We also examined the substrate specificity of human MDP and found that human MDP catalyzed the hydrolysis of S(substituent)-L-cysteinyl-glycine adducts such as L-cystinyl-bis(glycine) and S-N-ethylmaleimide-L-cysteinyl-glycine, as well as the conversion of leukotriene D4 to leukotriene E4.	cysteinylglycine	122-143	dipeptidase 1	Homo sapiens	52-55
2768222-6	1989	We also examined the substrate specificity of human MDP and found that human MDP catalyzed the hydrolysis of S(substituent)-L-cysteinyl-glycine adducts such as L-cystinyl-bis(glycine) and S-N-ethylmaleimide-L-cysteinyl-glycine, as well as the conversion of leukotriene D4 to leukotriene E4.	cysteinylglycine	122-143	dipeptidase 1	Homo sapiens	77-80
2493964-2	1989	In the present study, microinjection of 10 ng to 5 micrograms of TRH into the anterior hypothalamus (AHy) dose-dependently suppressed heat production in interscapular brown adipose tissue (BAT) in chloral hydrate-anaesthetized rats tested at a room temperature of 23 +/- 2 degrees C. This effect of TRH was mimicked by the structurally related peptides acid-TRH and luteinizing hormone releasing hormone (LH-RH), and by the TRH analog CG 3509, but not by the TRH fragments pGlu-His and His-Pro.	cysteinylglycine	435-437	thyrotropin releasing hormone	Rattus norvegicus	65-68
2464057-1	1989	The new calmodulin antagonist, CGS-9343B, was found to inhibit both histamine plus 3-isobutyl-1-methylxanthine and carbachol-induced [14C]aminopyrine accumulation in dispersed, fundic mucosal cells of rats.	cysteinylglycine	31-34	calmodulin 1	Rattus norvegicus	8-18
2464057-7	1989	Unlike trifluoperazine and fenoctimine, CGS-9343B had anticamodulin activity for inhibition of calmodulin-activated (Type I) phosphodiesterase in the same range of potency as observed for the inhibition of aminopyrine accumulation.	cysteinylglycine	40-43	calmodulin 1	Rattus norvegicus	95-105